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Chapter 1: Introduction 
Cognitive change 
 
Cognition refers to the processes and mechanisms of thought and is typically described by 
domain. Cognition can be operationalized and measured, and through this measurement, 
cognition is known to be subject to variation due to both internal and external factors. At 
either the acute or chronic level, cognitive change happens to everyone. It is the purpose of 
this thesis to explore and expand the current understanding of the inflammatory model of 
cognitive change, in order to identify potential therapeutic targets for intervention. 
 
Cognitive change is influenced by our mental and physical health 
 
Cognitive change is most commonly seen as a result of ageing but can be altered, either 
acutely or chronically, with the impact of a multitude of external events and internal factors. 
As a physical organ, the brain is subject to the same deterioration as the rest of the body, 
though it is protected from most physical trauma by the skull and from biochemical 
disruption via the blood-brain barrier. There are numerous modulating factors that can act to 
directly influence the brain either through physical damage to the brain itself or indirectly via 
changes to the permeability of the blood-brain barrier, which in turn leads to subsequent 
biochemical changes to the organ. It is the increased permeability of the blood-brain barrier 
and the role of factors that precipitate this permeability that form the major theme of this 
thesis. Oxidative stress and subsequent neuroinflammation have been implicated as potential 
drivers of cognitive change associated with a number of conditions, and the moderation of 
this process is increasingly the subject of inquiry (Berk, Malhi, Gray, & Dean, 2013; Dean, 
Data-Franco, Giorlando, & Berk, 2012). 
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The interaction of age, disease, and other biological factors has likewise been explored in 
depth. As ageing advances into seniority, cognitive processes become less efficient and trend 
towards declining performance (Deckers et al., 2015). This trajectory can be modulated 
because of acute events or chronic conditions, and a plethora of diseases and disorders are 
established cognitive modulators. For example, the presence of depression is associated with 
significant global cognitive deficits that are not limited to episodes of low mood and may 
persist after successful intervention (Rock, Roiser, Riedel, & Blackwell, 2014). The presence 
of depression after the age of 50 is also an established risk factor for cognitive deterioration 
in elders, including increased risk of Alzheimer’s disease and dementia (Diniz, Butters, 
Albert, Dew, & Reynolds, 2013; Ownby RL, Crocco E, Acevedo A, John V, & Loewenstein 
D, 2006). Even more pronounced are the cognitive deficits observed when comparing 
schizophrenia patients with healthy controls, and that this cognitive impact perseveres after 
successful treatment with antipsychotics (Keefe, 2014). Further, the cognitive deficits 
associated with schizophrenia begin to appear in childhood and can remain into adulthood. 
Significantly, recent research has demonstrated the efficacy of adjunct anti-inflammatories in 
comparison to regular treatment for psychosis (Rapado-Castro et al., 2016), though the 
investigation into longitudinal moderation is nascent. 
 
 
The longitudinal cognitive trajectory can also be altered with the presence of chronic 
infectious disease such as HIV (DeVaughn, Müller-Oehring, Markey, Bronte-Stewart, & 
Schulte, 2015). Management of HIV allows those diagnosed to live much longer than in 
previous decades, but there appears to be a cumulative effect of HIV infection on cognition 
with increasing age which is associated with greater levels of decline in comparison to 
healthy controls. It has been estimated that as many as one-third to one-half of all patients 
with HIV are also comorbid for HIV-Associated Neurocognitive Disorders (HAND; Saylor et 
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al., 2016). Recent evidence has emerged that the CNS is vulnerable to HIV monocytes and 
that this contributes to a cyclical feedback loop of increasing neuroinflammation and 
cognitive dysfunction (Veenstra et al., 2017). 
 
 
Other conditions combine acute cognitive dysfunction that, if sufficiently severe, can 
significantly and detrimentally alter longitudinal cognition trajectories. Traumatic Brain 
Injury (TBI) is associated with chronic cognitive deficit across multiple domains including 
memory, attention, executive function and processing speed, but also more general meta- 
cognitive insight and decision making (Rabinowitz & Levin, 2014). While TBI is often 
perceived as being the result of single traumatic events such as a head injury after a car crash, 
though the cumulative effect of sub-concussive repeated impact is also an established vector 
for neurodegeneration (Stein, Alvarez, & McKee, 2014). Treatment for cognitive restoration 
after TBI appears to be somewhat effective in addressing the cognitive deficits (Dougall, 
Poole, & Agrawal, 2015; Turner‐ Stokes, Pick, Nair, Disler, & Wade, 2015), though the risk 
of longitudinal decline appears to remain due to lingering physical damage (Mendez, 2017). 
The acute neuroinflammatory response of TBI has been identified as a potential therapeutic 
target of adjunct antioxidant administration, with preliminary yet promising results in acute 
(Hoffer, Balaban, Slade, Tsao, & Hoffer, 2013) and chronic brain injury (Amen, Wu, Taylor, 
& Willeumier, 2011). 
 
 
Beyond the acute effects of intoxication, chronic substance abuse is also an established 
contributor for cognitive dysfunction that persists even after successful treatment (London, 
Kohno, Morales, & Ballard, 2015; Novier, Diaz-Granados, & Matthews, 2015). In 
comparison to TBI, efforts to use anti-inflammatory medication to mitigate the cognitive 
impact of substance use have proven mixed, with greater success favouring the use of 
15  
longitudinal administration to address chronic damage as opposed to acute mitigation (Berk 
et al., 2013; Gunduz-Bruce et al., 2012). Again, it can be seen that ageing and cognitive 
change are strongly intertwined, and further that the presence of acute and chronic 
modulators can exacerbate the declining process. 
 
Australia is ageing 
 
The proportion of Australians aged 65 years and older has steadily increased for nearly two 
decades, from approximately 12% of the population in 1998 to over 15% in 2015 (Australian 
Bureau of Statistics, 1998, 2016). Like most Western nations, the cause of the ageing of 
Australia is multifactorial; Australians are living and working for longer, and having fewer 
children compared to past generations. Given the continued proportionate increase in the 
elderly population, the healthcare needs of Australia are also swiftly changing to reflect a 
greater requirement for services associated with elder morbidity and disability management. 
Age-related cognitive decline, including dementia, has become increasingly prevalent as has 
the need for joint replacement surgeries. 
 
The number of Australians with dementia is increasing 
 
Consistent with the increasing age of the population, dementia is increasingly present in 
Australia. Not only is the number of people living with dementia steadily increasing each 
year (Australian Institute of Health and Wellbeing, 2012), but the proportion of the 
population over the age 65 with dementia has likewise continued to increase for almost a 
decade (Australian Bureau of Statistics, 2013, 2016). Dementia is now the second most 
common cause of death in Australia, second only to ischaemic heart disease. Dementia is also 
costly with estimated costs of dementia increasing each year (Over $14 billion in 2016 
alone), and these costs are estimated to more than double by the year 2036 (Brown, Hansnata, 
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& La, 2017). In response to rising social and economic burden, in 2014 the Australian 
government identified the prevention, treatment, and management of dementia as a leading 
global health priority and allocated $200 million to fund research into the field (NHMRC, 
2014). As part of this call for research, numerous contributing risk factors have been 
identified and proposed including environmental (Killin, Starr, Shiue, & Russ, 2016) and 
medical health factors (Deckers et al., 2015). The role of medical factors, in particular, has 
come under increasing scrutiny in recent years with a number of studies identifying an 
association between surgical procedures and cognitive decline. The probability of undergoing 
surgery approaches certitude over the lifetime as organs, joints, and bodily systems 
deteriorate. Thus, it is unsurprising that in concordance with the increasing age of 
Australians, the number of surgical procedures undergone each year is also increasing. Since 
2010, the number of public hospital surgical admissions has risen each year, with orthopaedic 
surgeries demonstrating some of the most dramatic increases (Australian Institute of Health 
and Wellbeing, 2016, 2017). 
 
The neuroinflammatory hypothesis of cognitive decline 
 
The role of oxidative stress and subsequent CNS inflammation has long been implicated in 
cognitive change. Ageing is one of the primary drivers of CNS inflammation. While 
inflammation is not uniformly harmful in and of itself, excessive or prolonged 
neuroinflammation is associated with increased aberrant neuronal activity. Ageing is 
associated with increased microglia activity and decreased selectivity, thus resulting in an 
increase in pro-inflammatory cytokines and proteins associated with neurodegeneration such 
as amyloid-β (Harry, 2013). Over time, glia become overly sensitive (“primed”) to the 
presence of amyloid-β and respond with upregulation of inflammatory cytokines as part of 
the immune response, thus creating a feed-forward mechanism (Heneka, Kummer, & Latz, 
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2014). The increased production of CNS cytokines, in turn, is associated with decreased 
cognitive function (DiSabato, Quan, & Godbout, 2016; Norden & Godbout, 2013). 
 
 
Acute immune-activation events can also serve to contribute to the degenerative process. The 
presence of physical trauma either to the head or periphery can aggravate an inflammatory 
response, or if sufficiently severe trigger one (Heneka et al., 2015, 2014). Stroke, traumatic 
brain injury, sepsis, myocardial infarction, and burn injuries are all common acute events that 
exacerbate oxidative stress (Bar-Or, Bar-Or, Rael, & Brody, 2015; Bedreag et al., 2015; 
Margaritelis et al., 2015). In chronic conditions, oxidative stress and neuroinflammation are 
known to contribute to the progression or exacerbation of many medical and psychiatric 
conditions with cognitive sequelae. Major Depressive Disorder is known to involve oxidative 
pathophysiology (Liu et al., 2015). There is some evidence to suggest a potential cognitive 
protective effect of anti-inflammatory adjunctive treatments, but this is unestablished 
(Carvalho et al., 2014). Similarly, schizophrenia (Na, Jung, & Kim, 2014), Alzheimer’s 
disease (Heneka et al., 2015), and TBI (Rodriguez-Rodriguez, Egea-Guerrero, Murillo- 
Cabezas, & Carrillo-Vico, 2014) are associated with neuroinflammatory damage. Anti- 
inflammatory adjunctive treatments have demonstrated efficacy for reduction to symptom 
severity, including cognitive deficits, though large randomised control trials are lacking 
(Adair, Knoefel, & Morgan, 2001; Amen et al., 2011; Eakin et al., 2014; Hoffer et al., 2013; 
Keller et al., 2013; Rapado-Castro et al., 2016; Remington et al., 2015). 
 
 
Evidence suggests that the neuroinflammatory response to immune activation events 
coincides with the upregulation of CNS cytokines that in turn are associated with cognitive 
dysfunction and neurodegeneration. Importantly, the question of how to predict and manage 
cognitive change associated with neuroinflammation is not yet fully answered, particularly in 
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circumstances where the CNS does not undergo direct trauma. This is especially difficult in 
circumstances where an oxidative immune response is expected, such as in response to 
surgical tissue trauma. The combination of tissue damage and anaesthesia has been purported 
to also exacerbate the inflammatory response in the periphery and in the CNS, which in turn 
leads to the phenomena of post-operative cognitive change (Hu, Ou, Duan, & Jiang, 2010; 
Rovai et al., 2015; Silbert, Evered, & Scott, 2011; van Harten, Scheeren, & Absalom, 2012). 
 
The controversial relationship between surgery and cognitive change 
 
Cognitive change after surgery is a commonly observed phenomenon. Acute changes in 
mental status in the early postoperative period are extremely common, particularly among the 
aged. Excluding post-emergence delirium, the two most common changes to cognitive state 
are Post-Operative Delirium (POD) and Post-Operative Cognitive Dysfunction (POCD), and 
while acute changes in mental status after surgery are established risks of surgery, 
longitudinal decline (or decline that is exacerbated by surgery) is far more controversial. The 
mechanism for conversion of cognitive change from mild cognitive impairment to dementia 
is difficult to elucidate, though many reviews have demonstrated the upregulation of 
Alzheimer’s disease-related brain pathophysiology in the aftermath of surgery, such as 
amyloid-β or tau neurofibrillary tangles via the neuroinflammatory pathway (Kapila, Watts, 
Wang, & Ma, 2014; Yang & Fuh, 2015). Guided by this evidence, many researchers have 
explored the impact of surgery and anaesthesia upon cognitive trajectory with mixed results. 
For example, a large retrospective analysis performed by Chen et al., (2014) observed that 
patients who underwent major surgery were almost twice as likely to develop dementia up to 
7.5 years after the procedure in patients aged over 60 in comparison to non-surgical controls, 
after controlling for notable risk factors such as hypertension and depression histories. This 
outcome did not appear to be consistent with other contemporaneous meta-analyses for the 
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effect of anaesthesia exposure for cognitive decline, which suggests that the risk may be 
related to other surgical factors (Seitz, Reimer, & Siddiqui, 2013; Seitz, Shah, Herrmann, 
Beyene, & Siddiqui, 2011). This assertion is supported by the preponderance of evidence 
suggesting that acute post-operative cognitive change appears to be independent of the type 
(Jiang & Jiang, 2015) or location (Mason, Noel-Storr, & Ritchie, 2010) of anaesthesia, and 
only marginally associated with anaesthetic depth (Oliveira, Bernardo, & Nunes, 2017). 
 
 
Cognitive dysfunction after surgery appears to be at least in part controlled by genetic factors. 
Most recently, retrospective analyses have observed the significant interactions between 
surgery, anaesthesia, and the presence of the dysfunction-associated apolipoprotein E ε4 
(APOE4) allele (Schenning et al., 2016), though prospective research suggests that the 
cognitive interaction resultant from surgery and the presence of APOE4 is dependent upon 
the type of surgery. While the current field of evidence is relatively nascent, at least two large 
clinical trials have demonstrated that the presence of the APOE4 genotype is associated with 
cognitive dysfunction after cardiac, but not non-cardiac surgery (Bartels et al., 2015; 
McDonagh et al., 2010). As a further complication, the relationship between APOE4 and 
cognitive change after surgery may depend upon the classification of cognitive change. Acute 
cognitive dysfunction in the post-operative period (termed Post-operative cognitive 
dysfunction, or POCD) appears to be associated with the APOE4 allele (Cao, Wang, Gu, Du, 
& Song, 2014), but post-operative delirium does not (Adamis, Meagher, Williams, Mulligan, 
& McCarthy, 2016). 
 
Post-Operative Delirium 
 
Post-operative delirium (POD) is a common post-surgical condition characterised by an acute 
(and usually fluctuating) change in mental status, particularly noticeable in the areas of 
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attention and organization of thought. Patients may also demonstrate different levels of 
consciousness such as lethargy or hypervigilance, but the most prominent characteristic of 
POD is confusion and disorientation. POD has been grouped under ICD-10 FO5 - Delirium 
due to known physiological condition (Krenk & Rasmussen, 2011). Perceptual disturbances, 
such as hallucinations are also not uncommon, as is evidence of an altered sleep-wake cycle 
(Whitlock, Vannucci, & Avidan, 2011). POD is typically detected by medical staff during 
patient checks of orientation and confirmed through the use of confusion screening tools such 
as the Confusion Assessment Method (Inouye, Westendorp, & Saczynski, 2014), and the 
severity of the condition can be determined through the use of the Dementia Rating Scale- 
Revised (Grover & Kate, 2012). 
 
 
The estimated incidence of POD can vary wildly depending upon the procedure being 
undertaken. For example, incidence can be as high as two-thirds of patients in some vascular 
procedures, though the average incidence for most other procedures is much lower and tends 
to be around 30% (Raats, Steunenberg, de Lange, & van der Laan, 2016). The most 
predictive risk factors for POD include increasing age and the presence of cognitive 
impairment prior to surgery; though numerous other contributing factors including substance 
use, pre-operative pain, sleep deprivation, sensory deprivation, and polypharmacy 
(concurrent administration of more than one medication) have been reported. (Bettelli & 
Neuner, 2017; Delirium: Diagnosis, Prevention and Management, 2010). Evidence for the 
prevention of POD is mixed due to the heterogeneity of methodologies, design, and putative 
mechanisms of POD, though evidence for the preventative nature of antipsychotic 
administration is promising (Tremblay & Gold, 2016), albeit with low-quality evidence. In 
extension, a recent Cochrane review found little evidence for the prophylactic effect of 
antipsychotics, but good evidence for the efficacy of what is termed multi-component 
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interventions of post-operative mood and mental state monitoring, and individualised care 
(Siddiqi et al., 2016). 
 
Post-Operative Delirium and Dementia 
 
POD is known to be associated with increased risk of morbidity and mortality, particularly 
for patients with a history of cognitive impairment prior to surgery (Beishuizen et al., 2017), 
though the risk is less well established for cognitively intact patients (Cavallari et al., 2017; 
Gleason et al., 2015). Regardless, the emergence of POD in otherwise cognitively intact 
patients has been associated with an increased risk of deteriorating cognitive trajectory, 
which in turn is associated with an expedited onset of dementia (Silverstein & Deiner, 2013). 
Thus, it is unsurprising that POD contributed to an increased risk of mortality at 6 months 
(Mitchell, Shum, Mihala, Murfield, & Aitken, 2017), 12 months (Liang et al., 2015), and 5 
years (Moskowitz et al., 2017). 
 
Post-Operative Cognitive Dysfunction 
 
Post-operative cognitive dysfunction is a distinct decline in cognitive capacity after surgery 
in comparison to pre-surgical performance. POCD can be considered distinct from POD in 
that confusion and disorientation are not necessarily present, though the patient may report 
subjective difficulties to memory, attention, and concentration. POCD does not have a DSM 
or ICD code, and debate about the identification or even the existence of the condition 
continues to occur. 
 
 
In concordance with this controversy, there is no established criteria or method to reliably 
identify POCD, and prevalence estimates for the condition tend to vary wildly. In recent 
years research has favoured the of use of a cut-off of a 2 standard deviation change in post- 
surgical performance in comparison with pre-surgical estimates, but this is not universal 
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(Berger et al., 2015). Further, the prevalence is of POCD heavily dependent upon both the 
type of surgery and the timing of the cognitive assessments. For example, a recent review 
estimates rates of POCD at 3 months after major non-cardiac surgery to be approximately 
11% (Paredes, Cortinez, Contreras, & Silbert, 2016), though much higher estimates are 
commonly seen at one week post-surgery, and particularly after cardiac surgeries (Newman, 
Stygall, Hirani, Shaefi, & Maze, 2007; Wang, 2014). 
 
Post-Operative Cognitive Dysfunction and Dementia 
 
The longitudinal prognosis of POCD appears to be one of increased risk of morbidity and 
mortality, though evidence specifically related to continued cognitive decline is mixed. Most 
reviews of the longitudinal impact of POCD suggest that the relationship between POCD and 
dementia is non-significant (or, at least, unestablished) even though previous hypothetical 
models suggest that the two conditions should be related (Bilotta, Qeva, & Matot, 2016; 
Kapila et al., 2014; Vanderweyde, Bednar, Forman, & Wolozin, 2010). While individual 
studies have associated POCD and increased risk of dementia for coronary artery bypass 
surgery (Evered, Silbert, Scott, Maruff, & Ames, 2016), the same association is less 
established in non-cardiac patients (Steinmetz, Siersma, Kessing, & Rasmussen, 2013). One 
potential reason for the disparity in expected and observed outcomes is that despite recently 
increased research efforts, the field of POCD research and the potential contribution to 
longitudinal cognitive change is relatively small. This difficulty is compounded by the 
logistical difficulties of attempting to conduct large-scale research of appropriate design for 
sufficient lengths of time to detect cognitive change, to say nothing of the conceptual issues 
pertaining to the diagnosis of POCD itself (Nadelson, Sanders, & Avidan, 2014). 
 
 
In contrast to the lack of convincing evidence for an association between POCD and 
dementia, the contribution of POCD to longitudinal functional decline is comparatively well 
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established. The seminal International Study of Post-Operative Cognitive Dysfunction 
demonstrated a marked increase in mortality, and premature retirement (Steinmetz, 
Christensen, Lund, Lohse, & Rasmussen, 2009). These findings have been replicated in other 
trials (Kastaun et al., 2016; Monk et al., 2008; Phillips-Bute et al., 2006), but in similarity to 
the association between POCD and dementia, the area is under-researched. 
 
 
Given the potential long-term risks of POCD, there is a need to develop clear methods of 
prevention, identification, and treatment. While the risk factors of POCD are fairly well 
elucidated and include increasing age, low cognitive reserve, history of POD, and use of 
sedatives (Paredes et al., 2016), the precise mechanisms through which POCD occurs are 
unknown and thus no interventions or preventative agents have been established. 
Oxidative stress resultant from surgical tissue trauma and subsequent neuroinflammation is a 
key current hypothesis supported by both preclinical and clinical evidence (Hovens et al., 
2014, 2015; Vacas, Degos, Feng, & Maze, 2013; Vacas, Degos, Tracey, & Maze, 2014), 
though the current field of evidence has yet to fully explore the therapeutic targets in humans. 
 
Thesis aim 
 
While the overall aims of this thesis are to examine and explore the inflammatory model of 
cognitive change, the more specific objectives of this thesis are to examine the cognitive 
change that results from surgery; and examine the potential efficacy of novel therapies, 
including N-acetylcysteine. These aims can be conceptualized as underpinning three basic 
research questions: 
1. What is driving change after surgery, and what can be done about it? 
 
2. Can N-acetylcysteine mitigate cognitive decline? 
24  
3. What can we learn about Post-Operative Cognitive Dysfunction, and what can the 
current and future research teach us? 
 
Overview of the thesis and executive summary 
 
This thesis broadly follows an adjusted version of the UK Medical Research Council 
complex intervention process (Moore et al., 2015) wherein the context of an intervention is 
provided, the mechanisms of that problem are explored, and the suitable intervention based 
upon those mechanisms is tested and evaluated. 
Chapter 1, the introduction, provides the broad background and context of cognitive change, 
in particular, cognitive change related to ageing. In particular, the role of acute and chronic 
neuroinflammation secondary to oxidative stress is proposed as a potential contributor to 
cognitive change. Cognitive change after surgery is highlighted as a contributing factor to 
changes in national healthcare priorities and exacerbated by the increasing average age of 
Australians. 
The significance of this chapter: The purpose of the introduction chapter is to provide a 
contextual framework through which each of the proceeding chapters can be viewed both 
individually and as a whole body of work. 
Chapter 2 fulfils two criteria; firstly, the proposed neuroinflammatory hypothesis of POCD is 
described, and secondly, a number of potential novel therapies are evaluated based upon their 
ability to influence this neuroinflammation and subsequent cognitive change. N- 
acetylcysteine, among others, is identified as a suitable candidate for further exploration. This 
paper serves an important function for identifying future research paths into perioperative 
cognitive protection. Minocycline, dexmedetomidine, COX-II inhibitors, and N- 
acetylcysteine demonstrate significant promise while also being under-researched at present. 
25  
The significance of this chapter: The neuroinflammatory hypothesis for cognitive change is 
frequently mentioned but rarely examined, and almost never described in full; from the tissue 
trauma at the periphery to organic changes in the central nervous system. By more fully 
elucidating the biochemical processes of cognitive change a number of novel potential 
therapies are then examinable, and this aim is addressed in the second half of the chapter. 
This paper can, therefore, form part of a touchstone from which to build new research 
hypotheses, and this chapter thus serves as a significant and unique contribution to the field 
of cognitive change research. 
Chapter 3 is a systematic literature review of the evidence for N-acetylcysteine as a cognitive 
modulator in humans. The efficacy of N-acetylcysteine for Alzheimer’s disease, TBI, 
psychosis, and healthy participants are all examined with mixed results, though some 
potentially promising results for Alzheimer’s disease and TBI were observed. In addition, a 
series of meta-analyses that were not included in the published paper are presented and 
discussed. 
The significance of this chapter: This paper is one of the only published reviews examining 
the cognitive effects of N-acetylcysteine, albeit with the significant caveat that the most 
efficacious studies tended to use a combination antioxidant intervention. However, the 
potential benefit of antioxidant interventions for mitigating the cognitive change associated 
with oxidative stress can be clearly observed, which necessitates further investigation through 
randomised control trials. In particular, the present lack of oxidative stress biomarkers as a 
cognitive correlate presents a major opportunity for future research. 
Chapter 4 describes the research methodology of a large-scale randomised control trial 
designed to examine the efficacy of N-acetylcysteine for cognitive protection against POCD. 
This trial is then used as the basis for an examination of the risks and protective factors for 
cognitive change in chapter 5. 
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The significance of this chapter: The Post-Anaesthesia N-Acetyl-Cysteine Cognitive 
Evaluation (PANACEA) trial is currently the only existing clinical trial examining the 
potential protective effect of N-acetylcysteine for POCD. The trial is designed specifically to 
address identified issues associated with the neuroinflammatory hypothesis of cognitive 
change via the collection of blood samples before and after surgery. Further, the trial is 
designed to address the various logistical and conceptual challenges of research within the 
field such as the identification of POCD and timing of follow-up assessments. The use of the 
conservative two Z-score change composite serves to balance the risk of Type II error 
inherent in using a full battery of cognitive tests over multiple time points, while the 
implementation of short, medium, and long follow-up assessments at 7 days, 3 months, and 
12 months post-surgery allow for a useful cognitive trajectory to be calculated. 
Chapter 5 examines the contributing factors to cognitive change using the data collected in 
the study described in chapter 4. While the study is ongoing, these results provide an 
important finding regarding the role of neuroinflammation. Two potential predictive models 
for cognitive change after surgery are provided. 
The significance of this chapter: The PANACEA trial is ongoing and recruitment is expected 
to continue until late 2018, and subsequent follow-up assessments until late 2019, thus 
unblinded data were not available for analysis. However, data from a large proportion of 
patients were available for analysis and hypothesis generation. 151 patients provided 
cognitive performance scores before and after major non-cardiac surgery which allowed the 
interrogation of contributing factors to cognitive change, including demographics, medical 
and psychiatric history, and intra- and perioperative factors. Most significantly, the majority 
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of expected contributing factors were not observed to be significantly associated with 
cognitive change, including advanced age, BMI, surgery duration, or educational attainment. 
Only a handful of predictors significantly contributed to a model of cognitive change with 
sufficient power, most notably the protective effect of COX-II inhibitors prior to surgery. 
Thus, some preliminary support for the neuroinflammatory hypothesis for cognitive change 
can be inferred. 
Chapter 6 examines the research questions proposed by the thesis, and evaluates how well 
these questions have been addressed. Future directions for research are also proposed based 
upon the aforementioned research questions. 
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Linking the introduction to the exploratory 
mechanism chapter 
The increasing social and financial burden of ageing-related cognitive decline necessitates the 
conceptualization of models and mechanisms in order to facilitate interventions and 
preventative measures. In particular, the inflammatory response to surgical trauma as a 
cognitive aggravating event provides a useful therapeutic target. In order to best address the 
mechanisms of cognitive change after surgery, the biological and chemical pathways that 
facilitate the conversion of periphery tissue trauma into CNS degeneration needed to be 
described. This in turn partially fulfils one of the main aims of the thesis, which is the further 
examination and exploration of the neuroinflammatory model of cognitive change. 
 
 
Once the pathways of cognitive change via inflammation are elucidated, it then becomes 
possible to critically evaluate the efficacy of potential POCD interventions in accordance 
with this mechanism. The following chapter was published in Neuroscience and 
Biobehavioral Reviews in 2017. 
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Chapter 2: Post-Operative Cognitive 
Dysfunction: An exploration of the 
inflammatory hypothesis and novel 
therapies. 
 
Abstract 
 
Post-Operative Cognitive Dysfunction (POCD) is a highly prevalent condition with 
significant clinical, social and financial impacts for patients and their communities. The 
underlying pathophysiology is becoming increasingly understood, with the role of 
neuroinflammation and oxidative stress secondary to surgery and anaesthesia strongly 
implicated. This review aims to describe the putative mechanisms by which surgery-induced 
inflammation produces cognitive sequelae, with a focus on identifying potential novel 
therapies based upon their ability to modify these pathways. 
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Introduction 
Cognitive dysfunction following a surgical procedure can have a significant impact upon 
patients’ health, function and wellbeing. Post-Operative Cognitive Dysfunction or Decline 
(POCD) is a controversial condition that is the subject of much debate, but is purported to 
encompass acute or persistent deficits in attention, concentration, learning and memory 
following surgery that are not attributable to an overt complication or insult arising from the 
procedure (Niccolò Terrando et al., 2011; Tsai, Sands, & Leung, 2010). POCD is distinct 
from delirium (Tsai, Sands, & Leung, 2010), which describes an acute fluctuating and 
transient disturbance to perception and cognition that is not attributable to a pre-existing 
neurocognitive disorder (European Delirium Association and American Delirium Society, 
2014). The definition of POCD varies markedly across studies but is typically inferred from a 
comparison of pre-operative to post-operative cognitive function.  The investigation of 
POCD typically has focussed on an acute phase, lasting up to the time of discharge, and a 
more prolonged cognitive deficit that can occur months to years following the surgical event 
(Tsai, Sands, & Leung). In the absence of a DSM or ICD classification or biological marker, 
the condition has been defined by consensus as “a spectrum of postoperative central nervous 
dysfunction both acute and persistent” (Tsai, Sands, & Leung). 
 
 
POCD can occur in between 25% to 40% of elderly patients at the point of discharge, and the 
long-term impact of this is marked by a significantly higher mortality rate as compared to age 
and sex matched controls without POCD (Moller et al., 1998; Monk et al., 2008). These 
changes persist for some time, with 25% of patients over 65 years of age displaying evidence 
of POCD at 7 days following hip replacement surgery (M.-H. Ji et al., 2012; LI, XI, AN, 
DONG, & ZHOU, 2012) and 25% of patients displaying significant impairments in executive 
functions and/or memory functions 3 months following surgical intervention (Price, Garvan, 
& Monk, 2008). The consequences for such patients can be significant; a longitudinal follow 
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up of 700 patients diagnosed with POCD 3 months following surgery revealed a significantly 
higher rate of death and disability leading to loss of employment and a greater reliance on 
social security (Steinmetz, Christensen, Lund, Lohse, & Rasmussen, 2009). 
Bedford (1955), first described post-operative symptoms consistent with POCD. Since then 
there has been a concerted effort to determine aetiological factors that underpin the cognitive 
dysfunction. The majority of the early work has focused on factors specific to cardiac 
surgery but no aetiological factors conclusively emerged. Subsequent work reported that in 
the medium term similar numbers of people undergoing non-cardiac surgery develop POCD 
(Evered, Scott, Silbert, & Maruff, 2011) which has necessitated a broader examination of 
possible underlying causes. Increased attention has been focused on inflammatory markers. 
 
 
Preclinical studies suggest that neuroinflammation and oxidative events are key mechanisms 
underpinning the development of POCD (Cibelli et al., 2010; N. Terrando et al., 2010). This 
has also been shown in replicated clinical studies, with patients also displaying elevated 
levels of pro-inflammatory cytokines in both the systemic circulatory and central nervous 
systems following surgery associated with the degree of cognitive decline (Beloosesky et al., 
2007; Buvanendran et al., 2006). However, despite the strengthening evidence supporting this 
aetiological model, there has been minimal translation into therapeutic development, with no 
established preventive or ameliorating therapies. This review will explore the 
pathophysiology of POCD focussing on the aetiological role of neuroinflammatory and 
oxidative processes. Such mechanisms suggest potential therapies acting on such targets, 
including N-acetylcysteine, whose capacity to act as an anti-oxidant, anti-inflammatory and 
modifier of glutamate signalling, hypothetically could prove effective in ameliorating the 
pathways involved. 
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Aetiology of POCD 
 
Surgery induced inflammation 
 
Current theories regarding the mechanisms underlying cognitive dysfunction following 
surgery highlight the role of inflammation and immune activation. Surgery itself induces 
inflammatory processes; both localised and systemic expression of pro-inflammatory 
cytokines and related signalling molecules (Kohl & Deutschman, 2006; Reikerås, 2010). 
Tissue damage following surgery provokes the release of IL-1 and TNF-α from endothelial 
cells and phagocytes, triggering a cascade (Mannick, Rodrick, & Lederer, 2001; Menger & 
Vollmar, 2004) of downstream signalling events (E. Lin, Calvano, & Lowry, 2000). Elevated 
levels of IL-1 and TNF α induce the later production of IL-6, whose levels correlate 
positively with the extent of tissue trauma (Mannick, Rodrick, & Lederer, 2001; Menger & 
Vollmar, 2004). 
 
 
Copious pre-clinical data from animal models supports the association of immune system 
activation following surgery with the development of cognitive decline (Cibelli et al., 2010; 
N. Terrando et al., 2010; Niccolò Terrando et al., 2010, 2011). Multiple, although relatively 
small-scale, clinical studies have reported correlations between circulating peripheral 
inflammatory markers and cognitive dysfunction after surgery.  Li et al observed higher 
serum levels of IL-6 in patients developing POCD (LI et al., 2012), and similarly, Hudetz et 
al documented impaired memory in patients with high IL-6 or high C-reactive protein (CRP), 
a marker of the acute-phase inflammatory response (Hudetz, Gandhi, Iqbal, Patterson, & 
Pagel, 2010). The latter study also observed persistent decrements of cognitive function in the 
high-IL-6 group 1 month after surgery. A meta-analysis of clinical data showed that elevated 
peripheral inflammatory markers were indeed associated with POCD, and that this 
relationship was strongest for IL-6 (L. Peng, Xu, & Ouyang, 2013). Further support for the 
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role of Il-β, TNF-α and other pro-inflammatory cytokines in the genesis of cognitive 
dysfunction following surgery is provided by a number of animal experiments. These 
preclinical studies revealed that surgical trauma is associated with prolonged activation of 
macrophages with the capacity of maintaining elevated levels of cytokines and that those 
levels correlate with the severity of cognitive dysfunction as measured in several domains, 
especially in memory and learning (Cibelli et al., 2010; Rosczyk, Sparkman, & Johnson, 
2008; Niccolò Terrando et al., 2011). 
 
 
Insights into the interaction between inflammation and cognitive function can also be drawn 
from other inflammatory states. Associations between elevated circulating inflammatory 
markers and cognitive dysfunction have been documented in numerous clinical populations, 
such as in viral and bacterial infection (Cvejic, Lemon, Hickie, Lloyd, & Vollmer-Conna, 
2014), HIV infection (Yuan et al., 2015), following chemotherapy (Ganz et al., 2013), in 
sickle-cell disease (Andreotti, King, Macy, Compas, & DeBaun, 2014), and in non-surgery- 
related delirium (Adamis et al., 2014). The mechanism behind this association has been 
explored further in experimental mice models of induced inflammation, which show 
cognitive deficits in response to immune activation (Ming, Sawicki, & Bekar, 2015), or 
transgenic animal models which overexpress cytokines, including IL-6, in the brain (Heyser, 
Masliah, Samimi, Campbell, & Gold, 1997). IL-6, for example, increases with aging, in 
animal models and in human plasma (Ye & Johnson, 1999), and has been associated with the 
cognitive decline associated with aging (Godbout & Johnson, 2004). However, mice model 
studies of the effects of IL-6 on learning and memory have shown that the effects of this 
cytokine are complex and dependent on age, with both very low levels and excessive levels 
impairing cognition (Braida et al., 2004; Heyser et al., 1997). These findings are reflective of 
the requirement that inflammatory signalling be tightly controlled; baseline levels of 
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signalling are required for normal function, but dysregulated inflammation has pathological 
outcomes. 
 
 
The signalling pathways initiating, controlling and fine-tuning inflammation are complex. 
However certain key players have been identified which sit at nodes or intersections of these 
pathways and have particularly strong associations with the cognitive dysfunction associated 
with surgery. The high-mobility group box-1 chromatin protein (HMGB1) has a pivotal role 
in inflammatory pathways. The post-surgical environment of elevated cytokines and 
oxidative stress drives both the release and activation of HMGB1 in humans (Manganelli et 
al., 2010;) and in mice (N. Terrando et al., 2010; Niccolò Terrando et al., 2010). HMGB1 
then drives further inflammation, in a feed-forward mechanism which promotes further 
activation of inflammatory signalling pathways and the production of damaging oxidative 
molecules by inflammatory cells as demonstrated in both animal models (Lee et al., 2014); 
and in humans (Tang et al., 2011). HGMB1 can also promote long-term inflammation via 
promotion of immune cell proliferation and maturation (X.-M. Zhu et al., 2009). 
 
 
The pivotal role of this cytokine as a driver of systemic inflammation is highlighted by 
clinical evidence that levels of HMGB1 after surgery are predictive of the degree of post- 
surgery inflammation and morbidity over the short and long term (Kornblit et al., 2008; Suda 
et al., 2006; Takahata et al., 2011). Clinical and animal studies have demonstrated that 
elevations of HGMB1 post-surgery are associated with poor performance on cognitive tasks 
in both mice (R.-L. Li et al., 2013); and in humans (Lin, Wang, Chen, Hu, & Ouyang, 2014). 
Critically, levels of this inflammatory molecule are mechanistically linked with the 
development of POCD. In a landmark experiment, a single peripheral administration of 
HMGB1 induced cognitive deficits in a mice model (Vacas, Degos, Tracey, & Maze, 2014). 
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Furthermore, administration of an antibody neutralising HMGB1 prevented the cognitive 
decline associated with surgery and reduced the circulating inflammatory cytokine burden 
(Vacas et al.). These findings emphasise the central role of this factor in regulating post- 
surgical inflammatory responses and consequential cognitive deficits. Notably, in other 
animal studies, elevated expression of HMGB1 was observed not only in the periphery, but in 
the hippocampus, an area of the brain associated with memory functions (Li et al., Lin et al.) 
Both surgery and anaesthesia induce elevations in HMGB1 expression in the hippocampus in 
conjunction with the development of cognitive deficits (He et al., 2012). This raises the 
important question of the mechanisms by which alterations in peripheral inflammatory 
signals can impact on CNS function and therefore cognition. 
 
CNS inflammation 
 
The central nervous system was classically thought to be impervious to peripheral 
inflammatory factors, due to the existence of the blood brain barrier (BBB) and paucity of 
lymphatic drainage, although the recent discovery of a brain lymphatic system has challenged 
this assumption (Iliff, Goldman, & Nedergaard, 2015; Louveau et al., 2015). The BBB does 
tightly regulate the transit of inflammatory factors, cells and other substances into the CNS, 
and also monitors the peripheral environment. However, peripheral inflammatory states can 
compromise the integrity of the BBB, allowing for increased entry of inflammatory factors. 
Surgery and anaesthesia both induce blood-brain barrier dysfunction which may be driven by 
peripheral inflammatory factors such as HMGB1 but may also encourage further CNS 
expression of inflammatory cytokines (He et al., 2012). 
Considerable evidence from preclinical models demonstrates that elevated inflammatory 
cytokines in the periphery are a well-documented contributor to neuroinflammation via their 
capacity to disrupt blood brain barrier integrity (Cibelli et al., 2010; Terrando 2010a, 2010b, 
Poon, Ho, Chiu, Wong, & Chang, 2015). The activation and dysfunctional activity of 
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endothelial cells in the BBB in response to peripheral inflammatory stimuli is now considered 
to be the initial event in the development of neuroinflammation (X. Zheng et al., 2014). Pro- 
inflammatory cytokines can transverse the BBB directly using specific receptors and 
transporters on the surface of BBB endothelial cells (Pan et al., 2011). These inflammatory 
mediators can also gain access to the CNS via the circumventricular regions where the BBB 
is either absent or discontinuous. Markers of BBB dysfunction are elevated post-surgery, and 
are associated with both peripheral and central inflammation in animals (He et al., 2012); and 
in humans (Bromander et al., 2012). 
 
 
Increased levels of inflammatory markers in the CSF following surgery, including IL-6, 
TNFα and HMGB1, have been repeatedly observed in both cardiac and non-cardiac surgery 
(MacLullich et al., 2011; Reinsfelt et al., 2012; Tang et al., 2011; Woiciechowsky et al., 
1997). Importantly, such elevations have been directly associated with cognitive dysfunction 
in humans (Barrientos, Frank, Watkins, & Maier, 2012;) and mouse models Cibelli et al., 
2010;; K. Ji, Akgul, Wollmuth, & Tsirka, 2013; K. Ji, Miyauchi, & Tsirka, 2013), suggestive 
of a link between peripheral and central inflammation driving neurocognitive dysfunction. In 
the CNS, inflammation is mediated by the action of glial cells, to which we turn. 
 
Glial activation 
 
Microglia are the resident immune cells of the CNS and have a lineage similar to peripheral 
macrophages. Microglia have the capacity to modulate rearrangement of surface molecules 
mediating cell-cell and cell-matrix interactions, as well as releasing multiple factors and 
compounds with proinflammatory, immunoregulatory and oxidative effects (Kettenmann, 
Hanisch, Noda, & Verkhratsky, 2011). Microglia express specialised receptors for 
inflammatory signals such as bacterial endotoxin or endogenous ligands such as HGMB1, in 
particular the toll-like receptor 4 (TLR-4) (I.-D. Kim & Lee, 2013; J.-B. Kim et al., 2006). 
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The elevation of peripheral inflammatory factors induced by surgery prompts microglial 
morphology changes and upregulation of TLR-4 (F. Wang, 2014). Activated microglia 
themselves produce cytokines, resulting in de novo production of a range of inflammatory 
factors in areas of the CNS, in particular but not restricted to the hippocampus. These factors 
include TNFα, IL-1, IL-6, oxidative species and other signalling molecules (Norden & 
Godbout, 2013). 
 
 
Astrocytes are numerically the dominant CNS glial cell. The astrocytic protein S100β (S100 
calcium binding protein β) is highly abundant in the brain and serves key roles in multiple 
homeostatic and damage/infection associated processes, through both autocrine and paracrine 
signalling (Donato et al., 2013). Although this protein is expressed by some selected cells in 
the periphery, peripheral circulating levels of S100β are a key potential biomarker of CNS 
stress (Michetti et al., 2012; Sun & Feng, 2013). 
 
 
At low levels, S100β acts as a neurotrophic or supportive factor (Arcuri, Bianchi, Brozzi, & 
Donato, 2004). However, elevations of this protein can drive neurotoxic pathways, via a 
number of mechanisms. S100β may induce direct neuronal damage (Fano’ et al., 1993; Sorci 
et al., 2010), or activate both microglia and astrocytes (Petrova, Hu, & Van Eldik, 2000; 
Bianchi et al., 2007; Hu et al., 1997) and induce microglial oxidative species production 
(Adami, Bianchi, Pula, & Donato, 2004). When viewed as a whole there is considerable in 
vitro evidence that high levels of S100B have a causative role in the development and 
maintenance of neuroinflammation (Bianchi, Adami, Giambanco, & Donato, 2006; Bianchi, 
Kastrisianaki, Giambanco, & Donato, 2011) operating through similar receptors to HMGB1 
(Han, Kim, & Mook-Jung, 2011; R.-L. Li et al., 2013; Ryckman, Vandal, Rouleau, Talbot, & 
Tessier, 2003). 
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Peripheral inflammation, microglial activation, and microglial cytokine production are 
temporally and spatially correlated with the development of cognitive dysfunction in animal 
models (Wang et al., 2012; and Wang, 2014). This finding has been corroborated in several 
animal models of surgery-induced cognitive changes (Hovens et al., 2014, 2015). 
Interestingly these cognitive deficits, hippocampal microgliosis and cytokine expression 
associated with peripheral surgery could be ameliorated by administration of the non- 
selective inflammatory inhibitor ibuprofen, as suggested by mice models (Xu et al., 2014). 
Cognitive deficits after surgery could also be ameliorated by blockade of TNFα, a key player 
in inflammatory cascades (Terrando et al., 2010a). This was associated with suppressed 
microgliosis in the hippocampus and reduced peripheral and central inflammation in mice. 
Similarly, experimentally-induced peripheral inflammation induced hippocampal microglial 
activation was correlated with HMGB1 production and cognitive dysfunction, and this could 
be prevented by treatment with inhibitors of IL-1 signalling (Terrando, 2010b). 
 
 
Peripheral surgery is known to induce elevations of both CSF and serum S100β, and these 
have been correlated with neuropathological processes in humans (Reinsfelt et al., 2012). 
Multiple clinical studies have documented an association between serum S100β and impaired 
cognitive function after various surgery types (Bayram et al., 2013; Wang, 2014) and studies 
using narrower definitions of POCD have replicated this finding (LI et al., 2012; Linstedt et 
al., 2002). Preclinical studies show that S100β, HGMB1 expression and astrocyte 
morphological changes occur in concert with cognitive dysfunction after experimental 
surgical procedures (Li et al., 2013). A recent meta-analysis examined the association 
between S100β levels in the periphery and the development of POCD and confirmed that 
elevated levels of S100β post-operatively were strongly associated with POCD in humans 
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(Peng, Xu, & Ouyang, 2013). These data further reinforce both the hypothesis that POCD 
involves disordered CNS inflammatory signalling but also that peripheral levels of factors 
such as S100β can be used as potential biomarkers of cognitive dysfunction associated with 
inflammatory mechanisms. 
 
Oxidative stress in the CNS 
 
Production of reactive oxygen species is intrinsic to a variety of processes occurring during 
surgery (e.g. tissue trauma and wound healing) in addition to being a consequence of the 
inflammatory reaction peri- and post-surgery (Fu et al., 2014). Elevated levels of reactive 
oxygen species and markers of oxidative damage, along with depleted antioxidants have 
repeatedly been reported post-surgery in animal (Ko, Isoda, & Mobbs, 2015; Kotzampassi et 
al., 2009); and human studies as summarised in the review by Tsai et al., (2010). 
 
 
Peripheral oxidative stress may induce or exacerbate neuroinflammation via dysregulation of 
BBB integrity (Abdul-Muneer, Chandra, & Haorah, 2014). Damage to the BBB may also 
induce release of cytokines and oxidative species into the brain. The activation of the 
endothelium may also provoke microcirculatory dysfunction ultimately leading to 
compromised cerebral perfusion (Taccone et al., 2010). However, inflammation in the CNS 
is a major driver of the local production of oxidative species, primarily through microglial 
activation. Activated microglia release reactive oxygen species and nitric oxide along with 
pro-inflammatory cytokines, together providing a toxic milieu in which neuronal function is 
compromised (Heneka, Kummer, & Latz, 2014). Activated microglia and neurones may 
become entwined in a degenerative positive feedback loop, in which release of HMGB1 from 
activated microglia and damaged neurones promotes release of oxidative species from 
microglia, further precipitating injury (H.-M. Gao et al., 2011). Redox homeostasis may also 
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modulate microglial function in an autocrine manner, potentiating feed-forward activation of 
microglia in an environment of oxidative stress (Rojo et al., 2014). 
 
 
The neuroinflammatory effect of surgery is emphasised by the observation that surgical stress 
raises the levels of brain nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, a 
key player in oxidative stress regulation, and that this was correlated with behavioural 
changes in mice (Zhang et al., 2015). Levels of oxidative species were also positively 
correlated with the severity of cognitive impairment in patients with major depressive 
disorder (Talarowska et al., 2011, 2012). Experimental models of POCD show elevated 
markers of oxidative damage to lipids and proteins in the hippocampus (An et al., 2012). 
Critically, the level of the key oxidative species nitric oxide following surgery is predictive of 
the development of cognitive dysfunction in humans (Harmon et al., 2005; Iohom et al., 
2004). 
 
Impact of inflammation and oxidative stress on neuronal integrity & 
signalling 
 
Although multiple brain regions are involved in cognitive processes, the role of the 
hippocampus in many of the processes underpinning learning and memory formation is 
particularly well established (Epp, Chow, & Galea, 2013; K. Z. Tanaka et al., 
2014). This region of the brain also arguably contains the largest number of cytokine 
receptors (Gemma, Fister, Hudson, & Bickford, 2005; Parnet et al., 1994). In particular, the 
hippocampus contains the highest density of receptors for IL-1, and whilst physiological 
levels of this cytokine are essential for optimal memory and learning processes, excessive 
levels have been associated with diminished cognitive function in animal models (J. Chen et 
al., 2008; Rachal Pugh, Fleshner, Watkins, Maier, & Rudy, 2001). The hippocampus appears 
especially vulnerable to the detrimental effects of systemically elevated inflammatory 
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mediators such as HGMB1 due to the high density of the TNF-α receptor and numerous other 
receptors on the surface of endothelial cells in this region of the brain (Rothwell, Luheshi, & 
Toulmond, 1996). The mechanism underpinning impaired learning and memory resulting 
from excessive levels of IL-1 and other inflammatory mediators in the hippocampus involves 
detrimental effects on long term potentiation and neurogenesis in this region of the brain, as 
has been demonstrated in various animal models (A. J. Cunningham, Murray, O’Neill, 
Lynch, & O’Connor, 1996; Kelly et al., 2001; Vereker et al., 2001). 
 
 
Glutamate signalling is particularly important for the process of long term potentiation 
thought to underpin aspects of memory formation. Experimentally-induced peripheral 
inflammation fundamentally changes hippocampal neuronal activity, long-term potentiation 
and synaptic plasticity via modulation of glutamate receptors in rats (Riazi et al., 2015). 
Expression of the GluR2 subtype of glutamate receptor was decreased, leading to enhanced 
AMPA and NMDA mediated signalling. Mice genetically susceptible to inflammatory 
challenge through deficiency of a negative regulator of cytokine signalling show deficits in 
multiple cognitive domains and have impaired hippocampal long-term potentiation through 
pathways involving Il-1β, TNFα and HGMB1 (Costello et al., 2011). HMGB1 plays a critical 
role in modulating glutamatergic neuronal activity underlying cognitive function. HMGB1 
potentiates glutamate signalling through the NMDA receptor, and exacerbates glutamate- 
induced toxicity associated with degenerative processes (Balosso, Liu, Bianchi, & Vezzani, 
2014; Pedrazzi et al., 2012). 
 
 
Suppression of microglial activity abolished the effect of peripheral inflammation on 
hippocampal function, highlighting the key role of microglial-derived factors on the 
modulation of glutamate signalling and neuronal function. These findings were echoed in a 
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similar study which demonstrated that induction of peripheral inflammation promotes Il-1β 
production in the hippocampus and results in parallel decreases in glutamate release and 
long-term potentiation in mice (Di Filippo et al., 2013). Further evidence for the key role of 
glial inflammatory factors in the maintenance and modulation of hippocampal circuitry 
comes from a mice model study focussing on TNF-α (Stellwagen & Malenka, 2006). The 
level of this glial-derived pro-inflammatory cytokine was found to modulate the level of the 
AMPA form of glutamate receptor and thus fine-tunes the sensitivity of neurones to 
glutamate signalling. Inhibitory neurotransmission in the hippocampus is also compromised 
by neuroinflammation. Acute application of TNFα induces a persistent decrease of gamma- 
aminobutyric acid (GABA) receptors and a pervasive dysregulation of this important 
component of synaptic plasticity regulation (Pribiag & Stellwagen, 2013). 
 
 
Astrocytes, and to some extent microglia, also have the capacity to modulate availability of 
the key neurotransmitter glutamate. This facilitates the balance required between glutamate 
availability for signalling processes and prevention of the excessive levels associated with 
excitotoxicity. The expression of specific glutamate transporters on the astrocyte surface are 
regulated by cytokine stimulation, with the pro-inflammatory cytokine TNFα upregulating 
glutamate transporters on cultured astrocytes (Dumont, Goursaud, Desmet, & Hermans, 
2014). Infiltration of activated T cells into the CNS provokes glutamate release from 
microglia via a different subtype of glutamate transporter (Evonuk et al., 2015). Together this 
suggests that altered glutamate availability, in addition to glutamate receptor changes, may 
contribute to the changes in neuronal function and neuroplasticity observed in response to 
inflammation. 
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Microglia and astrocytes also actively regulate synaptic function via modulation of synaptic 
morphology and synaptogenesis ( Ji, Akgul, et al., 2013; K. Ji, Miyauchi, et al., 2013). Key to 
this is the release of neurotrophic factors such as brain-derived neurotrophic factor (BDNF). 
BDNF is now well established as a key player in multiple aspects of neural plasticity, 
learning and memory in various animal models (Heldt, Stanek, Chhatwal, & Ressler, 2007; 
Lu, Nagappan, & Lu, 2014). Inflammation and cytokine expression levels modulate the 
production of BDNF (Derecki et al., 2010; Yirmiya & Goshen, 2011). Stimulation of the 
immune response via administration of bacterial lipopolysaccharide induces hippocampal 
cytokine production, depletion of BDNF and learning and memory deficits (S. Tanaka et al., 
2006). Intrahippocampal administration of Il-1β was shown to block the upregulation of 
BDNF required for learning (Barrientos et al., 2004). Importantly, inflammatory processes 
associated with surgery also result in decrements in BDNF. In an animal model of surgery, 
rats showed cognitive deficits which were spatially and temporally correlated with decreased 
BDNF, increased inflammatory cytokines in the periphery and brain, and increased 
microglial activity (Hovens et al., 2014). 
 
 
A key facet of microglial activity is their capacity to induce production and release of 
reactive oxygen and nitrogen species, which are essential for the immune response to 
infection but in the context of prolonged activation, have deleterious effects on brain 
cytoarchitecture and neuronal function. Despite its high dependence on oxidative 
metabolism, the brain has relatively low levels of antioxidants and is vulnerable to oxidative 
stress. Microglia express 90% of brain glutathione, the main antioxidant species, which 
highlights both the centrality of these cells to oxidative processes in the CNS and the relative 
deficit of antioxidants in neurones (Rojo et al., 2014). In fact, circulating levels of glutathione 
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have been proposed to be a useful predictive biomarker of cognitive decline in patients with 
neurodegenerative disease (Revel et al., 2015). 
 
 
The role of inflammation-driven oxidative stress in neurodegenerative disease, and the 
centrality of this oxidative stress to pathophysiology has been the subject of much 
speculation. (Di Filippo, Chiasserini, Tozzi, Picconi, & Calabresi, 2010; Fischer & Maier, 
2015). For example, mice models have demonstrated that levels of the inflammatory cytokine 
TNF-α, which approximate those in the post-stroke brain, induce striking loss of neuronal 
integrity and function which was driven by dysfunction of mitochondria, the major source of 
oxidant species (Doll, Rellick, Barr, Ren, & Simpkins, 2015). However, more subtle 
dysregulation of inflammatory drive may also modulate the oxidative milieu of the CNS, and 
in turn alter neuronal function without inducing cell death. Elevation of the pro-inflammatory 
cytokine Il-1β in the CNS induces elevations of reactive oxygen species which are coupled to 
disruption of long-term potentiation, an element of neuroplasticity which is intrinsic to 
learning, memory and other aspects of cognition (Vereker et al., 2001). Oxidative stress may 
also be considered as a significant contributor. Oxidative stress is now seen as a key 
contributor to the cognitive decline associated with aging, and supplementation with anti- 
oxidants might ameliorate this process (Haxaire et al., 2012; Robillard, Gordon, Choi, 
Christie, & MacVicar, 2011). 
 
Potential contributions of anaesthetic agents to POCD 
 
In the surgical setting, the question of whether anaesthetic agents are contributors to 
cognitive dysfunction and underlying pathological processes is of particular importance. 
These agents penetrate the CNS and have direct activity on neuronal signalling and activity. 
It is therefore a question of some interest as to whether the changes in inflammatory and 
oxidative stress parameters associated with cognitive dysfunction can be attributed to surgical 
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procedures and their systemic consequences as outlined above, anaesthetic use or, perhaps 
most likely, a combination of the two. 
 
 
Anaesthetics used in surgery are a heterogeneous group of agents with differing 
pharmacological properties and mechanisms of action. In addition, studies of the effects of 
anaesthesia in the clinical setting are impeded by the confounding effects of the surgery itself. 
However, emerging evidence from pre-clinical studies suggests that anaesthetic use is, in 
isolation, a risk for cognitive dysfunction. Studies in aged mice suggest that isoflurane 
anaesthesia alone induced cognitive dysfunction, which was associated with microglial 
activation and CNS inflammation (F. Wang, 2014). These results are echoed by studies 
examining exposure to another volatile anaesthetic agent, sevoflurane, in which working 
memory impairments and alterations in proteins associated with synaptic plasticity and 
neuronal signalling were observed in rats (Ling, Ma, Yu, Zhang, & Liang, 2015). A recent 
study comparing epidural anaesthesia and general anaesthesia in elderly patients undergoing 
hip replacement demonstrated a higher risk of POCD in patients receiving general 
anaesthesia, which was associated with elevations of circulating amyloidogenic proteins (Shi 
et al., 2015). Similarly, poorer cognitive outcomes were observed following general 
anaesthesia as compared to epidural anaesthesia in an earlier study of hip and knee surgery 
(Pal et al., 2011).  Anaesthesia depth may also impact upon cognitive outcomes (Radtke et 
al., 2013; Short et al., 2015), with research suggesting lower bispectral index scores are 
associated with greater incidence of post-operative delirium, but not cognitive dysfunction in 
elderly surgical patients (Radtke et al). 
 
 
Both clinical and pre-clinical evidence suggests that the elevations in inflammatory and 
oxidative stress parameters observed following surgery may in part be attributed to the effects 
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of anaesthetic agents. When administered to aged animals, isoflurane induces significant 
upregulation of a number of pro-inflammatory cytokines and decrements in spatial memory 
skills (Li et al., 2013; Li et al., 2013). Conversely, very young mice were shown to be more 
susceptible to inflammation, microglial activation and cognitive dysfunction induced by 
general anaesthesia than adult (not aged) animals (Shen et al., 2013). Use of the anti- 
inflammatory agent parecoxib mitigated some of the cognitive deficit induced by general 
anaesthesia. 
 
 
There is contrary evidence regarding the aetiological role of general anaesthesia, with 
preclinical studies showing changes in S100B, HGMB1 expression and astrocyte morphology 
in concert with cognitive dysfunction after experimental surgical procedures, but not in an 
isoflurane anaesthesia control group (Li et al., 2013). The discrepancy between these studies 
may relate to the pathways being investigated, or methodological differences in isoflurane 
administration (i.e. duration of anaesthesia). 
 
 
Evidence that the type of general anaesthesia impacts on outcomes post-surgery is potentially 
suggestive of an aetiological role, though the nature and extent of this impact is far from 
clear. Elderly patients undergoing major surgery were found to experience a higher incidence 
of POCD following inhalational anaesthesia with sevoflurane than those who received 
intravenous propofol (Qiao et al., 2015). Importantly, this was associated with increased 
circulating levels of S100β and the proinflammatory cytokines TNFα and IL-6, which could 
be ameliorated by adjunctive treatment with the anti-inflammatory methylprednisolone. An 
aetiological role for anaesthesia in POCD was also evidenced in a study where patients 
(N=921) were randomly assigned to receive either bispectral index guided anaesthesia, 
associated with reduced anaesthetic exposure, or routine care. Guided anaesthesia was 
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associated with fewer patients with delirium (15.6% vs. 24.1%, P=0.01) and a lower rate of 
POCD at 3 months (10.2% vs. 14.7%, p=0.025) (Chan, Cheng, Lee, & Gin, 2013). 
 
 
Evidence from rat models also indicates that exposure to anaesthetics may also impair 
mitochondrial function and potentiate oxidative damage to neurones (Sanchez et al., 2011). 
Anaesthetic agents, particularly volatile anaesthetic agents targeting inhibitory GABA 
receptors, directly modulate neuronal signalling. Differences in GABA receptor affinity may 
underpin some of the variation between anaesthetic agents. Isoflurane, for example, 
depresses long-term potentiation and shifts the ability of neuronal synapses to respond to 
stimulation, which may contribute to cognitive impairment (Simon, Hapfelmeier, Kochs, 
Zieglgänsberger, & Rammes, 2001). Prolonged elevation of GABA receptor activity induced 
by general anaesthesia is associated with sustained impairments of cognitive function in 
mouse models (Zurek et al., 2014). Importantly, blockade of the oxidative damage induced 
by general anaesthetic agents by EUK-134 (a synthetic oxidative species scavenger) or 
pramipexole appears to prevent the development of cognitive impairment in the rat brain 
(Boscolo et al., 2012). Further, systemic inflammation can also modulate GABA receptor 
function and contribute to cognitive deficits, as observed in mouse models (Wang et al., 
2012). This suggests a mechanism by which both surgery and anaesthesia-induced 
inflammation may intersect with anaesthetic modulation of synaptic plasticity, a confluence 
of factors contributing to cognitive dysfunction. In addition, findings that surgical insults 
alone can induce significant inflammation and cognitive dysfunction in mice (Xu et al., 2014) 
highlight the likelihood that surgery and anaesthesia interact in a complex and synergistic 
manner to influence postoperative cognitive function. 
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Pre-existing risk factors for POCD 
 
POCD is far from a universal consequence of surgery, while neuroinflammation following 
even minor surgery appears to be a ubiquitous event. Hence while neuroinflammation is 
likely an essential element underpinning the development of POCD it is clearly not the sole 
driver. Other factors appear to be essential in the transition from ‘expected’ events post- 
surgery and enhanced neuropathology seen in patients with POCD. Pre-existing conditions or 
demographics may also act to decrease cognitive reserve; such as the presence of physical 
illness, frailty, lower education levels, history of alcohol or opiate use, and the presence of 
anticholinergic medication to risk post-operative cognitive change (Silbert et al., 2007; 2015; 
Wang et al., 2014b) (B. Silbert et al., 2015; B. S. Silbert, Scott, Evered, Lewis, & Maruff, 
2007; F. Wang, 2014). Nadelson et al. argue that the preoperative cognitive trajectory, the 
success of the surgery, and events in the perioperative period including ongoing pain have 
been argued to be the most important determinant of POCD (2014) and also make the point 
that cognitive decline will be observed in surgical patients if cognitive function is measured 
pre- and post-surgery if the patient is already on a trajectory of cognitive decline. 
 
 
One confounding factor that may be a significant contributor to the development of POCD is 
the presence of an abnormally potent and or prolonged neuroinflammatory response in a 
patient with pre-existing inflammatory pathology. For example, post-stroke patients have a 
significantly increased risk of developing POCD even without extensive neurological 
damage, due to the underlying inflammation pre-existing as part of the stroke event (Monk et 
al., 2008). Similarly, pre-existing metabolic syndrome is a recently confirmed risk factor in 
the development of POCD in both cardiac and non-cardiac patients (Hudetz et al., 2010; 
Hudetz, Patterson, Amole, Riley, & Pagel, 2011; Hudetz, Patterson, Iqbal, Gandhi, & Pagel, 
2011a, 2011b) which is of interest considering the role of systemic inflammation and 
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neuroinflammation in the development and pathological consequences of the illness (Cai & 
Liu, 2012; Purkayastha & Cai, 2013). 
 
 
Diabetes is also associated with an elevated inflammatory burden. In a study of patients with 
type-2 diabetes undergoing carotid endarterectomy, elevated pre-operative levels of C- 
reactive protein and monocytes were predictive of a higher risk of cognitive dysfunction post- 
surgery (E. J. Heyer, Mergeche, Bruce, & Connolly, 2013). These pathways have been 
further explored in animal models of metabolic syndrome, in which mice selectively bred for 
poor metabolic function were more susceptible to post-operative cognitive dysfunction (Su et 
al., 2012). This was associated with an elevated inflammatory milieu as measured by several 
different parameters, which appeared to be suggestive of a diminished capacity for resolving 
inflammation. 
 
 
Advancing age is another well documented risk factor which is in itself noteworthy as levels 
of circulating inflammatory markers generally increase with age. Neuroinflammatory 
responses to peripheral stimuli also change with age, and this may be important for cognition 
and memory (Barrientos et al., 2012; Dilger & Johnson, 2008). There is now evidence that 
microglia become highly reactive or ‘primed’ with age, in a similar manner to that observed 
in mild cognitive impairment or Alzheimer's disease (Cunningham, 2012; Norden & 
Godbout, 2013; Perry & Teeling, 2013). This primed state sets the scene for an exaggerated 
neuroinflammatory response following activation, with increased intensity and duration of 
microglial activation and cytokine production in the brain (Corona, Fenn, & Godbout, 2011; 
Godbout, 2005; Ritzel et al., 2015; Wynne, Henry, & Godbout, 2009). The link between 
these elevations in neuroinflammation and cognitive dysfunction has been illustrated in 
several experiments in which either peripheral experimentally induced inflammation or 
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surgical procedures precipitate much more florid microgliosis and cytokine expression, along 
with more pronounced cognitive changes, in old versus young mice (J. Chen et al., 2008; Xu 
et al., 2014). Importantly, these effects were restricted to aged mice receiving surgery under 
anaesthesia, and not to those receiving anaesthesia alone (Li et al., 2013). 
 
 
It is also of interest that there is a body of evidence suggesting that surgery accelerates the 
development of Alzheimer’s disease (AD) or worsens its severity in some patients (Bohnen, 
Warner, Kokmen, & Kurland, 1994; Fong et al., 2009; T. A. Lee, Wolozin, Weiss, & Bednar, 
2005), although the latter finding is not universally replicated (Avidan et al., 2009) and 
alternate biomarkers such as the ratio of amyloid-β to tau in cerebrospinal fluid have been 
proposed (Xie et al., 2013). Fluctuations of perioperative amyloid-β to tau ratios are 
predictive of verbal and visual memory dysfunction in AD (Xie et al., Ji et al., 2013) but this 
hypothesis cannot be applied to POCD without additional high quality research. Meta- 
analysis appears to show no association between exposure to general anaesthetics and the risk 
of Alzheimer’s disease in humans, although there has been a paucity of high-quality studies 
(Seitz, Shah, Herrmann, Beyene, & Siddiqui, 2011). Nonetheless, the presence of mild 
cognitive impairment has been observed to be a possible risk factor for the development of 
post-operative cognitive dysfunction, which in some studies has been correlated with higher 
levels of inflammatory factors (Kazmierski et al., 2014; Oldham et al., 2015; Veliz- 
Reissmüller, Torres, van der Linden, Lindblom, & Jönhagen, 2007). Interestingly the link 
between POCD and dementia and mild cognitive impairment may be under-reported as 
inclusion criteria for most studies are likely to exclude pre-existing diagnoses of 
neurocognitive impairment, and many cohorts could be considered healthier than a 
representative population of elderly surgical patients. 
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The presence of the ApoE allele has also been proposed as a risk factor for the development 
of POCD (Ely et al., 2007; E. J. Heyer et al., 2005; Leung et al., 2007), which may relate to 
the capacity for ApoE to regulate the intensity of microglial activation (Y. Liu et al., 2015) 
and pathways governing the magnitude of inflammation and its resolution (Laskowitz et al., 
2001). However, the association between ApoE genotype and postoperative cognitive 
changes has not been supported by all studies (Abildstrom, Christiansen, Siersma, & 
Rasmussen, 2004; B. S. Silbert, Evered, Scott, & Cowie, 2008; van Munster, Korevaar, de 
Rooij, Levi, & Zwinderman, 2007; Vasunilashorn et al., 2015), which is perhaps indicative of 
the complexity of genetic risk factors for both dementia and cognitive decline as a whole. 
Together these findings highlight the multilayered interactions between brain inflammatory 
signalling, glial activity, glutamate synaptic morphology and activity, long term potentiation 
and processes involved in cognition. Even in the non-injured or inflamed state, cytokines and 
neurotrophic factors have the capacity to modulate these processes, (Di Filippo et al., 2008; 
Yirmiya & Goshen, 2011) and therefore in states where the inflammatory drive is heightened, 
including the perioperative setting, there is increased potential for disruption of neuronal 
function and therefore cognitive dysfunction. 
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Figure 1 - Flowchart of the neuroinflammatory hypothesis of POCD 
 
 
 
 
 
The neuroinflammatory hypothesis of POCD provides a framework for potential intervention 
agents. The flowchart in figure 1 provides a descriptive mechanism for how peripheral 
trauma can feed forward into a cascade resulting in cognitive dysfunction, and each step is an 
opportunity to mitigate this potentiality. To date, neither preventative nor intervening agent 
has been established though a number of therapies have been investigated. A suitable 
effective treatment could also ameliorate the longitudinal sequelae of POCD. 
Novel therapies for POCD 
 
 
Parecoxib/COX-II Inhibitors 
 
Cyclooxygenase (COX) inhibitors, such as parecoxib and celecoxib, are a subtype of non- 
steroidal anti-inflammatory drugs (NSAIDs) routinely used as an intervention for 
inflammatory pain, including that experienced post-surgery (Derry & Moore, 2013). NSAIDs 
inhibit the production of the enzyme COX that acts as a precursor to vasodilator 
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prostaglandins. Selective COX-II inhibitors are a class of NSAIDs that specifically bind to 
the inflammatory COX-II isoform, and by interrupting the enzymatic conversion cascade 
secondary to COX-II production, ameliorate inflammatory pain (Mattia & Coluzzi, 2005). 
For this reason, a recent Cochrane review of clinical trials has suggested that COX-II 
inhibitors have demonstrated efficacy in the treatment and management of inflammatory 
arthritis and associated conditions (Kroon et al., 2015). 
 
 
The mechanism of COX inhibitors also reduces the activation of microglia and subsequent 
neuroinflammation (Choi, Aid, & Bosetti, 2009), and COX inhibitors are therefore routinely 
the subject of translational research into conditions associated with neuroinflammation, albeit 
with mixed results. A Cochrane review and meta-analysis for the use of COX-II inhibitors for 
Alzheimer’s disease found no evidence to suggest any significant positive effect, statistically 
or clinically (Jaturapatporn, Isaac, McCleery, & Tabet, 2012) a finding which has recently 
been replicated in a large scale RCT (ADAPT-FS research group, 2015). Similarly, evidence 
for the use of COX-II inhibitors as an adjunct or monotherapy for depression is extremely 
heterogeneous – studies showing significant improvement are roughly approximate in weight 
to studies showing no effect (Eyre, Air, Proctor, Rositano, & Baune, 2015). Meta-analysis 
showed that the use of celecoxib was efficacious in reducing the severity of positive and 
negative symptoms of schizophrenia, but only for first-episode schizophrenia participants as 
opposed to chronic participants (W. Zheng et al., 2017). However, beyond symptomology 
associated with psychiatric disorders, cognitive function appears to be a rarely examined 
outcome of COX-II inhibitor use. Some preclinical evidence suggests a cognitive protection 
effect in rats after traumatic brain injury, but controversy remains regarding the superiority of 
selective interventions for COX-I (Cernak, O’Connor, & Vink, 2002) or II (Girgis et al., 
2013) over placebo. In sum, there appears to be little support for the use of COX-II inhibitors 
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to treat chronic conditions, but research into acute inflammatory states may hold some 
promise. 
 
 
In humans, COX-II inhibitors are commonly used to treat post-operative pain, but the effect 
for post-operative cognition is rarely directly examined in research. As such, even though the 
existent evidence appears quite positive for the cognitive protection effect of COX-II 
inhibitors, the amount of evidence is quite small. For example, in a large (n = 1062) double- 
blind randomized control trial, Langford et al., (2009) demonstrated that the use of 
perioperative parecoxib and valdecoxib was associated with significantly lower rates of 
opioid-related confusion and concentration difficulties after major non-cardiac surgery, but 
this appeared to equalize at approximately four days post-surgery. In addition, confusion and 
concentration difficulties were approximated using patient self-report rating scales for 
descriptions of severity and duration rather than objective measures, which complicate 
comparisons with other studies. 
 
 
By comparison, Y.-Z. Zhu, Yao, Zhang, Xu, and Wang, (2016) compared post-operative 
cognitive performance on 122 elderly patients undergoing total knee arthroplasty at 7 days, 
and 3 months post-surgery, using a battery of neuropsychological tests across a range of 
cognitive domains. Participants were randomised to receive additional parecoxib or saline 
after administration of general anaesthesia, and while cognitive performance at POD7 was 
significantly better in the parecoxib group compared with controls, though there was no 
difference at 3 months. Crucially, this convergence in performance appears to be driven by an 
improvement in performance among the control group at 3 months, rather than a delayed 
decline for the parecoxib group. To date, only one new study appears to be examining the 
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cognitive effect of NSAIDs after surgery (NCT02689024), and appears to be focussed mainly 
on delirium incidence. 
 
Statins 
 
Statins are used to treat high cholesterol in humans. As the product of an enzymatic reaction 
cascade, cholesterol production is in part rate-limited by the production of mevalonic acid, 
which is itself rate-limited by conversion of the enzyme 3-hydroxy-3-methylglutaryl-CoA 
reductase (HMGCR). Statins work by inhibiting conversion of HMGCR into mevalonic acid 
through competitive binding of the active site of the enzyme (Friesen & Rodwell, 2004). It is 
by intervention into this melavonic pathway that statins are also purported to moderate 
inflammation. NADPH reduces HMGCR into mevalonic acid as part of cholesterol 
production, and is associated with the production of phagocytic ROS. Statins inhibit the 
HMGCR conversion process resulting in downregulation of NADPH production, and the 
subsequent production of oxidative species (Margaritis, Channon, & Antoniades, 2014). 
Statins have been widely researched as potential interventions for myriad of conditions, 
particularly those with cognitive sequelae. In 2012 the FDA warned of potential cognitive 
dysfunction after use of statins, though more recent safety reviews have found little evidence 
to support this, and conversely suggest a potential cognitive protective effect in some 
conditions (Mospan, 2016; Ott et al., 2015). However, the evidence for the use of statins for 
cognitive change associated with neurological conditions is promising but ultimately 
controversial. For example, a recent Cochrane review reported that statins do not appear to 
prevent or treat dementia (McGuinness, Craig, Bullock, & Passmore, 2016). However, 
McGuiness and colleagues limited included articles to only RCTs with a sample aged over 65 
years where a statin was administered for at least 12 months, which limited the available 
evidence to two (albeit large) RCTs. By contrast, an earlier systematic review and meta- 
analysis examining the use of statins for both short and long term cognitive function reported 
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a 29% reduction in long-term dementia incidence compared with controls (Swiger, Manalac, 
Blumenthal, Blaha, & Martin, 2013). However, the review by Swiger and colleagues 
allowed the inclusion of less controlled studies and included considerable heterogeneity 
across administration regimen, dosage, and duration, as well study design and sample 
characteristics. The clinical efficacy for the use of statins to treat neurological conditions 
appears to remain theoretical in the absence of more definitive evidence (Malfitano et al., 
2014). 
 
 
Research examining the use of statins to moderate acute neuroinflammatory states is 
promising but appears relatively undeveloped as a field. For example, in a systematic review 
of preclinical data, W. Peng et al., (2014) suggested that statins appeared to be particularly 
effective in protecting memory function after closed-head TBI in rodent models, though little 
cognitive data is available from clinical studies and so the translational potential has not yet 
been realised (Wible & Laskowitz, 2010). Similarly, the post-operative cognitive impact of 
pre and perioperative statins remains largely unexplored, with only a handful of non- 
randomised trials published. The evidence that is available is inconsistent – two retrospective 
analyses and one smaller non-randomised prospective study reported conflicting findings. For 
example, Mathew et al., (2005) observed no apparent impact of perioperative statins on 
cognitive function 6 weeks post-operation with 440 elderly cardiopulmonary bypass patients, 
while a post-hoc analysis of 585 carotid endarterectomy patients revealed that the use of 
perioperative statins ameliorated morbidity associated with post-operative cognitive 
dysfunction to the same degree as patients who did not experience post-operative cognitive 
dysfunction (Heyer, Mergeche, Wang, Gaudet, & Connolly, 2015). However, due to the 
retrospective nature of these studies the impact of confounding variables cannot be estimated. 
By comparison, in a smaller non-randomised control trial Das, Nanda, Bisoi, and Wadhawan 
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(2016) compared the cognitive protection effect of statins after off-pump CABG. Both the 
statin and control group demonstrated significant memory dysfunction at 6 days post- 
operation in comparison with pre-surgical performance, but the severity and breadth of 
dysfunction was significantly greater for the control group. However, the absence of 
longitudinal follow-ups does not allow for direct comparison with the earlier retrospective 
analyses. 
 
Pregabalin 
 
Initially developed as an anticonvulsant, pregabalin is being used in the treatment of 
neuropathic pain and fibromyalgia (Toth, 2013). The antiepileptic mechanism for pregabalin 
is thought to involve binding to voltage-gated calcium channels on the presynaptic 
membrane, specifically the α2δ subunit (Schulze-Bonhage, 2012). This effectively limits the 
rate of proconvulsant neurotransmitter release, and subsequently restricts seizures. Pregabalin 
has demonstrated efficacy in reversing induced inflammatory hyperalgesia (Patel et al., 2001) 
and suppresses the edema, neuronal damage, bleeding, and inflammation resultant from 
traumatic brain injury in rats (Calikoglu et al., 2015). Clinical studies have shown efficacy in 
modulating pain associated with multiple sclerosis; post-herpetic neuralgia, peripheral nerve 
injury, radiculopathy, spinal cord injury, neuropathy, and post-stroke pain (Dunn, Durieux, & 
Nemergut, 2016, p. 201; Moore, Wiffen, Derry, & McQuay, 2009). 
 
 
Modulation of voltage-gated channels interferes with the activation of cytokine receptors, and 
may subsequently contribute to neurotoxicity and neuron hyper excitability (Pexton, Moeller- 
Bertram, Schilling, & Wallace, 2011; Vezzani & Viviani, 2015). The α2δ subunit voltage- 
gated calcium channel is prominently expressed in the hippocampus (Cole et al., 2005). By 
binding to the α2δ subunit, it has been proposed that pregabalin alters the release of 
neurotransmitters in the hippocampus, moderating microglia activation (Kawano et al., 
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2016), and downregulating subsequent cytokine production. Kawano and colleagues 
demonstrated that pre-operative pregabalin reduced hippocampal production of IL-1β and 
TNF-α and was protective of cognition in a rat model, while post-operative administration 
was ineffective on these outcomes. In a model of diabetic mice, 10mg/kg pregabalin 
significantly reduced levels of brain COX-II, glucose-transport type 4, cytosolic 
prostaglandin E synthase, and nuclear factor-κB expression compared with controls, and 
impaired but did not improve measures of learning (Sałat et al., 2016). 
 
 
In a rat model of cardiopulmonary bypass with deep hypothermic circulatory arrest (Shim, 
Ma, Zhang, Podgoreanu, & Mackensen, 2014), acute pre-operative administration of 
pregabalin (30mg/kg) preserved some indices of neurologic function compared with saline, 
though this did not translate to significant between-groups differences on the water-maze test 
of long-term spatial memory. Percentages of necrotic neurones were significantly reduced 
within the cerebral cortex for the pregabalin group, though no significant effect was detected 
within the hippocampus. In sum, pre-clinical evidence suggests a neuroprotective dose- 
response effect for pregabalin in inflammatory models, but the impact upon cognition is less 
clear. 
 
 
In humans, evidence for cognitive preservation is less well established. On the contrary, 
acute cognitive change is an established risk of pregabalin use (Zaccara, Gangemi, Perucca, 
& Specchio, 2011). In their meta-analysis, Zaccara and colleagues identified a dose- 
dependent relationship between pregabalin administration in clinical populations and acute 
confusional state and disturbance of attention, with positive correlation between dose and 
risk. However, despite the large number of clinical studies examining psychiatric and 
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cognitive symptoms associated with pregabalin administration, comparatively few studies 
directly examine and measure change within specific cognitive domains. 
Evaluation of the cognitive impact of pregabalin is complicated due to the heterogeneity of 
dose regimen across studies, though it is possible to observe a dose-response effect for 
cognition. For example, Hindmarch, Trick, and Ridout (2005) found mixed evidence of 
cognitive change after administration of 150mg TID for three days in a small sample of 
healthy adults. Small but significant dysfunction in attention, CNS arousal and subjective 
arousal was observed, while no significant changes to reaction speed, visual processing, and 
memory were detected. Comparatively, significant dysfunction to executive function and 
visual processing in healthy adults was associated with a larger dose of 600mg per day for 8 
weeks (Salinsky, Storzbach, & Munoz, 2010). By contrast, Myhre, Diep, and Stubhaug 
(2016) found no evidence of cognitive change in healthy adults after two 150mg doses of 
pregabalin, at 13 hours and 1 hour prior to testing respectively. However, the combination of 
remifentanil and pregabalin adversely impacted performance on cognitive tests beyond that 
of either drug in isolation, suggesting an interaction effect of pregabalin with other 
medications. 
 
 
Despite some promising pre-clinical data, the cognitive impairment witnessed in the clinical 
setting suggests it would not be a prime candidate for targeted exploration as an agent to 
protect against POCD. Given its increasing use in the perioperative setting for the treatment 
of acute neuropathic pain and in the prevention of chronic post-surgical pain, it would be 
useful to analyse any influence it does have on early and late cognitive function within 
studies examining POCD. 
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Dexmedetomidine 
 
Dexmedetomidine is a α2 receptor agonist, used as a sedative agent with analgesic properties 
(Dunn et al., 2016). In comparison with other α2 receptor agonists, dexmedetomidine is 
highly selective for the locus coeruleus in the brainstem, suppressing release of noradrenaline 
and adrenaline resulting in sedation purported to be akin to natural sleep (Giovannitti, Thoms, 
& Crawford, 2015; Nelson et al., 2003). The modulation of spinal noradrenaline and 
adrenaline is purported to be responsible for the analgesic properties of dexmedetomidine 
(Coursin, Coursin, & Maccioli, 2001; Funai et al., 2014; Yaksh, 1985). In vitro evidence 
suggests that dexmedetomidine mediates levels of inflammation in human whole blood (ex 
vivo) through the moderation of inflammatory cytokines induced by administration of 
lipopolysaccharide (Kawasaki et al., 2013), while administration of dexmedetomidine in rats 
was associated with increased vagal nerve activity and inhibited cytokine production (S.-T.  
Li & Wu, 2015; Xiang, Hu, Li, & Li, 2014). 
 
 
Pre-clinical evidence suggests that dexmedetomidine is effective in protecting against 
anaesthetic-induced cognitive impairment in a dose-dependent manner, though this is not a 
universal finding. In a model of neonatal rats exposed to isoflurane 0.75% for 6 hours, higher 
doses of dexmedetomidine (1, 10, and 25µg/kg respectively) were associated with greater 
levels of neuroprotection compared with controls, with a specific reduction in caspase-3 
induced apoptosis in the hippocampus, thalamus, and cortex (Sanders et al., 2009). High dose 
dexmedetomidine (25µg/kg) also preserved learning at 40 days post isoflurane exposure 
controls relative to isofluorane alone, and reversed neurotoxicity to pre-isoflurane exposure 
baseline levels in the hippocampus and thalamus, but not in the cortex. 
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In a similar investigation, Qian et al., (2015) reported that the pre-operative administration of 
25 µg/kg but not 15 µg/kg of dexmedetomidine was sufficient to protect against cognitive 
dysfunction induced by splenectomy accompanied by 1.5-2.0% isoflurane and 100mg/kg pre- 
operative ketamine in a rat model. By comparison, both 15 and 25 µg/kg dexmedetomidine 
significantly reduced Il-β and TNF-α mRNA and protein expression relative to controls. Qian 
and colleagues were also able to demonstrate that dexmedetomidine administration reduced 
hippocampal levels of the pro-apoptotic genes caspase-3 and BAX to attenuate neuronal 
apoptosis induced by anaesthesia and surgery trauma. Hippocampal protection of 10 µg/kg 
dexmedetomidine after laparotomy in rats, in comparison to the control group has also been 
observed in conjunction with preserved learning and memory function (Wan, Xu, & Bo, 
2014). 
 
 
However, the dose-response effect of dexmedetomidine and neurotoxicity secondary to 
inflammation may not adhere to a normal distribution. Sato, Kimura, Nishikawa, Tobe, and 
Masaki (2010) demonstrated that 100µg/kg of intraperitoneal dexmedetomidine alone was 
insufficient to protect against neurologic performance impairment 3 days after cerebral 
ischemia in rats, despite a statistically significant protective effect upon neuronal survival in 
the hippocampus compared with controls. However, the combination of dexmedetomidine 
and induced hypothermia after ischemia (body temperature cooled to a mean of 35°C) not 
only preserved hippocampal neuron survival, but also preserved neurological function scores 
3 days after ischemia. Dexmedetomidine alone was also ineffective for reducing caudate 
nucleus apoptosis, and only when combined with hypothermic treatment was caudate nucleus 
survival preserved. 
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Meta-analyses by B. Li, Wang, Wu, and Gao, (2015) and Man, Guo, Cao, and Mi, (2015) 
show that dexmedetomidine was superior to controls and comparative anaesthesia groups for 
reducing the risk of post-operative delirium in ICU patients, across a broad range of research 
methodologies and dose regimens. Additionally, the majority of included studies only 
included assessments of global cognition such as the Mini-Mental State Exam or the ICU- 
Confusion Assessment Method, potentially obscuring cognitive change in specific domains. 
For example, clinical evidence has shown that intra-operative administration of 
dexmedetomidine has shown promise in significantly reducing acute episodic delirium after 
cholecystectomy (Y. Li, He, Chen, & Qu, 2015) and carotid endarterectomy (Ge et al., 2016), 
with approximately comparable outcomes despite dexmedetomidine dose disparity; 1mg/kg 
for ten minutes followed by 0.4mg/kg/hour for the duration of surgery in Li and colleagues, 
and 0.3 µg/kg for ten minutes before anaesthesia followed by a continuous 0.3 µg/kg/hour 
until 30 minutes before surgery conclusion in Ge and colleagues. Both studies demonstrated 
marked reduction in inflammatory biomarkers; IL-1β, IL-6 and CRP (Li et al.,) and in S100B 
and the concentration of malondialdehyde but not neuron-specific enolase (Ge et al.). 
Interestingly, in both studies the dexmedetomidine group demonstrated significantly reduced 
rates of cognitive impairment at around 6 to 24 hours after surgery compared with the control 
groups, in which cognition tended to recover and approximate the dexmedetomidine groups 
at approximately days 3 to 4. In sum, the available evidence suggests that dexmedetomidine 
is a potentially effective protective agent for cognition in the early post-operative period, 
though the longitudinal impact of this protection is not yet widely examined. 
 
Lidocaine 
 
Lidocaine works by targeting specific voltage-gated sodium channels associated with 
neuropathic and inflammatory pain (Lauretti, 2008; Oliveira, Issy, & Sakata, 2010). 
Lidocaine allosterically couples with the channel to stabilise it in an inactive state (Amir et 
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al., 2006; Sheets & Hanck, 2003), effectively halting the transmission of action potentials 
from the administration site. 
 
 
Due to the capacity of lidocaine to suppress pain, it has been proposed that this agent may 
likewise reduce inflammatory responses. The majority of available research supports this 
hypothesis, with in vivo and in vitro evidence demonstrating a significant reduction in 
biological correlates of inflammation such as IL-6, & IL-8 in rabbits; TNF-α and IL-1β in 
mice and rats, and levels of IL-8 and CRP in humans after surgery (Caracas, Maciel, Martins, 
de Souza, & Maia, 2009; van der Wal et al., 2015). Reduction in biological correlates of 
inflammation in preclinical models has also translated to cognitive protection, including the 
attenuation of memory impairment after intraoperative lidocaine administration (Tan, Cao, 
Zhang, & Zuo, 2014) increased neuronal survival and cognitive protection after transient 
global ischaemia (Popp et al., 2011); and the attenuation of memory and learning sequelae 2- 
4 weeks after isoflurane exposure (D. Lin et al., 2012); all in rat models, and all with 
comparable lidocaine administration (1.5-2 mg/kg during the perioperative period). 
 
 
Clinical evidence for post-operative cognitive protection due to lidocaine is mixed (Bilotta et 
al., 2013). The majority of studies examine elderly cardiac patients, and typically use 1-1.5 
mg/kg loading lidocaine doses immediately prior to, or at the commencement of surgery, 
followed by maintenance until surgical conclusion (Bilotta et al.). Lidocaine administration in 
this fashion appears to provide neuroprotection early in the post-operative period (Mitchell et 
al., 2009; D. Wang et al., 2002), but does not appear to be associated with longer-term 
outcomes (Mitchell et al.; Mathew et al., 2009). For example, cardiac artery bypass surgical 
patients were administered 1.5 mg/kg lidocaine immediately after surgical incision, and 
maintained at 4mg/min for the duration of the procedure and post-operative cognitive 
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outcomes were compared with a control group that was given saline. Both groups 
experienced significant levels of cognitive dysfunction at 9 days after surgery with significant 
decreases to executive function, processing speed, short-term memory, and visuospatial 
motor function compared with pre-surgical performance; while working memory and verbal 
associative learning were preserved in the lidocaine group (D. Wang et al.). 
 
 
Lidocaine for neuroprotection in non-cardiac patients is less extensively examined, and may 
be similarly controversial. In an examination of urologic and orthopaedic patients, Heidari, 
Rahavi, and Hashemi, (2013) found no difference in post-operative cognition as measured by 
the MMSE in the first 24 hours between a 1.5 mg/kg lidocaine bolus-and-maintenance treated 
group compared with saline controls; while K. Chen, Wei, Zheng, Zhou, and Li, (2015) 
found that intravenous 1 mg/kg bolus followed by 1.5 mg/kg maintenance lidocaine was 
neuroprotective in elderly spinal surgery patients. At 3 days after surgery, the lidocaine group 
had significantly lower levels of S100B, malonaldehyde, and NSE compared with controls, 
while the levels of TNFα were unchanged in either group. Post-operative cognition at day 3 
was showed a small but significant decline in the control group compared with baseline 
function, whereas cognition in the lidocaine group was preserved. More recently, Y. Peng et 
al., (2016) demonstrated that perioperative lidocaine did not confer greater cognitive 
protection from neurological compromise in patients following supratentorial tumour 
removal at any stage up to 6 months after surgery, compared with saline controls, though 
brain oxygen consumption and metabolism was significantly lower throughout surgery in the 
lidocaine group and this is a neurologically compromised group. 
 
Ketamine 
 
Ketamine is a common anaesthetic agent with hypnotic, analgesic, and amnesiac properties, 
shown to be an NMDA receptor antagonist (M. Gao, Rejaei, & Liu, 2016). At sub-anaesthetic 
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doses, ketamine can be used to manage chronic neuropathic pain (Zgaia et al., 2015). 
Ketamine has been shown to moderate inflammatory macrophage activation and production 
of cytokines including IL-1β, IL-6 and TNF-α in both preclinical and clinical models (De 
Kock, Loix, & Lavand’homme, 2013; F.-L. Liu, Chen, & Chen, 2012). As a glutamate 
antagonist, ketamine has also been purported to potentially ameliorate depressive symptoms 
associated with excessive glutamate levels, as observed in a number of clinical trials 
(DeWilde, Levitch, Murrough, Mathew, & Iosifescu, 2015). Subsequent upregulation of 
BDNF and mammalian target of rapamycin (mTOR) in the prefrontal cortex after ketamine 
administration may promote synaptogenesis in preclinical models, along with cognitive 
protective effects (Y. Lee et al., 2016). X. Zhu et al., (2015) demonstrated that administration 
of 100mg/kg ketamine reversed upregulation of IL-β, TNF-α and amyloid- β after 
electroshock therapy in a rat model, and attenuated associated memory dysfunction. 
Reversing the upregulation of amyloids suggests that ketamine may show therapeutic 
promise for management of neurodegenerative disorders. A study by Murman et al., (1997), 
was able to demonstrate in a small pilot that patients with Huntington’s disease did not 
appear to be more susceptible to cognitive change due to ketamine infusion compared with 
controls, but this area is not well explored. 
Few human studies have directly examined perioperative ketamine administration for 
protection of post-operative cognition. Mortero et al., (2001) demonstrated that a 
combination of propofol and ketamine (mean dose: 3.7 µg/kg) significantly improved post- 
operative cognition in a non-cardiac sample in comparison to propofol alone. Hudetz et al., 
(2009) and Nagels et al., (2004) both examined elderly cardiac surgery patients, but with 
differing ketamine regimens and inconsistent cognitive effects. Nagel and colleagues 
administered a 2.5mg/kg bolus prior to surgical commencement and maintained this infusion, 
whereas participants in Hudetz and colleagues were administered a single 0.5mg/kg bolus at 
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induction. Hudetz and colleagues were able to demonstrate a significant protective cognitive 
effect at one-week post-surgery, while Nagels and colleagues found no effect at either one or 
ten weeks with the exception of improved performance on a single outcome for the ketamine 
group. 
 
Minocycline 
 
Minocycline is a tetracycline antibiotic typically used in the treatment of acne, and has shown 
anti-inflammatory and microglial inhibitory properties (Dean, Data-Franco, Giorlando, & 
Berk, 2012; Garner et al., 2012). Minocycline is highly fat soluble and is able to easily cross 
the blood-brain barrier (Garrido-Mesa, Zarzuelo, & Gálvez, 2013). Substantial evidence from 
animal models demonstrates the potential of minocycline as an adjunct therapy in managing 
neurodegenerative disease (Garrido-Messa et al.). In vitro evidence suggests that the 
therapeutic mechanism of minocycline relates to its anti-inflammatory and microglial 
inhibitory effects (Karachitos, Solis Garcia del Pozo, W.J. de Groot, Kmita, & Jordan, 2012; 
H.-S. Kim & Suh, 2009). Specifically, it has been proposed that minocycline to reduce the 
excitoxicity resultant from increased production of glutamate, mediating the subsequent 
production of mitochondrial ROS and associated neurodegeneration (Karachitos et al.). The 
potential for pro-cognitive effects of minocycline is further evidenced by the capacity of this 
drug to regulate long-term potentiation and glutamatergic function via modulation of 
microglial inflammatory cytokine production (S.-Y. Li et al., 2013; Riazi et al., 2015). 
Clinical evidence for minocycline as a pro-cognitive agent is promising but mixed, with few 
placebo-controlled trials to date. Grieco et al., (2014) demonstrated a significant cognitive 
improvement in children with Angelman syndrome through open-label administration of 
minocycline, with medium-to-large effects upon communication and language 
comprehension, at doses of 3mg/kg BID for 16 weeks; positive effects of comparable size 
were observed in an open-label trial of minocycline for Fragile X syndrome (Paribello et al., 
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2010). Open-label adjuvant administration of 100mg of minocycline each day for 2 years 
appeared to significantly delay the progression of cognitive and motor decline in patients 
with Huntington’s disease (Bonelli, et al., 2004). Evidence from placebo-controlled trials is 
less encouraging; Nakasujja et al., (2012) and Sacktor et al., (2011) both found that the 
administration of 100mg of minocycline orally every 12 hours for 24 weeks did not attenuate 
cognitive dysfunction associated with HIV in humans when compared with placebo, and later 
examination of the biomarkers of oxidative stress revealed limited positive change in 
minocycline patients in comparison with placebos (Sacktor et al., 2014). Interestingly, 
minocycline may actually promote CNS apoptosis in the brain of adolescents and children via 
exacerbation of synaptic pruning (Inta, Lang, Borgwardt, Meyer-Lindenberg, & Gass, 2016; 
Na, Jung, & Kim, 2014); suggesting that the effects of minocycline in the developing brain 
may differ from those observed in the adult. 
 
 
Given the putative neuroinflammatory hypothesis of POCD and similarity with other 
conditions associated with neuroinflammation, it is possible that minocycline may have 
potential for the prevention and treatment of POCD. Pre-clinical evidence suggests that 
minocycline is effective in reducing the severity of post-operative cognitive dysfunction, 
purportedly via anti-inflammatory mechanisms. For example, H.-L. Wang, Liu, Xue, Liao, 
and Fang, (2016) examined minocycline for reducing post-operative cognitive dysfunction in 
aged mice, with mice separated into control, minocycline, isoflurane, minocycline + 
isoflurane, surgery, or minocycline + surgery. All minocycline was administered at 45 mg/kg 
12 hours before surgery or isoflurane exposure, with isoflurane at 1.4% concentration in 50% 
oxygen for 2 hours. Mice who received isoflurane or surgery without minocycline 
demonstrated significantly increased levels of IL-β, TNF-α, and TNF-γ as well as 
significantly impaired processing speed and learning compared with controls. Pre-treatment 
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with minocycline attenuated these differences substantially. The findings of Wang and 
colleagues support earlier findings documenting the capacity of minocycline to alleviate 
surgery and anaesthesia-induced cognitive deficits via anti-inflammatory mechanisms in 
rodent models (Jin et al., 2013; Kong et al., 2013; S.-Y. Li et al., 2013; Tian, Guo, Wu, Ma, 
& Zhao, 2015). Similarly, in transgenic models of Alzheimer’s disease (Biscaro, Lindvall, 
Tesco, Ekdahl, & Nitsch, 2012) and animal models of amyloid angiopathy-related cognitive 
dysfunction (Fan et al., 2007), minocycline demonstrated significant pro-cognitive effects 
which were correlated with anti-inflammatory rather than anti-amyloid effects. Minocycline 
has also been shown to alleviate age-related cognitive deficits via modulation of microglial 
activation in aged and adult mice (Kohman, Bhattacharya, Kilby, Bucko, & Rhodes, 2013). 
The protective effects of minocycline appear to be dose-dependent in mice; Z. Li et al., 
(2016) found significant post-operative spinal microglia and macrophage inhibition with 
0.05mg/kg minocycline for 14 days, but not within the prefrontal cortex. 
 
N-acetylcysteine 
 
N-acetylcysteine (NAC) is a widely available supplement, and is FDA approved for a number 
of indications, including paracetamol overdose. Additionally, NAC is used to assist in the 
management of bronchitis and COPD. NAC is a bioavailable precursor for glutathione, and 
acts to reduce systemic markers of inflammation and suppress mitochondrial dysfunction. 
NAC thus appears to target many of the cellular processes implicated in cognitive 
dysfunction. Substantive evidence from multiple pre-clinical pathological models indicates 
that NAC exerts protective effects via anti-inflammatory activity. In vitro evidence has 
shown that NAC has the capacity to downregulate pro-inflammatory cytokine production and 
downstream signalling pathways, including critical pro-inflammatory cytokines such as IL-6 
and HGMB-1 (Gabryel, Bielecka, Bernacki, Łabuzek, & Herma, 2011) in multiple tissue 
types (Y.-H. Lee et al., 2014b; Usatyuk et al., 2003; C. Wang et al., 2015). NAC also 
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suppresses the transcription and activity of TLR-4 and similar key receptors in the 
inflammatory system (Hou et al., 2012). Interestingly, evidence from clinical studies suggests 
that NAC also increases the production of anti-inflammatory cytokines, notably IL-10, IL-4 
and IL-1 (Santiago et al., 2008). Strong preclinical evidence from rat models also 
demonstrates that NAC reduces the reactivity of microglia (Amar Karalija, Novikova, 
Kingham, Wiberg, & Novikov, 2012), their level of activation (Berman et al., 2010) and the 
levels of cytokines and reactive oxygen species released following the activation of these 
glial cells (B. Wang, Navath, Romero, Kannan, & Kannan, 2009). This in turn reduces 
damage to neuronal cells due to inflammatory processes (A. Karalija, Novikova, Kingham, 
Wiberg, & Novikov, 2014). 
 
 
A series of studies have reported improvements in cognitive function in animals with induced 
traumatic brain injury following NAC supplementation (Eakin et al., 2014; Günther et al., 
2015). These studies indicate that suppression of inflammation and microglial activation may 
be key to the therapeutic response to NAC (G. Chen, Shi, Hu, & Hang, 2008; Nazıroğlu, 
Şenol, Ghazizadeh, & Yürüker, 2014a; Şenol, Nazıroğlu, & Yürüker, 2014). NAC acting as a 
glutathione precursor can reduce the evoked oxidative stress and reverse the behavioural 
deficits in mice resultant from glutathione depletion (Choy, Dean, Berk, Bush, & van den 
Buuse, 2010; Dean et al., 2011), and mice engineered to exhibit mitochondrial dysfunction 
and elevated reactive oxygen species show deficits of learning and memory on complex tests 
which can be reversed by NAC treatment (Otte et al., 2011). Mitochondrial dysfunction and 
oxidative stress is also a feature of the neurodegenerative Huntington’s disease. NAC is able 
to ameliorate the cognitive deficits observed in mice expressing elevated levels of the 
amyloidogenic proteins implicated in Alzheimer’s disease (Hsiao, Kuo, Chen, & Gean, 2012; 
Parachikova, Green, Hendrix, & LaFerla, 2010), and Huntingtons’s disease (Sandhir, Sood, 
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Mehrotra, & Kamboj, 2012) which appears to be associated with modulation of oxidative 
stress (Huang et al., 2010; Tchantchou, Graves, Rogers, Ortiz, & Shea, 2005). The 
improvement in cognitive function with NAC treatment following brain injury following 
resolution of oxidative stress has also been observed in preclinical models (G. Chen et al., 
2008; Nazıroğlu, Şenol, Ghazizadeh, & Yürüker, 2014b; Şenol et al., 2014; Xiong, Peterson, 
& Lee, 1999). Promisingly, support for this mechanism and subsequent cognitive protection 
has also been demonstrated in preclinical rat models of post-operative cognitive change. 
(Dhanda, Kaur, & Sandhir, 2013; Prakash, Kalra, & Kumar, 2015). 
 
 
There is accumulating clinical evidence for the potential efficacy of NAC in various 
psychiatric and neurological conditions (Berk, Malhi, Gray, & Dean, 2013) and a recent 
systematic review suggested that supplementation with NAC as either an adjunct or 
monotherapy was associated with significantly pro-cognitive effects for a variety of 
conditions, including psychiatric disorders, Alzheimer’s disease, traumatic brain injury, and 
healthy populations (Skvarc et al., 2017). Importantly for translation to acute induction of 
cognitive dysfunction, a recent study demonstrated efficacy of NAC in the setting of mild 
traumatic brain injury (Hoffer, Balaban, Slade, Tsao, & Hoffer, 2013). Individuals exposed to 
blast injury in the course of active military service received NAC (4 grammes daily) for 
seven days following the event, and a series of symptoms including headaches, memory loss, 
sleep disturbance and neurocognitive dysfunction were assessed. Those receiving NAC 
showed improved performance in multiple cognitive domains relative to the placebo group, 
and also showed milder ancillary symptoms of brain injury. Although limited and 
preliminary, the available clinical studies provide intriguing evidence for the pro-cognitive 
effects of NAC. Perhaps more importantly, these studies highlight the potential efficacy of 
NAC in settings where inflammation and oxidative stress play a role in the pathological 
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process. As far as could be ascertained, only one trial is currently examining the efficacy of 
NAC for POCD, though no data are available yet (Skvarc et al., 2016). 
 
Preoperative cognitive exercise 
 
Cognitive reserve is an established protective factor for POCD (Silbert et al., 2007; F. Wang, 
2014) and increased levels of cognitive reserve are strongly protective for incidence of 
dementia; including higher educational attainment, increased occupational complexity, 
premorbid IQ, and preference for mentally stimulating leisure activities (Valenzuela & 
Sachdev, 2006). Additionally, the possibility of enhancing this reserve in humans through 
cognitive exercise (“brain-training”) has been demonstrated, albeit with low quality data 
(Valenzuela & Sachdev, 2009). 
 
 
Evidence from preclinical models suggests that the provision of a cognitively stimulating 
environment actively promotes neurogenesis. Fares et al., (2013) and Hannan, (2014) 
reported significantly larger proportions of hippocampal surface area and cortical thickness in 
rats housed in enriched environments compared to conventionally housed animals. Strikingly, 
enrichment of the preoperative environment has demonstrated significant neuroprotection in 
rat models of POCD, with significant reduction in TNF-α and IL1-β after surgery in aged rats 
(Kawano et al., 2015). In cognitively healthy humans, physical but not cognitive exercise 
improved global cognition and was associated with increased grey matter volume, while 
cognitive but not physical exercise was associated with reduced memory loss (Suo et al., 
2016). Two clinical trials are currently planned to examine the efficacy of pre-operative 
cognitive exercise for reducing cognitive dysfunction in cardiac patients (NCT02053207) and 
delirium in non-cardiac patients (NCT02230605), but no data was available at the time of 
writing. 
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Conclusions 
 
There is speculative yet promising evidence to suggest that immuno-inflammatory and redox 
processes contribute to the disruptions in synaptic plasticity and glutamate signalling which 
underpins cognitive dysfunction in a number of settings, including POCD. POCD may have 
long-term consequences for quality of life following surgery and may have a significant 
impact on the experience of the patient, their family and the healthcare burden in the 
community. Emerging evidence supports the potential efficacy of neuroprotective agents in 
ameliorating POCD, though clinical research remains relatively embryonic and can be 
considered mixed at best without considerably more investigation. The majority of potential 
therapies showed great pre-clinical promise for the mitigation of POCD, but translation into 
clinical efficacy has proven to be problematic so far for a number of reasons. For example, 
evidence for the efficacy of lidocaine or ketamine for POCD in humans is scant and 
conflicting, with the few papers available rarely in agreement. Research into the use of 
dexmedetomidine or COX-II inhibitors is extremely encouraging but requires larger and 
more longitudinal randomised control trials. Conversely, perioperative use of statins or 
pregabalin may be associated with increased severity of POCD, though the reliance upon 
retrospective studies does not allow for potential confounds to be adequately controlled. 
Further, despite good evidence for the preclinical efficacy of minocycline, NAC, or 
preoperative cognitive exercise for mitigation of POCD, clinical studies remain in the 
embryonic stage. To date, most research has focused upon exploration of analgesic 
interventions, though anti-inflammatory interventions are a sizeable minority. 
Given the lack of conclusive findings, the prevalence and impact of POCD, exploration into 
potential therapies should be encouraged to the point of priority. Given the inherent 
vulnerability of surgical patients, researchers and clinicians should be especially vigilant of 
potential risks and complications resultant from such interventions. In particular, 
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dexmedetomidine, COX-II inhibitors, minocycline, and NAC appear to show the greatest 
promise for potential translation via research and should be thoroughly investigated through 
randomised control trials. Presently, a large-scale trial specifically exploring NAC for POCD 
is currently underway (ANZCTR12614000411640). Trials such as this allow the evaluation 
of suitable therapies, and once more therapies (both pharmacological and behavioural) have 
been similarly evaluated, the clinical, health, and economic impact of a multi-pronged 
evidence-based intervention could then be evaluated for overall efficacy. 
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Linking the mechanisms of POCD to N- 
acetylcysteine as a potential cognitive 
modulator 
What questions needed to be answered? 
 
The previous chapter served two purposes; a. demonstrating the biological pathway from 
oxidative stress to cognitive change, and b. critically examining the current field of evidence 
for the novel therapies for POCD. In this fashion, Chapter 2 directly addresses both of the 
broad aims of the thesis and allows further consideration of the specific objectives into 
potential novel therapies. A number of suitable candidates for future research into the 
mitigation of POCD were identified in Chapter 2, including minocycline, dexmedetomidine, 
COX-II inhibitors, and N-acetylcysteine. 
 
 
Dexmedetomidine is one of the most promising intraoperative agents for the prevention and 
reduction of POCD, though its status as a prescription only medication made it an unlikely 
target for this thesis. Minocycline and most COX-II inhibitors are the same. N-acetylcysteine, 
therefore, presented as a compromise between the known medical efficacies of the 
aforementioned substances but without their restrictive nature. However, although N- 
acetylcysteine is widely used and broadly believed to be safe for most populations, it was still 
necessary to demonstrate that there is sufficient evidence to suggest that N-acetylcysteine 
might have a beneficial impact upon human cognition. To this end, a systematic literature 
review and meta-analysis was performed. 
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What new questions arise? 
 
Chapter 2 provides significant impetus for hypothesis generation. While the efficacy for 
dexmedetomidine for mitigation of POCD is relatively well-established, most other potential 
interventions are under-researched. For example, most interventions proposed lack 
replication or consist largely of preclinical studies. Future research could more directly 
measure the efficacy of the interventions in humans, such as the use of COX-II inhibitors, 
ketamine, lidocaine, and stimulation of cognitive reserve via “brain training”. Further, the 
included interventions were selected for their ability to moderate the inflammatory pathway. 
Future research into the compensatory mechanisms that reduce the efficacy of unsuccessful 
interventions should be carried out. 
 
 
Chapter 2 also identified the neuroprotective effects of N-acetylcysteine, and so an 
examination of that evidence is necessary and presented in Chapter 3. The following chapter 
was published in Neuroscience and Biobehavioral Reviews in 2017. 
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Abstract 
 
Oxidative stress, neuroinflammation and neurogenesis are commonly implicated as cognitive 
modulators across a range of disorders. N-acetylcysteine (NAC) is a glutathione precursor 
with potent antioxidant, pro-neurogenesis and anti-inflammatory properties and a favourable 
safety profile. A systematic review of the literature specifically examining the effect of NAC 
administration on human cognition revealed twelve suitable articles for inclusion: four 
examining Alzheimer’s disease; three examining healthy participants; two examining 
physical trauma; one examining bipolar disorder, one examining schizophrenia, and one 
examining ketamine-induced psychosis. Heterogeneity of studies, insufficiently powered 
studies, infrequency of cognition as a primary outcome, heterogeneous methodologies, 
formulations, co-administered treatments, administration regimes, and assessment 
confounded the drawing of firm conclusions. The available data suggested statistically 
significant cognitive improvements following NAC treatment, though the paucity of NAC- 
specific research makes it difficult to determine if this effect is meaningful. While NAC may 
have a positive cognitive effect in a variety of contexts; larger, targeted studies are warranted, 
specifically evaluating its role in other clinical disorders with cognitive sequelae resulting 
from oxidative stress and neuroinflammation. 
Highlights: 
 
• Oxidative stress and inflammation are widely implicated as cognitive 
modulators, through a variety of vectors. 
• N-acetylcysteine, a glutathione precursor, has demonstrated efficacy in reducing 
the severity of oxidative stress and neuroinflammation, with correlating 
cognitive improvement in pre-clinical models. 
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• Evidence for the efficacy of N-acetylcysteine as an adjunct monotherapy for 
human cognition is inconsistent but promising, though the weight of evidence is 
approximately equivalent. 
• Combined interventions of N-acetylcysteine and other antioxidants have 
demonstrated efficacy for positively impacting human cognition in a range of 
contexts, but it is not possible to determine the degree to which N-acetylcysteine 
is contributing. 
• There is considerable scope to evaluate the cognitive protective effects of NAC in 
clinical conditions associated with neuronal oxidative stress and inflammation. 
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Introduction 
 
Oxidative stress is a disturbance in the balance between the production of reactive oxygen 
species and antioxidant defences and may occur as a response to tissue damage, and may 
cause subsequent damage. It has been implicated in cognitive impairment in a variety of 
conditions including intrinsic neuropsychiatric disease processes (Berk et al., 2013), impact- 
related trauma (Abdul-Muneer et al., 2014; Amen et al., 2011a; Hoffer et al., 2013), 
neurodegenerative disorders (Cahill-Smith and Li, 2014; Schrag et al., 2013), and post- 
operative cognitive dysfunction (Mason et al., 2010; Newman et al., 2007; Zywiel et al., 
2014). Given the putative effect of oxidative stress on cognitive function, it is theoretically 
plausible that the application of an antioxidant agent may to some degree mitigate this 
dysfunction. Previous studies of the efficacy of antioxidant intervention for cognitive 
dysfunction in humans have reported mixed results, such as those for vitamin E (Farina et al., 
2012), Acetyl-L-Carnitine (Hudson and Tabet, 2003), and folic acid (Malouf et al., 2003). N- 
acetylcysteine (NAC) is a nutraceutical capable of replenishing brain glutathione and 
consequently protects against oxidative stress and is likely neuroprotective demonstrating 
pre-clinical efficacy in reducing markers of oxidative stress and the severity of cognitive 
dysfunction in animal models (Hsiao et al., 2012; Huang et al., 2010). Similar oxidative 
responses have been detected in humans (Moreira et al., 2007), though cognition has not been 
widely studied. To date, no review of the effect of the antioxidant N-acetylcysteine on human 
cognition has been conducted, and will form the focus of this systematic review. 
 
Oxidative stress as a mechanism of cognitive change 
 
Oxidative stress has been implicated as a critical pathophysiologic factor in numerous 
conditions, including neurodegenerative diseases. Oxidative stress can lead to cellular 
dysfunction, increased rates of apoptosis, neuroinflammation, and alter the permeability of 
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the blood brain barrier (BBB) to neuropathic proteins, aggregate mechanisms which 
theoretically contribute to cognitive dysfunction (Enciu et al., 2013; Erickson et al., 2012). 
Trauma has been regularly implicated as a precipitating factor to oxidative stress, 
inflammation, and subsequent cognitive dysfunction (Abdul-Muneer et al., 2014), and 
inflammation induced by trauma has been shown to share inflammatory sequelae in the BBB 
with long-term neurological disorders such as Alzheimer’s disease (Erickson et al., 2012); 
epilepsy (Liu et al., 2012); stroke (Khatri et al., 2012); and multiple sclerosis (Lund et al., 
2013); among other conditions. 
Oxidative stress as a moderator of cognitive function has been examined as a likely sequel of 
an acute inflammatory immune response to traumatic tissue damage, including that sustained 
during surgery (Cai et al., 2011; Giannoudis et al., 2006); high impact contact sports (Amen 
et al., 2013; Amen et al., 2011a); and blast-induced mild traumatic brain injury (Hoffer et al., 
2013), as well as being implicated in neurodegenerative and neuropsychiatric disorders 
(Cahill-Smith & Li, 2014; Guidl et al., 2006).This assertion is supported by strong indications 
within the pre-clinical literature that trauma can facilitate the production of reactive oxygen 
species associated with neuroinflammation and is associated with cognitive decline 
(Barrientos et al., 2012; Cibelli et al., 2010; Rosczyk et al., 2008; Vacas et al., 2013). 
The hippocampus in particular appears to be highly vulnerable to the effects of 
neuroinflammation and pro-inflammatory cytokines (Vacas et al., 2013; & Montange et al., 
2015) potentially leading to impairments of memory and learning (Chen et al., 2008; 
Montagne et al., 2015; Rachal Pugh et al., 2001). In humans, this vulnerability may be 
partially responsible for the exacerbated dementia conversion rate associated with amnestic 
mild cognitive impairment (MCI; Kline et al., 2012; Silbert et al., 2011). Therapeutic agents 
that moderate such vulnerabilities may theoretically have effects on the cognitive trajectory. 
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The use of antioxidant agents, such as NAC, can be protective against the proliferation of 
cytokines and reactive oxygen species and increased rates of neuronal survival and decreased 
apoptosis have been observed in many models (Zhou and Ma, 2014). At present, while there 
is a comparative lack of clinical data directly examining potential interventions for post- 
traumatic oxidative stress in humans, a growing body of research has examined potential 
mechanisms. 
 
How NAC might work to mitigate oxidative stress 
 
NAC has been examined in a wide range of chronic neuropsychiatric disorders, including 
bipolar disorder, schizophrenia, trichotillomania, depression and addiction among others 
(Berk et al.2013). NAC functions as a precursor to glutathione which is the principal 
antioxidant produced by the body. Glutathione assists in maintaining oxidative homeostasis 
by removing reactive oxygen species, reactive nitrogen species, and peroxides (Samuni et al., 
2013; Berk et al., 2013). 
NAC has been shown to reduce inflammatory cytokines and reduce markers of oxidative 
stress in a number of indications (Allameh et al., 2015; da Silva et al., 2015; Vidart et al., 
2014; & Skov et al., 2014). Furthermore, NAC has also been shown to modulate immune 
system function and has been used for some time to prevent T-cell decline in HIV (Yang et 
al. 2013; & Treitinger et al. 2004). Further, there is clinical evidence to suggest NAC may be 
neuroprotective based on imaging data (Amen et al. 2011; Holmay et al. 2012; Amen et al. 
2013; Levin et al. 2014). For example, Levin and colleagues observed that the administration 
of a combination of NAC and oral cysteamine bitartrate was able to significantly reduce 
leukocyte pathology in children with infantile neuronal ceroid lipofuscinosis. Similarly, 
Amen and colleagues detected significantly increased levels of regional cerebral blood flow 
to a host of brain organs after administration of a NAC-inclusive nutrient formulation. 
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Curiously, improvements to some organs, in particular the hippocampus, only occurred in 
healthy participants (Amen et al, 2013) and not in participants with traumatic brain injury 
(Amen et al., 2011.). This is perhaps emblematic of NAC research as it pertains to human 
cognition, where NAC is rarely examined as a monotherapy but often as an adjunct to regular 
treatments, and even then as part of a nutrient formulation. Despite this, NAC has favourable 
effects in multiple models of mitochondrial dysfunction; in particular there is evidence to 
suggest that NAC can reduce mitochondrial stress in Alzheimer’s disease (Moreira et al., 
2007). Recent pooled analyses of data in people with bipolar disorder and schizophrenia 
revealed significant improvement in working memory function compared to placebo controls, 
though this data was unpublished at the time of writing (Rapado-Castro et al., 2016). 
Different indicative models of cognitive dysfunction are purported to have different 
mechanisms of deterioration, and the relevant mechanism through which NAC is theorized to 
work likewise differs. For example, cognitive dysfunction in Alzheimer’s disease has been 
characterised by increased levels of amyloid and tau proteins in the brain (Cai et al., 2011, & 
Sinha et al., 2015), and NAC has demonstrated efficacy to mitigate this in animal models 
(Hsaio et al., 2012, & Sinha et al.,) though translational research into humans is scarce. In 
psychiatric disorders cognitive dysfunction is linked with NMDA dysregulation, and NAC is 
purported to act as an agonist for the glycine NMDA receptor (Singh et al., 2011). NAC is 
demonstrably broadly applicable from a theoretical perspective, though rarely clinically 
examined in isolation. However, mono-therapeutic NAC research is more common in animal 
models. 
 
Animal models of cognitive dysfunction 
 
There is considerable evidence that NAC is effective in mitigating cognitive dysfunction in a 
variety of animal models. In particular, NAC has shown striking pro-cognitive effects in 
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multiple models in which oxidative or inflammatory damage is a feature of the pathological 
process. This includes models of metabolic dysfunction such as diabetes and other less 
common disorders of metabolism (Prakash, Karla, & Kumar, 2015; Rodrigues et al., 2013; 
Scaini et al., 2012; Kamboj, Chopra, & Sandhir, 2008), metal toxicity (Goncalves et al., 
2010; Prakash & Kumar, 2009), stress (Moller et al, 2013), antioxidant depletion (Choy et al., 
2010), and mitochondrial dysfunction (Sandhir et al., 2012; Otte et al., 2011). The common 
feature of these findings is the capacity for NAC to reverse or ameliorate the induced 
cognitive dysfunction in a manner associated with reductions in oxidative damage, 
mitochondrial dysfunction or markers of inflammation. 
Importantly, NAC has also shown efficacy in pre-clinical models of both age-related 
cognitive decline and models of Alzheimer’s disease expressing elevated levels of the 
amyloidogenic proteins implicated, which can be ameliorated by NAC administration, and 
this improvement may be mediated by decreases in the toxic forms of these proteins (Hsiao, 
2012; Parachikova et al., 2010) as well as by modulation of oxidative stress (Huang, et al., 
2010). More gradual onset of cognitive deterioration changes is associated with accumulation 
of amyloidogenic proteins and oxidative damage in the brain. NAC appears to also be 
effective in preventing or attenuating age-related cognitive changes, and ameliorating the 
more subtle signs of age-related pathology in mice (Sinha et al., 2015; Thakurta et al., 2014). 
Of note is the capacity for NAC to improve age-related changes in glutamate signalling, 
which is intrinsic to cognitive function. Supplementation with NAC prevented oxidative 
stress-driven changes in glutamate receptor activity associated with cognitive aging (Haxaire, 
2012). This finding highlights an additional potentially therapeutic capacity for NAC to 
modulate the availability of glutamate in the brain, a process controlled by the levels of the 
NAC derivative cysteine. This is supported by studies in mice with deficits of specific 
glutamate transporters, who show early onset of age-related cognitive deficits. NAC 
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significantly attenuated the learning and memory deficits in these mice (Cao, Li, & Zuo, 
2012.) 
Together these studies demonstrate the capacity for NAC to exert pro-cognitive effects in a 
variety of settings, and suggest that this versatile agent may be working through multiple 
interconnected pathways. This supports the hypothesis that NAC may be an effective agent in 
clinical settings of cognitive dysfunction. 
This systematic review brings together the research exploring NAC as a potential adjunct 
therapy for cognitive change in a variety of indications. 
Methods 
 
Search Strategy 
 
A PubMed database search and a Medline database search using the terms: n acetyl cysteine 
OR "NAC" OR antioxidant AND cognit* was conducted. Only studies examining human 
cognition were included. No time limit was imposed upon the search, up until the final search 
date of November 14th 2014. Additionally, the reference lists of applicable studies were 
manually examined for additional articles for inclusion. In total, 2175 articles were screened 
for inclusion, and a subset of 95 was selected for full text evaluation (See Appendix A). 
These articles were manually screened for relevance, first by title and then secondly by 
examining the abstract in cases where the title was not sufficient to exclude. If a paper 
appeared to meet inclusion criteria after reading the abstract it was flagged for full text 
examination. Upon communication with the authors of included studies, data from two 
additional articles were included and have since been published (Remington et al., 2015, 
Rapado-Castro et al., 2016). Rapado-Castro and colleagues performed pooled analyses of 
previously unpublished data (Berk et al., 2008a & 2008b). 12 articles were included in the 
qualitative analysis, with a total of 588 participants across studies. 
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Studies were included if human participants completed repeated-measure neurocognitive 
assessments and NAC was included as an intervention. We excluded studies that did not 
directly measure cognition both before and after intervention. Reviews or re-analyses of 
previously published data were not included. Assessments of general functioning; such as the 
Global Functioning Scale or subjective measures of cognition such as Child Autism Rating 
Scale; were not considered sufficient for inclusion. 
 
Risk of Bias 
 
The risk of bias was considered in line with the recommendations from the Cochrane 
Collaboration. The included studies were examined for potential biases, and the authors 
judgements are provided in Appendix B. The majority of studies had moderate levels of bias, 
with the exception of Chan et al (2008) which had an entirely open-label design, and high 
degree of participant drop-out. Publication bias was investigated with funnel plot analysis. 
Results 
The characteristics of the included studies can be seen in Table 1. The sample size ranged 
from 12 to 106. The mean age of included participants across all studies ranged from 18 years 
to 85 years. The variability between studies, including dosage, design, participant 
demographics and pathologies, and intervention formulation demonstrated that the available 
evidence was not suitable for quantitative meta-analysis, and so a systematic review of the 
research was performed. 
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Table 1. Clinical Trials of NAC with cognition as a primary or secondary endpoint 
Study Participants Design Cognitive 
Outcomes 
Cognition as 
primary outcome 
Intervention (NAC 
in bold) 
Cognitive change results 
Adair et al 
(2001). 
43 participants who 
met criteria for 
having probable 
Alzheimer’s 
disease. Age and 
gender 
demographics not 
supplied. Allocated 
to intervention (n 
=23) or placebo (n 
=20). 
Double-blind, 
randomized 
control trial. 
Assessment of 
function at 
baseline, 3 
months, and 6 
months. 
Mini Mental 
State Exam, 
Boston Naming 
Test, Gesture to 
Command, 
Weschler 
Memory Scale - 
Figure 
Reproduction 
(Immediate), 
Hopkins Verbal 
Learning Task – 
Immediate 
Recall 
Recognition, 
Letter fluency, 
Categorical 
Fluency, 
Judgement of 
Line 
Orientation. 
Primary: MMSE, 
Activities of Daily 
Living. Secondary: 
Boston Naming Test, 
Gesture to Command, 
Figure Reproduction, 
Verbal Learning 
Task, Verbal Fluency, 
Judgement of Line 
orientation. 
Placebo, or NAC at 
50mg/kg/day. 
Intervention was 
spread over three 
doses, and was 
continued for 6 
months. 
No significant change on 
placebo condition over 6 
months. Significant 
improvement for NAC 
group at 3 months WMS – 
Figure Reproduction 
compared to baseline; 
significant improvement 
for NAC group at 6 months 
Letter fluency compared to 
baseline. No change to 
MMSE or other cognitive 
measures. 
Hauer et al. 
(2003). 
36 community 
dwelling 
participants, 
cognitively healthy 
but physically frail 
Double-blind, 
randomized 
control trial. 
Assessment of 
function at 
Mini Mental 
State Exam, 
Modified Trail 
Making Test 
(Zahlen- 
Primary: Physical 
activity, strength, and 
motor function. 
Secondary: 
Biomarkers of 
Placebo, or NAC 
200mg per day for 6 
weeks. Concurrently, 
both treatment arms 
participated in 
No significant cognitive 
change over the course of 
the trial for the placebo 
group, but significant 
cognitive improvement on 
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 and aged over 65 
years. Allocated to 
intervention (n 
=20), or placebo (n 
=16). In the 
intervention group, 
the mean age was 
77.3 years (SD = 
8.8). 
baseline, 3 
weeks, 6 
weeks, and 12- 
13 weeks. 
Verbindungs 
Test), Digit 
symbol 
substitution. 
oxidative stress, 
Modified Trail 
Making test, Digit 
symbol substitution. 
resistance exercise 3 
days a week for 6 
weeks. 
the Trail Making Test and 
Digit symbol substitution 
test within the NAC group. 
However, there were no 
significant between-groups 
changes. 
Chan et al. 14 Community- Open-label, Dementia Primary: Clock Placebo (treatment as Improvement on DRS at 6 
(2008). dwelling early-stage pilot trial. 12 Rating Scale-2, Drawing Test, usual), or Vitamin months, maintained at 12 
 Alzheimer’s disease months Clock Drawing Dementia Rating formulation (VF): months. Clinical 
 patients, 50 years or longitudinal Test. Scale, Activities of Folic acid (400µg), improvement on Clock 
 older. No specific study. Follow  Daily Living, Vitamins B12 (6ug) Drawing Test 1 between 6 
 age or gender up at 3, 6, 9,  Neuropsychiatric & E (30 IU), S- & 12 months. No change 
 information 12 months.  Inventory. adenosylmethionine on ADL scores. Improved 
 supplied.    (SAM, 400mg), symptoms on NPI over 12 
     acetyl-carnitine months. 
     (ALCAR, 500mg),  
     and NAC (600mg),  
     taken twice daily.  
     Intervention  
     continued daily for 12  
     months.  
Remington et al. 12 community- Randomized Dementia Primary: Dementia Placebo (treatment as Participants in the VF 
(2008). dwelling moderate- Placebo- Rating Scale 2, Rating Scale, Clock usual), or Vitamin group experienced 
 to-late stage controlled, Clox Drawing Drawing Test. Formulation (VF): significantly delayed rates 
 Alzheimer’s disease subsequent Test-I. Secondary: Activities Folic acid (400µg), of decline as measured on 
 patients, allocated to open-label  of Daily Living, Vitamins B12 (6ug) the Dementia Rating Scale 
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 receive vitamin trial.  Neuropsychiatric & E (30 IU), S- and Clox Drawing Tests 
formulation (n = 6), Assessment of Inventory. adenosylmethionine compared to the placebo 
or 6 treatment as function at  (SAM, 400mg), group over 3 months. 
usual (n = 6). No baseline, 3, 6,  acetyl-carnitine Caregiver reports indicated 
age or gender 9 months.  (ALCAR, 500mg), a significant improvement 
information   and NAC (600mg), on Neuropsychiatric 
supplied.   taken twice daily. Inventory and Activities of 
   Intervention Daily Living. Trial halted 
   continued daily for 9 at 9 months when the 
   months. participants were no longer 
    able to continue the 
    intervention. 
Chan et al. 
(2010). 
115 participants 
allocated to 
Intervention (n = 
59) or placebo (n = 
56). Age ranged 
from 18-86 years. 
No gender 
information was 
supplied. 
Open label, 
cross-over, 
and placebo 
controlled 
trial. 2 weeks; 
3, 6, 9, 12 
month follow 
ups. 
California 
Verbal Learning 
Test II, Trail 
Making Test. At 
week 2, the 
treatment group 
was also given 
the Digit 
Primary: California 
Verbal Learning Test, 
Trail Making Test, 
Digit Memory Test. 
Placebo, or Vitamin 
Formulation (VF): 
folic acid (400µg), 
Vitamins B12 (6µg) 
and E (30 IU), SAM 
(400mg), ALCAR 
(500mg), NAC 
(600mg), taken twice 
At 3 and 12 months, 
Improvement in short-term 
recall in VF group, no 
change for delayed recall 
in either group. VF group 
also displayed significant 
improvement upon TMT, 
while the placebo group 
   Memory Test.  daily. Intervention did not. Participants who 
     continued for 6 were taken off VF showed 
     months, was functioning consistent with 
     discontinued for 3 non-treatment, but returned 
     months, and initiated to improvement once VF 
     at 9 months for 3 was re-initiated. 
     months.  
Amen et al. 
(2011). 
30 Retired National 
Football League 
Open-label, 
repeated 
Microcog 
Assessment of 
Primary: Microcog 
Assessments (full 
Pragmatic 
intervention of 
After an average 
intervention length of 6 
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 (gridiron) players, measures Cognitive battery). Secondary: smoking and drug months, participants 
who had presented design. Follow Function, a SPECT scans of brain reduction, weight loss demonstrated significantly 
with degrees of up time ranged battery perfusion, subjective support if necessary. improved percentile scores 
acquired brain from 2 to 12 containing measures of mood, All participants on the following subtests: 
injury and cognitive (M = 6) subtests motivation, memory, received a daily general cognitive 
impairment. All months after measuring attention, and sleep. formulation of fish functioning/proficiency, 
participants were recruitment. processing  oil (5.6g), unspecified processing speed/accuracy, 
male, aged between  speed,  multi-vitamins, and a attention, reasoning, and 
25-82 years (Mean  processing  combination of memory, though these 
= 57.27, SD =  accuracy,  ginko, vinpocetine, changes did not remain 
12.37).  attention,  actyl-l-carniltine, significant after conversion 
  reasoning,  huperzine A, alpha- into Hedges g. No change 
  memory, spatial  lipoic acid, and on subtests of spatial 
  processing,  400mg NAC. processing or reaction 
  reaction time,  Treatment continued time. No raw scores were 
  and general  for between 2 – 12 reported. Significant 
  cognition  months. increases in brain perfusion 
  function &   within the prefrontal 
  proficiency.   cortex, anterior cingulate 
     gyrus, parietal lobes, 
     occipital lobes, and 
     cerebellum where detected, 
     but not in the temporal 
     lobes and fusiform gyrus 
     without alpha level 
     adjustment (0.001 to 0.05). 
Dean et al. 
(2012). 
47 participants 
diagnosed with 
bipolar disorder, 
Randomized 
double-blind, 
control trial. 
Digit Span 
forward & 
backward, Trail 
Primary: 
Montgomery-Asberg 
Depression Rating 
Placebo, or NAC 
(2000mg/day) for 6 
months. 
No significant changes to 
cognitive measures over 
study period. 
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 allocated to Analysis of Making Tests A Scale, Young Mania   
intervention (n =21) data from a & B, Word Rating Scale. 
or placebo (n =26). larger study, Learning, Secondary: Digit 
The mean age of the including only Verbal Fluency. Span, Trail Making 
intervention group participants  Tests, Word 
is 44.6 (SD = 12.5), who  Learning, Verbal 
and 13 of the completed  Fluency. 
intervention group cognitive   
were women. assessments   
 (Berk et al,   
 2008).   
Gunduz-Bruce et 16 participants Randomized Spatial Working Primary: Spatial Placebo (inactive NAC did not significantly 
al. (2012). allocated to either double blind, Memory, Rapid Working Memory, NAC), or active NAC mitigate the cognitive 
 NAC intervention (n control trial. Visual Rapid Visual (2000mg and effects induced by 
 = 8) or placebo (n = Participants Processing. Processing, Positive 1000mg divided ketamine. In addition, 
 8). The mean age were tested  and Negative doses). Intervention ketamine brought about 
 was 27 years (SD = over 2 days.  Syndrome Scale, consisted of a single significant cognitive 
 5.6), 13 of the   Visual Analogue dose. Cognitive symptom and behavioural 
 participants were   Scale of mood states, dysfunction was changes that were not 
 male.   Clinical Administered simulated using attenuated by NAC 
    Dissociative States ketamine. administration. 
    Scale. Secondary:   
    Auditory Oddball   
    Paradigm, Mismatch   
    Negativity.   
Amen et al. 30 healthy Randomised WebNeuro Primary: Brain Pseudo-placebo At the end of the study, the 
(2013). participants double blind battery, SPECT imaging, and containing nutrients intervention group 
 recruited from the control for MicroCog Region of Interest but no NAC, or a demonstrated significant 
 community. initial 2 battery. analysis. Secondary: formulation of brain- cognitive improvements 
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 Randomised to months, cross-  MicroCog targeted nutrients, compared to baseline and 
receive an over study for Assessment battery, detailed in text but placebo. Significant 
intervention of further 2 WebNeuro too large to include improvements were 
brain-targeted months. Assessment battery, here. Contains detected in executive 
nutrients, or a  Brief Symptom 400mg NAC. function, reasoning, 
pseudo-placebo. 15  Inventory. Intervention was memory, and information 
women were present   administered once per processing efficiency and 
in the sample, and   day for 2 months, at accuracy. In addition, 
15 men. No age data   which point the significant increases in 
was supplied   intervention and regional cerebral blood 
beyond minimum of   pseudo-placebo flow to 30 areas of the 
18 years.   groups switched. brain. During the 
    withdrawal period of the 
    cross-over, participants 
    returned to baseline levels 
    on cognitive and blood 
    flow measures. 
Hoffer et al. 81 participants Randomized Trail Making Primary: Trail Placebo, or NAC in By day 7, participants in 
(2013). allocated to either double blind, Tests, and Making Tests, staggered doses. the NAC condition 
 NAC intervention (n placebo Controlled Oral Controlled Oral Word Participants were demonstrated significantly 
 = 31) or placebo (n controlled Word Association Test. given 4g NAC on the improved performance on 
 = 40). All trial. Association Secondary: first day as a loading both the TMT-A and TMT- 
 participants were Assessment at Tests. Symptoms associated dose, then over the B compared to the placebo 
 active duty military baseline, 3  with blast-induced next 3 days 2x2g group. The NAC group 
 personnel with mild days, and 7  mTBI were recorded morning and night also had significantly 
 traumatic brain days after  throughout the trial. per day. For the next fewer and less severe 
 injury from initiation.   3 days, dosage was symptoms of mTBI 
 explosions. 80 of    reduced to 2x1.5 g compared to the placebo 
 the participants    daily before group. No group 
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 were male, with an 
age range of 18-43 
(Median = 22) 
years. 
   termination. differences were found on 
the COWAT. 
Remington et al. 106 participants Randomized Clox-1, Primary: Clox-1, Placebo (treatment as By 3 months, the VF group 
(2015). with Alzheimer’s double-blind Dementia Dementia Rating usual), or Vitamin had improved significantly 
 disease randomized multi-site trial Rating Scale. Scale. Secondary: Formulation (VF): on Clox and DRS 
 to receive either VF for 3 -6  Neuropsychiatric Folic acid (400µg), performance, while the 
 (n =62) or placebo months, open  Inventory, Activities Vitamins B12 (6ug) control group did not. 
 (n =44). The mean label trial for  of Daily Living, & E (30 IU), S- However, neither arm 
 age was 77.8 (SD = additional 6   adenosylmethionine demonstrated significant 
 8.4) years. No months will all   (SAM, 400mg), change to either Activities 
 gender information participants   acetyl-carnitine of Daily Living or the 
 supplied. receiving VF.   (ALCAR, 500mg), Neuropsychiatric 
     and NAC (600mg), Inventory. 
     taken twice daily.  
Rapado-Castro 58 participants with Randomised Digit Span Primary: Placebo, or NAC At 24 weeks, participants 
et al., (2016) either bipolar doubled-blind, forward & Montgomery-Asberg (2000mg/day) for 6 within the NAC group 
 disorder or placebo backward, Trail Depression Rating months. demonstrated significantly 
 schizophrenia. The controlled Making Tests A Scale, Young Mania  better working memory 
 intervention group control trial. & B, Word Rating Scale.  compared with controls. 
 had a mean age of 24-week Learning, Secondary: Digit  No other significant 
 38.6 (SD = 12.2) treatment Verbal Fluency. Span, Trail Making  changes observed. 
 years, and 34 of the period.  Tests, Word   
 sample were male.   Learning, Verbal   
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An examination of NAC as an adjunct treatment for cognition in Alzheimer’s 
disease (AD) 
 
Four studies examined the effect of NAC upon cognition in AD; three through the use of a 
nutrient combination including NAC in addition to treatment as usual (Chan et al., 2008; n = 
14, Remington et al.,. 2008; n = 12, and Remington et al., 2015; n = 106), and one where 
NAC was administered in isolation with treatment as usual (Adair et al., 2001; n = 43). With 
the exception of Adair et al., the lack of exclusivity of NAC supplementation to treatment 
makes direct evaluation of its impact upon cognition difficult and therefore can at best be 
described as an approximation of any true effect due to NAC. 
Adair and colleagues observed a statistically significant improvement on WMS performance 
within the NAC cohort at 3 months, and while this remained relatively stable, at 6 months the 
improvement was no longer significant. Further, the purported protective effect appears to 
have been confined to visual memory, with Adair and colleagues observing no change to 
verbal memory after intervention. This preservation of memory function appears consistent 
with research by Chan et al., (2008) and Remington et al., (2008) where no significant 
changes to memory function on the DRS were observed. Given that memory impairment is 
the core presenting symptom in AD, NAC (and adjunct nutraceuticals in the cases of Chan et 
al. & Remington et al.) may have acted to delay the decline, though more rigorous 
examinations of memory are needed. Additionally, the NAC arm of the Adair study 
demonstrated significant improvement in the letter fluency task at 6 months in comparison to 
baseline, though no other comparisons were significant. 
While heterogeneity was apparent across studies, a disease severity trend was observed in the 
studies examining AD. Part of the included research (Adair et al., 2001; Chan et al., 2008; 
Remington et al., 2008) tracks three different cohorts with AD at three different stages of the 
disease (probable but unconfirmed, early stage, and moderate-to-late stage). Both studies 
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observing participants in the earlier stages of AD (Adair 2001 & Chan et al., 2008) observed 
a statistically significant improvement in initiation and executive function as measured by 
verbal fluency over the course of the trial, reaching significance at 6 months in the case of 
Adair et al (Letter Fluency), and 12 months in Chan et al (initiation/conceptualization 
subscale of the Mattis Dementia Rating Scale). Given that reduced verbal fluency in the early 
stages has been shown to be one of the few neuropsychological measures predictive of 
mortality in AD (Cosentino et al., 2006) findings of improvement on this test, in this 
population is particularly intriguing. 
Comparative analysis amongst AD research literature was complicated by the heterogeneity 
of assessment types reported, particularly for the multi-ingredient formulation studies where 
NAC was not administered as an isolated, adjunct monotherapy. For instance, while 
Remington and colleagues (2008) reported the total performance of participants on the Mattis 
Dementia Rating Scale, the subscale scores were not provided. However, cross-study 
comparisons were possible through the examination of the clock drawing tasks. Both Chan 
and colleagues (2008) and Remington and colleagues suggested that clinically significant 
between-treatment group improvements were observed upon the clock drawing tasks at 3 
months, though statistical significance was achieved in neither case. Replication of the 
studies with a larger sample achieved both statistical and clinical significance (Remington et 
al., 2015). Additionally, sub-group analysis performed by Remington and colleagues (2015) 
corroborated previous findings that severity of dementia was significantly influenced by the 
intervention; cognitively healthy and early stage AD participants within the experimental 
groups demonstrated significant improvements over placebo groups. While cognition of 
participants with moderate and late stage dementia did not improve on intervention, decline 
was significantly delayed in comparison to control groups. 
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In sum, while there is some evidence to suggest that NAC supplementation in AD may be 
beneficial to preserving memory or improving language initiation and executive function, this 
is largely based upon a single study (Adair et al., 2001). As other substances were co- 
administered alongside NAC in this work (Chan et al., 2008, Remington et al., 2008, and 
Remington 2015), the contribution of NAC, if any, to the protective effect is impossible to 
determine and thus the evidence base can only be considered indicative. More trials are 
needed, particularly those that examine NAC supplementation in isolation with treatment as 
usual. 
 
An examination of NAC as an adjunct treatment for cognition in psychiatric 
disorders and psychotic symptoms 
 
The efficacy of NAC as an adjunct treatment for psychiatric disorders was examined by Dean 
et al. (2012; n = 47), and Rapado-Castro et al., (2016; n =58). A third study, Gunduz-Bruce et 
al., (2012; n = 16); proposed to approximate the psychotic and cognitive symptoms of 
schizophrenia in otherwise healthy participants through use of the drug ketamine. All three 
studies utilized a randomised, double-blind, placebo-controlled research design. Similarly, all 
three included studies included measures of mood and cognition, though the assessments 
used by Gunduz-Bruce and colleagues were largely computerised in comparison to the pen- 
and-paper tasks used by Dean et al., and Rapado-Castro et al. The administration of NAC did 
not appear to reduce the severity of psychotic symptoms for any sample, and the only 
significant cognitive outcome change was an improvement in working memory at 6 months 
in Rapado-Castro et al. The research samples differed significantly between studies. The 
research by Dean et al., and Rapado-Castro et al., examined participants with diagnosed 
bipolar and schizophrenia disorders with a treatment intervention administration of 6 months; 
whereas Gunduz-Bruce and colleagues observed otherwise healthy participants receiving 
ketamine to approximate psychosis as an experimental condition, and administered a single 
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treatment intervention dose. It is possible to interpret this as the potential for NAC 
supplementation being beneficial with sustained administration, but given the present lack of 
studies and the relatively small sample sizes used in the available evidence, the efficacy of 
NAC for improving cognition in psychotic disorders requires further exploration to establish. 
 
An examination of NAC as an adjunct treatment for cognition following 
physical trauma 
 
Two studies examined the efficacy of NAC as an adjunct treatment for cognitive dysfunction 
believed to result from physical trauma (Amen et al., 2011; n = 30, and Hoffer et al., 2013; n 
=81). Both studies differed substantially. Amen and colleagues (2011) examined retired 
professional athletes from the National Football League in the USA, all of whom had played 
professionally for at least 3 years and had suffered traumatic brain injury. Participants within 
this study received NAC only as part of a multi-ingredient formulation, whereas Hoffer et al. 
administered NAC as an adjunct to regular blast-trauma treatment. Statistically significant 
improvements to performance were observed upon measures of general cognitive function, 
proficiency, processing speed and accuracy, attention, reasoning, and memory. There was no 
significant overall change on either the spatial reasoning or reaction time tasks. The 
magnitude of effect was highly variable between participants with large proportions of 
participants showing both statistical and clinically significant improvement. For example, 14 
of 30 participants demonstrated at least 50% improved performance on tasks measuring 
general cognitive function. Pre and post-intervention comparisons from brain imaging data 
suggested an increase in blood perfusion in the prefrontal cortex, anterior cingulate gyrus, 
parietal and occipital lobes, and the cerebellum of participants. However, the results are 
confounded by the presence of additional adjunct treatments and interventions that were not 
controlled for within the analysis. In addition to being administered a nutrient combination, 
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participants were also offered additional wellbeing and lifestyle education to assist with 
global function. 
Hoffer and colleagues (2013) examined the effect of NAC in blast-induced traumatic brain 
injury in active-duty soldiers. The results were amongst some of the most promising observed 
throughout the literature, with statistically and clinically significant improvements associated 
with NAC administration, including reduction in symptom severity and duration. 
Cognitively, significant improvements upon the Trail-Making Tests A and B (TMT A & B) 
were recorded 7 days after the initial blast injuries. When treatment was administered within 
24 hours after the injury, participants who received NAC were approximately twice as likely 
to report symptom resolution within 7 days compared to placebo; and over three times as 
likely to report complete symptom resolution when treatment was delivered within 24-48 
hours. This suggests that the protective effects of NAC may significantly interact with current 
treatment strategies to address blast-induced traumatic brain injury, but effects were largely 
confined to administration within 24 hours of injury. However, in contrast with studies 
examining Alzheimer’s disease (Adair et al., 2001; Chan et al., 2008; Remington et al., 
2008), the participants assessed in Hoffer et al. did not show significant improvement in 
verbal fluency and executive function. 
It is difficult to properly estimate the effect of NAC on cognition following physical trauma. 
The available evidence suggests that NAC positively affects cognition but this is based on a 
small number of studies that examined NAC in conjunction with co-administered 
interventions. In addition, the populations with head injuries sustained through years of 
professional sports and those sustained as a result of blast injuries are likely to be highly 
heterogeneous. The evidence can therefore be considered promising, but highly preliminary 
without replication. 
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NAC as a cognitive modulator in cognitively and psychiatrically healthy 
adults 
 
Two studies (Amen et al., 2013; n = 30 & Chan et al., 2010; n = 115) examined the 
possibility that NAC in conjunction with a number of additional nutraceuticals may improve 
cognitive performance in cohorts without known cognitive impairment or psychiatric 
conditions. Neither Amen and colleagues nor Chan and colleagues examined the efficacy of 
NAC in isolation. Both studies revealed significant cognitive improvement within the 
intervention groups in comparison to controls. A third study, (Hauer et al., 2003) examined a 
cohort of cognitively healthy but physically frail elderly participants, aged over 65 years, 
with a combined intervention of resistance training and either NAC or placebo. All studies 
reported significant cognitive improvement within the intervention groups. Like the later 
research of Chan et al. (2010) and Amen et al. (2013) the cognitive changes observed by 
Hauer and colleagues were observed on the Trail Making and Digit Span tests (or analogous 
alternatives) examining executive function, working memory and short term memory. 
Further, Hauer and colleagues reported that the administration of NAC also appeared to 
modulate the production of TFN-alpha to a significantly greater degree compared with 
controls, though no such effect was detected for ING-1 or growth hormone. In combination 
with the other included findings, and given the contribution of executive function, working 
memory may be particularly receptive to NAC treatment in healthy adults. 
Discussion 
The results of the review revealed enormous variability across studies investigating the 
impact NAC has on cognition. Participant demographics, research design, sample size, 
treatment regimen, dosage strength and duration of invention all varied across studies. The 
examined studies suggest that the administration of NAC alone may be beneficial in some 
circumstances but the sum of the evidence must be described as equivocal. In combination 
with other substances, in conjunction with other treatments, there was some evidence that 
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supplementation was beneficial compared with control groups on some measures of general 
cognition, executive function, processing speed, and visuospatial reasoning, memory, verbal 
fluency, and spatial reasoning, but the proportion of this effect due to NAC is indeterminable. 
Partialling out the effect of NAC supplementation from other confounding substances is 
difficult. Half of the included studies examined NAC as part of a vitamin or therapeutic 
combination, and of the remainder, only Gunduz-Bruce et al. (2011) examined the effect of 
NAC administration as a monotherapy. The studies where NAC demonstrated efficacy (either 
in combination with additional non-pharmaceutical treatments, alone, or as an adjunct with 
treatment as usual) were quite heterogeneous and varied in their treatment regimens and 
proposed avenue of oxidative stress. Evidence for the efficacy of NAC alone as a cognitive 
protector was equivocal. For example, NAC as an adjunctive treatment for bipolar disorder 
did not appear to attenuate associated cognitive deficits (Dean et al., 2012), whereas Rapado- 
Castro and colleagues (2016) demonstrated significantly improved working memory after an 
identical intervention regimen in a pooled bipolar disorder and schizophrenia sample. By 
comparison, studies that examined efficacy of combined nutraceuticals were typically 
positive (see Amen et al., 2011, 2013; Chan et al., 2008, 2010; Hauer et al., 2003 etc.). The 
dose and administration regimens of NAC were also highly variable between studies. 
Dean et al. used a significantly higher daily dose of NAC compared with both Amen et al. 
and Chan et al.; 1000mg twice per day in comparison to 400mg and 600mg twice daily, 
respectively, and substantially higher still compared with Hauer et al, (2003). Hauer and 
colleagues were able to detect significant cognitive improvement after administering a 
relatively lower dose of 200mg per day for six weeks in adjunct physical resistance training 
in elderly participants with no psychiatric or cognitive diagnoses, though this was not 
significantly different from the control group at follow-up. In sum, there is presently a lack of 
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evidence for the efficacy of NAC alone as a cognitive modulator, and any indications should 
be considered preliminary. 
 
Dose response and the influence of administration length 
 
The relationship between cognitive changes as a result of intervention, dose strength, and 
administration length within the included studies was not entirely clear. As seen in Table 1, 
both the study with the highest mean daily NAC intervention (Hoffer et al. 2013), and the 
studies with the longest dose administration (Berk et al., 2008a; Dean et al., 2012; Rapado- 
Castro et al., 2016) demonstrated significant cognitive changes for the experimental group. 
Conversely, the participants observed by Hauer et al. (2003) had both relatively short 
intervention times and the lowest intervention dose, but demonstrated significant cognitive 
improvements over controls. There was similar variability within the studies where no 
significant cognitive change was detected; two weeks of multi-ingredient intervention did not 
appear to effect cognitive change for the participants observed by Chan et al. (2010) but 
significant changes were detected when doses were continued for 3 months. By comparison, 
participants observed by Amen et al. (2011) with a mean administration length of 6 months 
and weaker dose reported significant cognitive improvement. Gunduz-Bruce et al. (2012) 
utilized a large dose on a single day, while Dean et al. used a comparable dose daily for over 
6 months, but neither reported cognitive improvement. Taken as a whole, this suggests that 
there are additional confounds at play when determining successful NAC intervention, such 
as the presence or progression of disease. 
Prolonged regimens appeared to show the highest degree of change for chronic conditions. 
Studies examined NAC as an intervention for chronic conditions such as Alzheimer’s disease 
(Adair et al., 2001), bipolar disorder (Dean et al., 2012), and schizophrenia (Rapado-Castro et 
al., 2016). As part of a prolonged multi-ingredient antioxidant formulation, corroborative 
100  
beneficial effects were further observed for Alzheimer’s disease (Chan et al., 2008; 
Remington et al., 2015; Remington et al., 2008), and long-term physical trauma of high 
impact sport (Amen et al., 2011.) Evidence for NAC as an intervention for acute conditions 
associated with oxidative stress was equivocal; in an approximation model of psychosis 
Gunduz-Bruce et al. (2012) were unable to moderate the cognitive effects induced by 
ketamine in otherwise healthy participants, while Hoffer and colleagues demonstrated 
considerable advantage for the inclusion of NAC as an adjunct treatment for brain injury 
(Hoffer et al., 2013). 
 
A consideration of age and natural cognitive change 
 
Chan and colleagues (2010) reported an interaction effect for age and combined antioxidant 
intervention efficacy. While there was a main effect for intervention response on cognitive 
performance, this effect diminished with increasing age, even in cognitively healthy 
participants. At face value, the results of this study complicate the understanding of other 
research – given that the participants were without detected cognitive impairments or 
psychiatric disorder, it is not clear by which mechanism the treatment regimen was able to 
promote cognitive improvement. Increasing age is an established risk factor for the onset of 
mild cognitive impairments and dementia (Armstrong, 2013), and so the ability to reliably 
distinguish between cognitive change through ageing rather than pathology is complicated. 
However it is possible that this is concordant with the results of Hoffer et al., (2013), 
suggesting the need to use the agent as soon as possible after the neuronal insult. 
 
Implications and conclusions 
 
There is ample evidence to suggest that increased levels of oxidative stress, inflammation, 
mitochondrial dysfunction and apoptosis are associated with clinically meaningful cognitive 
deterioration. Our review found that there is some evidence to suggest that the 
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supplementation of NAC can be efficacious in reducing the severity of cognitive changes 
associated with a variety of disorders characterised by oxidative stress, though this is 
extremely preliminary and is subject to multiple caveats. While various individual positive 
results could be considered as evidence of potential clinical benefit of NAC administration, 
results more generally were inconsistent and subject to limitations of sample size, absence of 
control conditions, heterogeneity of assessment modalities and treatment regimens that 
prevent drawing firm conclusions to inform clinical practice. While there appears to be some 
promise for the possibility of NAC as a useful cognitive protector, there is a scarcity of strong 
evidence of an effect that could be attributed solely to NAC supplementation and further 
research is warranted. Indeed, there was insufficient congruent data to conduct a meta- 
analysis. Additionally, while levels of oxidative stress were often cited as part of the rationale 
for investigating the benefits of antioxidant treatments, few studies included biomarkers of 
oxidative stress within the analyses. Further larger-scale clinical trials specifically designed  
to examine the ability of NAC to modulate cognitive outcomes in conditions associated with 
oxidative stress and neuroinflammation are warranted, and could have significant individual 
and public health benefits across a wide spectrum of disease. 
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Meta-analyses of cognitive domains 
Rationale for exclusion from publication 
The manuscript presented in Chapter 3 was originally planned with the inclusion cognitive 
outcome meta-analyses, though the relatively small amount of includable studies and 
considerable variation between those that were includable reduced the reliability of the 
results. Numerous attempts to obtain additional data or to restructure the available data in 
such a way to make meta-analysis suitable were unsuccessful or even compounded the 
problem. For example, the first set of analyses sought to compare within similar conditions 
but the heterogeneity of target populations for most conditions made this data uninterpretable, 
or the cognitive measure used were of such contrasting domains that the analyses were unfit 
to be pooled. The second set of analyses attempted to rectify this through the production of 
statistical composite scales to describe any cognitive change at all. These composite measures 
not only lacked sufficient nuance to identify specific changes in cognitive domains (for 
example, changes in memory versus changes in executive function) but were also unable to 
account for changes that appeared to cancel each other out, such as circumstances where two 
different measures obtained inverse outcomes. 
Prior to submission of the manuscript to Neuroscience and Biobehavioral Reviews, it was 
decided that the grouping of cognitive outcomes into broad domains but without accounting 
for participant condition would present a suitable balance. These cognitive domains were 
used in the original submission, but upon peer review were not accepted due to their small 
number of studies with comparable samples. The reviewers suggested that the systematic 
review would be sufficient for the explorative purposes identified in the introduction and that 
meta-analyses should be re-visited in future with the publication of additional materials. 
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Meta-analysis methodology 
 
Data Extraction 
 
Design characteristics, participant demographics, and sample sizes were extracted, in addition 
to the intervention regimens and timelines. The study only included data that directly 
measured cognition, rather than third person impressions of functioning. Data was therefore 
extracted for the Mini-Mental State Exam (MMSE), the Boston Naming Test (BNT), Gesture 
to Command, Wechsler Memory Scale (WMS) – various subtests, Hopkins Verbal Learning 
Task (HVLT), Judgement of Line Orientation, Trail Making Tests (TMT), Digit Symbol 
substitution, Dementia Rating Scales (DRS) 1 and 2, Clox Drawing Tests 1 and 2, California 
Verbal Learning Test (CVLT), Cambridge Neuropsychological Test Automated Battery 
(CANTAB), and the MicroCog battery. Re-analysis of reported values was performed where 
sufficient information was provided to do so, in other circumstances the authors were 
contacted or scores were estimated using alternative means, such as using graphing software 
to digitally investigate published graphs and figures. This data is included in the results (See 
Table 2). When studies contained both blinded and open label designs, scores were extracted 
up until the final blinded point. 
 
Categorization of cognitive outcomes 
 
To improve interpretability of the findings, separate outcomes have been grouped by broad 
cognitive domains; general cognition, executive function, verbal memory, visual memory, 
reaction speed, processing speed, and visuospatial reasoning. General cognition assessments 
include MMSE, Gesture to command, DRS, and MicroCog Accuracy, Proficiency, and 
Function indices. Executive function assessments include verbal fluency tasks, TMT-B, 
WebNeuro Executive Function index, MicroCog Reasoning index, and Digit Span 
Backwards. Verbal memory assessments included CVLT, HVLT, Digit Span Forwards, and 
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MicroCog Memory and Attention indices. Visual memory was assessed using the WMS 
Figure Reproduction test, and the CANTAB Spatial Working Memory index. Reaction speed 
was assessed by the MicroCog Reaction Time index and the CANTAB Rapid Visual 
Processing index. Processing Speed was assessed by TMT-A, ZVT Trails, WebNeuro 
Information Efficiency index, and Digit Symbol Substitution. Finally, visual processing was 
assessed by the Clock drawing tasks, judgement of line orientation tasks, and specific derived 
scores from the CANTAB Rapid Visual Processing index. 
 
Calculation of composite outcomes 
 
In order to minimise error arising from multiple includable outcomes from single studies, 
composite means and standard deviations for related measures were calculated according to 
the guidelines outlined in Borenstein, et al., (2009). 
 
Risk of Bias 
 
The risk of bias was considered in line with the recommendations from the Cochrane 
Collaboration. The included studies were examined for potential biases, and the author's 
judgements are provided in Appendix B. The majority of studies had low to moderate levels 
of bias, with the exception of Chan et al (2008) which had an entirely open-label design, and 
a high degree of participant drop-out. 
 
Statistical Analysis 
 
Review Manager software was used to calculate the Standardized Mean Difference (as 
Hedges g) in all analyses, using a random effects model. Hedge’s g uses pooled standard 
deviations and adjusts for small samples (Riley, Higgins, & Deeks 2010). In all cases, a 95% 
confidence interval was also calculated, and an alpha level of .05 was used to designate 
significance. Heterogeneity of variance was automatically calculated as an I2 statistic. To 
preserve the integrity of the data and simplify calculation, all values are converted to positive 
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values where greater values indicate better performance. To this end, the values of some 
scores (such as time to complete tasks; the number of errors etc.) were converted to negative 
values. 
Results 
A meta-analysis of all calculable between-treatment cognitive outcomes at study end-points 
was performed and is presented as a forest plot. Due to the broad variability in dosing 
regimens, sample characteristics, and study designs, the results should be interpreted as the 
effect of any amount of NAC upon cognition, and should, therefore, be interpreted with 
caution. 
Hauer et al., (2003) did not provide standard deviations for baseline values, so this was 
estimated by the product of the standard error (obtained from the p value) and the square root 
of the sample size. MMSE data was only collected at baseline and so was not included in the 
meta-analysis. Comparison of Clox-1 scores between NAC and controls at 3 months was not 
possible for Remington et al., (2008), as no standard deviation was calculable for this 
endpoint. No control or groups were utilized by Chan et al., (2008), and so data from this 
paper were excluded from the meta-analysis. The authors of Chan et al., (2010) supplied the 
means and standard deviations for the Trail Making Tests to allow the calculation of effect 
sizes. Additional analysis of the data from Chan and colleagues was estimated using a digital 
data extraction tool (GetData Graph Digitizer 2.26; Federov, 2012); the estimated means and 
standard error of the means (SEM) were extracted from the published graphs. These 
estimations were then used to convert the reported standard error of the mean (SEM) into 
standard deviations (SD) to allow for effect size calculation. The SEM was converted to SD 
using the suggested method outlined by Cochrane (Cochrane Handbook, 7.7.3.3, Deeks & 
Higgins, 2008). 
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The authors of Gunduz-Bruce et al., (2011) supplied the means and standard deviations for 
cognitive outcomes to allow the calculation of effect sizes. Hoffer et al., (2013) separated 
treatment groups into those who received interventions within 24 hours after injury and those 
who did not; these results were pooled together for the analysis. Rapado-Castro et al., (2015, 
submitted) performed an analysis of a combination of previously published data from Dean et 
al., (2012), and unpublished data from Berk et al. (2008a & 2008b). Data included in this 
analysis is only that which is unique to either Dean and colleagues or Rapado-Castro and 
colleagues to avoid over-estimation. Where data overlaps between Dean and colleagues and 
Rapado-Castro and colleagues, the data is included under Rapado-Castro for simplicity. 
There was broad variability among the articles selected for inclusion in the meta-analysis, 
across participant inclusion criteria, intervention regimen and dose, and treatment length. For 
example, Dean et al. (2012) targeted participants with a long-term history of bipolar disorder, 
with 2,000 mg of NAC or placebo daily for 6 months in addition to regular medication; 
Hoffer et al. (2013) examined soldiers who had suffered acute brain trauma as a result of 
explosives with a staggered 4,000 mg dose of NAC for 4 days after the explosion tapered off 
to 3,000 mg daily for the next 3 days; and Chan et al. (2010) examined the effects of a 
nutraceutical formulation that included 600 mg of NAC twice daily for at least 3 months as 
part of a cross-over design in cognitively healthy adults. Given this variability, the internal 
validity of the meta-analysis is extremely limited and needs to be interpreted with great 
caution. Therefore, the calculable cognitive outcomes for each included paper are presented 
in Figures 3 to 9. 
Significant between-treatment differences were detected upon measures of general cognition 
(g = 0.41, [0.12, 0.70], p < .01); executive function (g = 0.36, [0.11, 0.62], p < 0.1); 
processing speed (g = 1.44, [0.29, 2.59], p <.05; and visuospatial processing (g 0.56, [0.23, 
0.89], p <.001. Heterogeneity was low for significant outcomes, with the exception of 
107  
visuospatial processing where substantial heterogeneity was present (I2= 92%). No significant 
between-treatment differences were detected for verbal memory, visual memory, or reaction 
speed. Heterogeneity for non-significant outcomes was negligible for reaction speed, and 
substantial for memory outcomes (I2 = 82%). 
 
Publication bias and Sensitivity analysis 
 
Funnel plot analysis did not indicate publication bias, though this is limited due to the small 
number of included studies. Sensitivity analysis for each cognitive domain was conducted by 
removing one study and recalculating the analysis to observe any changes in outcomes. In 
general cognition, excluding Remington et al., (2015) did not alter the heterogeneity, but the 
outcome became non-significant (g = 0.31 [-0.07, 0.68], p > .05). For executive function, 
removing Amen et al. (2013) completely reduced heterogeneity but did not alter the 
significance of the outcome. For verbal memory, removal of either Dean et al. (2012) or 
Rapado-Castro et al., (2015) did not substantially alter the heterogeneity of the outcome but 
did result in significance (g = 0.63 [0.09, 1.17], p < .05). For processing speed, excluding 
Hauer (2003) did not alter the significance, but substantially reduced the heterogeneity of the 
outcome. For visuospatial processing, excluding Remington et al. (2015) did not alter 
heterogeneity of the outcome, but the outcome became non-significant (g =0.43 [-0.05, 0.91], 
p >.05). 
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Figure 2 - General Cognition 
 
 
Adair (2001) data is a composite of MMSE and Gesture to Command. Amen (2011) data is a composite of the MicroCog Cognitive Function, Proficiency, 
and Accuracy indices. 
Figure 3 - Executive Function 
Adair (2001) data is a composite of letter and categorical fluency, and the BNT. Hoffer et al. (2013) data is a composite of TMT-B, letter and categorical 
fluency. Amen (2013) data is a composite of WebNeuro Executive Function and MicroCog Reasoning indices. Rapado-Castro (2015) data is a composite of 
letter and categorical fluency, digits backwards, and TMT derived indices. 
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Figure 4 - Verbal Memory 
 
Adair (2001) data is a composite of short list recall and the HVLT. Chan (2010) data is a composite of short list recall and CVLT. Amen (2011) data is a 
composite of MicroCog Memory and Attention indices. Dean (2012) data is a composite of short list and digit span recall. 
Figure 5 - Visual Memory 
Gunduz-Bruce (2012) data is a composite of the CANTAB Spatial Working Memory derived scores. 
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Figure 6 - Reaction Speed 
 
Gunduz-Bruce (2012) data is a composite of the CANTAB Rapid Visual Processing signal detection and latency scores. 
 
Figure 7 - Processing Speed 
Hauer (2003) data is a composite of ZVT Trails and Digit Symbol Substitution. Hoffer (2013) data is a composite of TMT-B and letter and categorical 
fluency. Dean et al. (2012) data is a composite of TMT derived indices. 
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Figure 8 - Visuospatial Processing 
 
 
Gunduz-Bruce (2012) data is a composite of the CANTAB Rapid Visual Processing accuracy scores. 
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Summary and Interpretation 
Despite the difficulties of pooling the study’s results, a number of significant cognitive 
effects were observed within the meta-analyses. 
 
General cognition 
 
Despite the favourable total pooled effect for general cognition, only one of four included 
trials actually demonstrated a significant improvement and did so with sufficient magnitude 
to influence the others (Remington et al., 2015). With the exception of Amen et al. (2011), 
each of the included studies examined Alzheimer’s disease samples. 
 
Executive Function 
 
Executive function was the most commonly examined cognitive domain among the included 
studies and included studies from each of the Alzheimer’s disease, TBI, psychosis, and 
healthy samples. As with the general cognition outcome, only one study (Amen et al. 2013) 
individually reached the threshold of statistical significance. 
 
Verbal Memory 
 
The results of the meta-analysis of verbal memory outcomes are among the most interesting. 
When examined as a whole as presented here, the sum of the effect is non-significant. 
However, it can be clearly seen that there are three distinct pairs of studies that report similar 
outcomes. The two studies examining psychosis (Dean et al. 2012 & Rapado-Castro et al. 
2015) trend towards a negative result of the intervention (g = -0.30 [-0.69, 0.09], p = .13, I2= 
0%). By contrast, the two studies examining healthy samples (Amen et al., 2013 & Chan et 
al., 2010) observed an extremely large positive effect of verbal memory function (g = 1.13 
[0.73, 1.53], p < .001, I2= 12%). The two remaining studies observed a significant protective 
effect in Alzheimer’s disease, though of a more modest size (g= 0.50 [0.11, 0.90], p < .01, I2= 
0%). 
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Visual Memory 
 
In contrast to verbal memory, visual memory was relatively unexamined by the included 
studies, and the results reflect this. Interestingly, both verbal and visual memory deficits 
associated with psychosis appear to be resistant to N-acetylcysteine. 
 
Reaction Speed 
 
Similarly to visual memory, reaction speed was not commonly examined, and no significant 
changes were detected. 
 
Processing Speed 
 
Processing speed was examined for psychosis, TBI, and healthy samples. Significant, 
positive results were observed for each individual study with the exception of Dean et al. 
(2012). Hauer et al. (2003) was an extreme outlier, but even when these results are excluded 
the overall effect remains significant and positive for the experimental condition (g = 0.57 
[0.16, 0.99], p < .01, I2=40%). 
 
Visuospatial Processing 
 
Three studies examined visuospatial processing, including two for Alzheimer’s disease 
(Adair 2001 & Remington et al. 2015), and one for psychosis (Gunduz-Bruce et al., 2012). 
No significant effect was observed for the psychosis sample, but when the Alzheimer’s 
samples are pooled a clear positive effect can be seen for the intervention (g = 0.63 [0.27, 
1.00], p < .001, I2 = 0%). 
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Apparent resistance of psychosis to antioxidant intervention 
 
It is noteworthy that the antioxidant interventions appeared to be least effective in addressing 
cognitive change associated with psychosis. The results of the meta-analyses suggest that 
Dean et al., (2012), Gunduz-Bruce et al., (2012), and Rapado-Castro et al., (2015) were 
unable to demonstrate any protective or mitigating effect in samples of bipolar, ketamine- 
psychosis, or pooled bipolar and schizophrenia data respectively. The interventions used were 
N-acetylcysteine as a monotherapy to treatment as usual in the case of Dean et al. and 
Rapado-Castro et al., and as the sole intervention agent for Gunduz-Bruce et al. However, 
other studies that used similar regimens were successful; suggesting that cognitive change 
associated with psychosis may be particularly resistant to mitigation via N-acetylcysteine. 
For example, Adair et al. (2001), Hauer et al. (2003), and Hoffer et al. (2013) all used N- 
acetylcysteine as an adjunct monotherapy to treatment as usual (in contrast with the 
combined antioxidant interventions used by other researchers) and found generally 
favourable results. 
 
 
Significant avenues for future research can be observed from these data, including one that 
can be examined in depth in this thesis. Primarily, antioxidant administration has 
demonstrated efficacy for cognitive protection in neuroinflammatory conditions. Adjunct n- 
acetylcysteine alone appears to have little impact upon cognitive deficits associated with 
psychosis, but evidence suggests combined antioxidant therapies have demonstrable pro- 
cognitive efficacy in Alzheimer’s disease, TBI, and healthy samples. 
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Linking the review of N-acetylcysteine for 
cognitive change to the PANACEA trial 
What questions needed to be answered? 
 
Chapter 2 identified a number of potential interventions based upon their purported efficacy 
for moderating the cognitive effect secondary to neuroinflammation, particularly amongst a 
post-surgical population. N-acetylcysteine was selected in part due to the suitability of the 
substance for use in research, but also due to the paradoxical lack of current evidence. Thus, 
the systematic review of clinical research into the cognitive effect of n-acetylcysteine was 
necessary, and the results buttressed here with the inclusion of the subsequent meta-analyses. 
 
 
Chapter 3 examined the evidence for a cognitive effect of N-acetylcysteine and demonstrated 
the need for future research to more closely examine the circumstances in which N- 
acetylcysteine could be considered to be useful. When the meta-analyses are included clear 
trends within specific cognitive domains and conditions are also observed, even though the 
data is limited. For example, verbal memory appears to be quite responsive to antioxidant 
administration in Alzheimer’s disease, while healthy participants were more likely to 
experience improvements in processing speed. 
 
 
What new questions arise? 
 
Despite being fairly well examined for other outcomes, evaluations for cognition after N- 
acetylcysteine are relatively few and non-existent for post-surgical populations. In order to 
fully examine the potential for n-acetylcysteine as a POCD mitigating agent randomised 
control trials are necessary. Importantly, any new research would need to be designed to 
account for as many of the previously identified logistical and conceptual issues, such as a 
clear identification of POCD, use of suitable assessments, and a large enough sample size in 
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order to achieve sufficient statistical power. It is from this perspective that the Post- 
Anaesthesia N-Acetylcysteine Cognitive Evaluation (PANACEA) trial was developed, and 
Chapter 4 consists of the trial protocol manuscript published by Trials in 2016. 
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Chapter 4: The Post-Anaesthesia N- 
acetylcysteine Cognitive Evaluation 
(PANACEA) trial: study protocol for a 
randomised control trial. 
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Abstract 
Background: Some degree of cognitive decline after surgery occurs in as many as one- 
quarter of elderly surgical patients, and this decline is associated with increased morbidity 
and mortality. Cognition may be affected across a range of domains, including memory, 
psychomotor skills, and executive function. While the exact mechanisms of cognitive change 
after surgery are not precisely known, oxidative stress and subsequent neuroinflammation 
have been implicated. N-acetylcysteine acts via multiple inter-related mechanisms to 
influence oxidative homeostasis, neuronal transmission and inflammation. N-acetylcysteine 
has been shown to reduce oxidative stress and inflammation in both human and animal 
models. There is clinical evidence to suggest N-acetylcysteine may be beneficial in 
preventing the cognitive decline associated with both acute physiological insults and 
dementia-related disorders. To date, no trials have examined perioperative N-acetylcysteine 
as a potential moderator of post-operative cognitive changes in the non-cardiac surgery 
setting. 
Design: A single centre, randomised, double-blinded placebo-controlled trial, with a between 
group, repeated-measures, longitudinal design. 
Methods: The study will recruit 370 non-cardiac surgical patients at the University Hospital 
Geelong, aged 60 years or more. Participants are randomly assigned to receive either N- 
acetylcysteine or placebo (1:1 ratio), and groups stratified by age and surgery type. 
Participants undergo a series of neuropsychological tests prior to surgery, 7 days, 3 months 
and 12 months post-surgery. It is hypothesised that the perioperative administration of N- 
acetylcysteine will reduce the degree of post-operative cognitive changes at early and long- 
term follow-up, as measured by changes on individual measures of the neurocognitive 
battery, when compared with placebo. Serum samples are taken on the day of surgery and on 
day 2 post-surgery to quantitate any changes in levels of biomarkers of inflammation and 
oxidative stress. 
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Discussion: The PANACEA trial aims to examine the potential efficacy of perioperative N- 
acetylcysteine to reduce the severity of post-operative cognitive dysfunction in an elderly, 
non-cardiac surgery population. This is an entirely novel approach to the prevention of post- 
operative cognitive dysfunction and will have high impact and translatable outcomes if NAC 
is found to be beneficial. 
Registration: The PANACEA trial has been registered with the Therapeutic Goods 
Administration, and the Australian New Zealand Clinical Trials Registry: 
ACTRN12614000411640 (15th April, 2014). 
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Background 
Cognitive decline after surgery is common amongst elderly surgical patients (Moller et al., 
1998, Rundshagen, 2014, Zywiel et al., 2014). Post-Operative Cognitive Dysfunction 
(POCD) refers specifically to dysfunction in post-operative cognitive performance relative to 
pre-surgical performance, however the exact threshold delineating when cognitive decline 
can be classified as POCD varies considerably within the literature(Rudolph et al., 2010). 
One of the most robust studies places the early post-operative incidence rate of POCD at 
approximately 25% of major surgery patients, aged over 60 years(Moller et al., 1998, 
Rudolph et al., 2010, Zywiel et al., 2014) Generally, cognitive decline after surgery 
manifests as subtle dysfunction across a number of cognitive domains, such as memory, 
attention, and psychomotor function. It may persist in some patients for months or years and 
herald the onset of a dementia process, to the significant detriment of quality of life (Krenk 
and Rasmussen, 2011, Nadelson et al., 2014, Steinmetz et al., 2009, Abildstrom et al., 2000). 
Given the lack of consensus regarding the exact demarcation of POCD, it is useful to instead 
refer to an absolute difference in cognitive function after surgery controlling for baseline 
values, regardless of whether or not such a change in function meets the specifications for 
POCD. 
 
 
At present, there are neither pharmacological interventions nor preventative agents for 
POCD. Recently the role of oxidative stress and neuroinflammation as a result of a surgical 
stress response has been well-characterised, and now provides a potentially modifiable target 
for therapeutic intervention (Bilotta et al., 2013, Enciu et al., 2013, Erickson et al., 2012, Li et 
al., 2012, Hovens et al., 2012). Pre-clinical literature has identified the relationship between 
surgery and anaesthesia, and the production of inflammatory signals and reactive oxygen 
species in the periphery and brain which are associated with cognitive dysfunction 
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(Barrientos et al., 2012, Chen et al., 2008, Cibelli et al., 2010, Rachal Pugh et al., 2001, 
Rosczyk et al., 2008, Vacas et al., 2013). 
 
Why N-acetylcysteine? 
 
N-acetylcysteine (NAC) provides the rate-limiting molecule, cysteine, for glutathione 
production. Glutathione is the major antioxidant species in the brain, enhancing the brain’s 
capacity to respond to oxidative stress conditions which are associated with cognitive deficits 
(Choy et al., 2010, Otte et al., 2011). NAC also mitigates the negative effects of inflammation 
on cognition, suppressing the over activation of the brain’s inflammatory cells (Haddad, 
2011, Lanté et al., 2008, Palacio et al., 2011). Importantly, NAC is also effective in reducing 
cognitive deficits in pre-clinical models of Alzheimer’s disease via modulation of 
inflammation and oxidative stress (Fu et al., 2006, Hsiao et al., 2012, Huang et al., 2010, 
Robinson et al., 2011). 
 
 
NAC has been found to be beneficial in the clinical setting for a variety of psychiatric, 
neurological and medical conditions with cognitive sequelae, including late-stage 
Alzheimer’s disease (Adair et al., 2001, Chan et al., 2008, Remington et al., 2015, Remington 
et al., 2009). NAC has demonstrated efficacy in reducing the elevations of markers of 
inflammation and oxidative stress seen after major surgery; markers which are now thought 
to be predictive of risk of cognitive sequelae (Kuyumcu et al., 2015, Mahmoud and Ammar, 
2011, Ozaydin et al., 2013). Hence, we propose NAC may protect against post-surgical 
cognitive decline in the at-risk population. 
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Aims 
 
Primary 
 
   To investigate the effectiveness of NAC in reducing the severity of cognitive decline following 
major elective non-cardiac surgery. 
Secondary 
 
   To investigate the effectiveness of NAC in reducing biomarkers of inflammation and oxidative 
stress in the perioperative setting. 
   To examine correlations between changes in cognition and biomarkers. 
 
   To identify potential predictors of cognitive change following surgery. 
 
 
Hypotheses 
 
Primary 
 
   Administration of NAC in the perioperative setting is superior to placebo for reducing the 
severity of early POCD, as measured by changes in performance on the psychomotor-attention 
composite of the CogState Brief Battery (CBB). 
Secondary 
 
   Administration of NAC in the perioperative setting is superior to placebo for reducing the 
severity of enduring cognitive change in the late post-operative period, as measured by changes 
in performance on the psychomotor-attention composite of the CogState Brief Battery 3 months 
after surgery, and 1 year after surgery. 
   Administration of NAC in the perioperative setting is superior to placebo for reducing the 
severity of cognitive change in the early post-operative period, as measured by changes on the 
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), the Controlled 
Oral Word Association Test (COWAT), and Trail Making Tests A & B (TMT) seven days after 
surgery. 
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   Administration of NAC in the perioperative setting is superior to placebo for reducing the 
severity of cognitive change in the late post-operative period, as measured by changes on the 
RBANS, COWAT, and TMT at 3 months after surgery, and 1 year after surgery. 
   Administration of NAC in the perioperative setting is superior to placebo for reducing serum 
levels of biomarkers of inflammation and oxidative stress in the post-operative phase. 
   There is an inverse correlation between performance on the neuropsychological battery and 
serum biomarkers of oxidative stress, at baseline, in the post-operative period and at follow-up. 
 
Methods and Design 
 
A randomised, double-blind, placebo-controlled, single centre clinical trial. A total of 370 
participants are randomised into either a placebo or treatment (NAC) group in a 1:1 ratio. 
Trial Procedures 
Participants undergo an initial recruitment and screening interview, a baseline assessment of 
cognition, mood, and quality of life prior to surgery, and follow up visits at post-surgery day 
2, day 7, 3 months and 12 months. Serum sampling for biomarker assessment occurs 
immediately prior to surgery, and then again on post-surgery day 2 to correlate with peak 
oxidative stress levels. 
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Post Operative Day 
7 Follow Up 
3 Month Post 
Operative Follow 
Up 
12 Month Post 
Operative Follow 
Up 
Figure 1 – Trial flow chart 
 
Recruitment 
Post Operative Da 
3 
2400mg NAC/Placebo 
Pre Surgical 
Baseline 
Assessments 
Post Operative Day 
2 
2400mg NAC/Placebo 
2nd Blood sample taken 
Day of Surgery 
2400mg NAC/Placebo 
1st Blood sample taken 
Post Operative Day 1 
2400mg NAC/Placebo 
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Figure 2. Timeline of Instruments 
Instruments Recruitment Prior to 
 
surgery 
Day of 
 
Surgery 
POD 
 
1 
POD 
 
2 
POD 
 
7 
3m 12m 
MMSE* X        
CBB**  X    X X X 
RBANS**  X    X X X 
COWAT**  X    X X X 
TMT**  X    X X X 
CAM*     X X   
HADS**  X    X X X 
WHOQOL-BREF**  X     X X 
NRS11*  X   X X   
Modified Brief Pain 
 
Inventory** 
      X  
Neuropathic Pain 
 
Questionnaire** 
       X 
Research blood 
sample – 
biomarkers* 
  X  X    
CAM: Confusion Assessment Method; CBB: CogState Brief Battery; COWAT: Controlled 
Oral Word Association Test; HADS: Hospital Anxiety and Depression Scale; MMSE: Mini 
Mental State Exam; NRS11: Numerical Rating Scale for Pain; RBANS: Repeatable Battery 
for the Assessment of Neuropsychological Status; TMT: Trail Making Tests A & B; 
WHOQOL-BREF: World Health Organistion Quality of Life scale. *To be performed by 
trained research staff; **To be performed by research staff trained in neuropsych assessment. 
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Setting and Participants 
 
The study is being conducted at the University Hospital Geelong, a public teaching hospital 
that caters for the majority of surgical subspecialties, other than neurosurgery, organ 
transplantation, and cosmetic plastic surgery. Patients undergoing major non-cardiac surgical 
procedures of vascular; ear, nose, and throat; plastic surgery; gynaecological; orthopaedic; 
urological; ophthalmological; and general surgery are invited to participate. Based upon data 
from the 2014 calendar year, there are over one thousand potentially eligible patients 
annually. Potential participants are identified and approached during pre-surgical outpatient 
clinics by experienced research nurses. Prospective participants are provided with an 
information and consent form that must be signed and witnessed by a member of the research 
team before enrolment. Participant visits will take place at University Hospital or at the home 
of the participant where applicable. 
 
Regulatory Approval 
 
Barwon Health Human Research Ethics Committee and Deakin University Human Research 
Ethics Committee have provided ethics approval. Approval was required, and granted by, the 
Therapeutic Goods Administration (TGA) under the Clinical Trials Notification Scheme to 
conduct the study. 
 
Inclusion criteria 
 
Patients aged greater than or equal to 60 years undergoing major elective non-cardiac 
surgery, defined as surgery expected to last at least one hour in duration and requiring 
admission to hospital for at least two nights are eligible for recruitment. This is in accordance 
with findings from the seminal International Study of POCD, where increased length of 
surgery was significantly associated with increased risk of POCD after approximately 1 hour 
(Moller et al., 1998, Rundshagen, 2014). 
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Exclusion criteria 
 
Participants are ineligible to take part if they; 
 
   Have known contraindications to NAC, including allergies and concomitant nitrate therapy. 
   Are unable to comply with the requirements of informed consent or the study protocol. 
   Are already taking NAC. 
 
   Are undergoing carotid endarterectomy, due to the high incidence of perioperative. 
cerebrovascular accidents (Rajeswaran et al., 2011). 
   Are undergoing surgery for trauma. 
 
   Lack the capacity to consent to their own surgery. 
 
 
Randomisation, Allocation, and Concealment 
 
Once consent is confirmed, participants are randomised to a treatment group. Randomisation 
is stratified by surgery type (orthopaedic or non-orthopaedic) and age (less than 80 years or 
80 years or older) to provide four strata for the study. The allocation code was produced by 
an independent researcher prior to the commencement of recruitment and was generated by a 
computer-generated list, using permuted block randomisation with variable block sizes. The 
allocation code is concealed to all trial personnel, with the exception of the dispensing 
pharmacist. The pharmacist allocates the participant number, based on the relevant stratum 
and holds the code if unblinding is required, but is not involved in data collection. All other 
relevant persons, including investigators, research assistants, research nurses, and participants 
are blind to the treatment allocation until the end of the data analysis. 
 
 
To aid treatment concealment, all trial materials appear identical. Further, the placebos have 
been dusted with a non-therapeutic amount of NAC to assist with matching odours (given 
NAC has a strong odour). The placebos and NAC capsules are identical to in size, taste, and 
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appearance. All trial medication is provided in identical bottles. Any unused medication is 
returned to the pharmacy for auditing. 
 
 
Stratification by age enhances parity between groups in terms of its effects upon cognition, in 
accordance with established risk factors (Krenk and Rasmussen, 2011, Monk et al., 2008). 
Despite the relative safety and success of orthopaedic surgeries compared with non- 
orthopaedic surgeries, the risk of cognitive dysfunction is still significant (Zywiel et al. 
2014). Accordingly, orthopaedic patients represent an opportunity to examine potential 
cognitive change that is less likely attributable to other factors. Additionally, stratification by 
orthopaedic and non-orthopaedic counteracts the wide variability of reported POCD in the 
literature (Rasmussen, 2006). Meta-analyses suggest small cognitive improvements from 
pooled data yet individual studies note an incidence of POCD as high as 45% (Rasmussen). It 
is widely held that this variability is due mostly to discrepancies in diagnostic criteria 
(Mahanna et al. 1996) but the concern remains that a significant subset of individuals within 
the orthopaedic cohort do experience cognitive improvement. The literature to date has not 
provided the means to identify them prospectively, but it has been suggested that a low 
cognitive baseline secondary to chronic inflammation, pain, opioid consumption and 
restricted mobility, coupled with the potential for surgical remedy, is a potent confounder of 
post-surgical cognition (Lewis, Maruff, Silbert, Evered, & Scott, 2006). This complex and 
not yet fully characterised surgical profile suggests that the broad classification of surgeries 
into orthopaedic and non-orthopaedic may help to minimise any confounding in the collected 
data, with negligible loss of power with respect to a non-stratified design. 
 
Dose and Treatment Regimen 
 
Administration of NAC in a wide variety of medical settings has been shown to be safe (Brok 
et al., 2006, Gu et al., 2012). Whilst there is variation within the literature regarding dose and 
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timing of NAC, recent reviews have suggested oral NAC administered at doses of 
2400mg/day to be efficacious in delivering demonstrable biomarker change with a negligible 
adverse effect profile (Atkuri et al., 2007, Sadowska et al., 2007). Kuyumcu et al. (2015) 
showed improved oxidative status in abdominal surgery patients with a total dose of 2400mg 
of NAC administered intravenously over two days prior to surgery. Dose regimens well in 
excess of 2400mg/day have been safely explored with some regularity, but are likely to be 
burdensome during oral administration, a route which offers greater safety and ease of 
administration than intravenous infusion. Bearing in mind the previously established 
effective doses, the expected duration of the surgical stress response (Gu et al., 2012), the 
oral bioavailability of NAC and the relative ease, safety and cost effectiveness of oral 
administration, we have chosen a regimen of 1200mg NAC orally twice daily, consisting of 
two 600mg capsules in the morning and again in the evening, starting on the day of surgery 
and continuing for four days to a total cumulative dose of 9600mg. Administration takes 
place during the patients regular morning and evening drug rounds, facilitated by the ward 
staff and recorded from the patient chart by the research nurses. Placebo is administered in an 
identical fashion. Medication is dispensed by the pharmacy and administration coordinated 
by the research nurses, and recorded in the trial records for each participant. Unused 
medication is returned to the pharmacy for disposal. Episodes of nausea and vomiting are 
recorded by research staff. 
 
Assessments and Information 
 
Demographic data and details of participants’ medical history are recorded to explore 
potential risk factors and confounders, gathered from participant interview, chart review, and 
examination of medical history. The following variables are specifically sought to identify 
potential predictors of outcome: age, gender, participants who identify as having Aboriginal 
and Torres Strait Islander descent, educational attainment, chronic inflammatory diseases 
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(such as rheumatoid arthritis), osteoarthritis and inflammatory bowel disease, medications 
with anti-inflammatory properties (including statins, NSAIDs and steroids), pre-existing 
psychiatric conditions and/or medication, and vascular risk factors including diabetes, total 
cholesterol, smoking status, hypertension, atrial fibrillation, heart disease – ischaemic/cardiac 
failure, and previous transient ischaemic attack/stroke. 
 
Cognitive Function Measures 
 
Cognitive function is assessed prior to surgery, 7 days post-operation, 3 months after surgery, 
and again 12 months after surgery. Cognitive dysfunction at approximately one week post- 
surgery has been shown to be a significant predictor of further cognitive change in elderly 
post-surgical patients, and so comparisons of cognition at post-operative day 7 with pre- 
operative baseline is considered the primary outcome (Lim et al., 2013). A number of 
cognitive domains are measured using a selection of validated neuropsychological tests. All 
assessments are reliable and validated for the use in detecting cognitive change (Johnston et 
al., 2000; Wei et al., 2008; Lucas-Carrasco et al., 2011; Malek-Ahmadi et al., 2011; 
Karantzoulis et al., 2013; and Terada et al., 2013). All assessments, with the exception of the 
CBB, are recorded in specially created case report forms, and stored securely after the 
transcription of data into the secure computer database (Research Electronic Data Capture, 
REDCap). The CBB automatically uploads data into a secure database, and does not require 
paper records. All assessments are performed by trained research staff, supervised for 
compliance and quality by the senior clinicians. Psychomotor, attention, learning and 
working memory domains are assessed with the computerised CBB. The CBB consists of 
four tasks; detection, identification, one card learning, and one card back. In the detection 
task, the participant is asked to press a button as soon as a displayed card is turned over. The 
psychomotor-attention composite is made up of the detection and identification tasks on the 
CBB and represents the reaction time of the participant, where higher scores indicate lower 
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reaction speed and can be used to suggest the presence of impairment. The CBB has shown 
efficacy in detecting cognitive change in healthy participants over 12 months (Fredrickson et 
al. 2009), and in clinical samples (Lim et al. 2013). 
 
 
Immediate memory, visuospatial, and delayed memory domains are assessed with the 
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS; Karantzoulis 
et al., 2013). The RBANS consists of 12 subtests measuring immediate and delayed verbal 
and visuospatial memory, and is commonly used for the detection of cognitive change. 
Alternate forms are used at each assessment. 
 
 
Verbal fluency and executive function is assessed with the Controlled Oral Word Association 
Test (COWAT). Over three attempts, participants are given one minute to list as many words 
beginning with a specified letter. Errors and perseverations are recorded (Malek-Ahmadi et 
al., 2011). 
 
 
Visuospatial and executive function is assessed with the Trail Making Test A and B (TMT). 
Participants are asked to connect a series of numbered scattered dots in sequential order. Only 
numbered dots are used in Test A; alternating numbers and letters are used in Test B (Terrada 
et al. 2013). 
 
Delirium Assessment 
 
Post-operative delirium typically manifests between 24-72 hours after surgery, and may last 
up to several days (Silverstein & Deiner, 2013). Delirium is assessed on post-operative days 
2 and 7 using the short form of the Confusion Assessment Method instrument (CAM; Wei et 
al., 2008). 
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Mood Disorder Measurement 
 
Depression and Anxiety is assessed prior to surgery, 7 days post operation, 3 months post 
operation, and 12 months after surgery using the HADS questionnaire. The HADS is a brief 
self-report Likert scale where participants report how well a depressive or anxious symptoms 
describes them in the past seven days (e.g. “I felt tense or ‘wound up’” (Johnston et al. 2000). 
 
Quality of Life Measurement 
 
Quality of life is assessed prior to the operation, at 3 months post operation, and again at 12 
months post operation using the World Health Organization Quality of Life – BREF 
questionnaire (Lucas-Carrasco et al., 2011). 
 
Blood levels of inflammation and Oxidative Stress 
 
Serum samples are collected during placement of an intravenous line during surgery 
(baseline), and again in conjunction with routine post-operative bloods on post-surgery day 2. 
This is timed to capture the approximate time of peak post-operative inflammatory markers 
of approximately 24-72 hours after surgery (Hudetz et al., 2011).. Blood samples (30ml) are 
taken by research staff and spun in equal portions into separate plasma, serum, and whole 
blood aliquots. These are then stored onsite at -80C in preparation for analysis by research 
staff at the end of data collection. 
 
 
Whilst surgery and anaesthesia are associated with a systemic inflammatory response, 
patients who develop POCD tend to show higher levels of inflammatory markers including 
interleukin-(IL)1β and Ridel et al. 2010), relative to those with intact cognition. Similarly, 
markers of oxidative stress, previously correlated to neuroinflammation, may be upregulated 
in POCD (Hudetz et al. 2011). Circulating inflammatory factors are thought to potentiate 
neuroinflammation through stimulation of microglia, which produce both pro-inflammatory 
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cytokines and potent reactive oxygen species and are instrumental in neuronal dysfunction 
(Lim et al. 2013). Thus measurement of peripheral inflammation and oxidative damage are 
reflective of not only systemic inflammation in the post-operative context, but also central 
neuroinflammatory processes. We intend to examine a panel of related biological correlates, 
focusing on inflammatory cytokines, the primary CNS antioxidant species and markers of 
oxidative damage to lipid, DNA and protein. Unspecified consent has been requested to 
allow for the exploration of relevant biological markers should they be identified during the 
course of the trial. Changes in peripheral markers will be correlated to clinical improvements. 
 
Perioperative Assessment of Pain 
 
A numerical rating of perioperative pain experienced by the participants is recorded at baseline, 
post-operative days 2 and 7 using the Numerical Rating Scale-11. Additionally, the Modified 
Brief Pain Inventory is conducted at 3 months, and the Neuropathic Pain Questionnaire is 
conducted at 12 months. 
 
Outcome Variables: 
 
Primary outcome variable: 
 
   A between groups comparison of cognitive performance in the early post-operative period 
(day 7), as measured using the psychomotor-attention composite score of the CogState Brief 
Battery (CBB). 
Secondary outcomes: 
 
   Between groups comparison of cognitive performance in the early and late post-operative 
period, as measured using the extended neuropsychological battery, at day 7, 3 months and 1 
year post surgery. Comparisons at each time point will be made to scores obtained at pre- 
surgical baseline. 
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   Between groups comparison of mood disorder, as measured using the Hospital Anxiety and 
Depression Scale (HADS), at day 7, 3 months and 1 year post surgery. Comparisons at each 
time point will be made to raw scores obtained at pre-surgical baseline. 
   Between groups comparison of quality of life, as measured using the World Health 
Organisation Quality of Life – BREF (WHOQOL-BREF) scale, at 3 months and 1 year post 
surgery. Comparisons at each time point will be made to raw scores obtained at pre-surgical 
baseline. 
   Between groups comparison of delirium, as measured using the Confusion Assessment 
Method (CAM), on post-surgery day 2 and 7. Incidents of delirium are recorded 
dichotomously. 
   Between groups comparison of post-operative pain, as measured using the Numerical Rating 
Scale (NRS) on post-surgery days 2 and 7; the Modified Brief Pain Inventory at 3 months, 
and the Neuropathic Pain Questionnaire at 12 months post-surgery. 
   Between groups comparison of levels of serum neuroinflammation and oxidative stress, 
including but not restricted to, TNFα, IL-1 β IL-6, S100β, malondialdehyde, and reduced and 
oxidised glutathione on post-surgery day 2. 
 
Withdrawal 
 
Participation is entirely voluntary and consent may be withdrawn at any stage. Withdrawal 
reasons are documented and recorded. Participants are not considered withdrawn if they are 
lost to follow-up, and research staff will attempt to re-connect with participants for 
subsequent assessments. For example, a participant who is unable to be contacted for the 3 
month follow-up is recorded as a missed session, but research staff will attempt to contact the 
participant for the 12 month follow-up. Participants are withdrawn from treatment and/or 
assessment if they: 
   Withdraw consent for participation, 
 
Are unblinded for any purpose prior to the end of the treatment period, 
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   Are requested to withdraw by their treating medical team due to interference with their 
appropriate clinical management, 
   Require subsequent surgery or anaesthesia prior to measurement of the primary outcome 
variable. 
 
Adverse Events 
 
Adverse events (AEs), serious adverse events (SAE), and suspected unexpected serious 
adverse reaction (SUSAR) monitoring and reporting are conducted in strict accordance with 
the processes established by both governing ethics committees. 
AEs are recorded from the time that informed consent has been obtained until the end of the 
12 month study period. For each, the following parameters are described: 
   The investigator’s assessment of the causal relationship between the event and the 
investigational treatment. 
   A description of the AE, including its nature, start and stop date, action taken with regards to 
the investigational treatment, intensity and outcome. 
   A statement if the AE fulfils the criteria for an SAE or SUSAR. 
 
Intensity is determined according to the following categories: 
 
   Mild: an AE which is easily tolerated by the participant, causing minimal discomfort and not 
interfering with everyday activities. 
   Moderate: an AE which is sufficiently discomforting to interfere with everyday activities. 
 
   Severe: an AE which is incapacitating and prevents everyday activities and/or requires 
therapeutic intervention, i.e. use of a prescription drug or hospitalisation. 
 
Follow up of Adverse Events and SUSAR’s 
 
AEs are followed up until either they are resolved, they persist despite cessation of the trial 
medication and its elimination from the body (given the half-life of NAC is roughly 6 hours, 
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this is estimated to take no longer than 2 days), or for longer at the discretion of the 
investigators. 
 
Reporting of Serious Adverse Events and SUSAR’s 
 
Reporting of SAEs to regulatory authorities is done within the requisite twenty four hour period 
by an investigator in accordance with local regulations. A copy of the SAE report is sent to the 
Barwon Health Human Research and Ethics Committee, the Sponsor and the Principal 
Investigator. If unblinding is required, a report will also be sent to the Therapeutic Goods 
Administration. 
 
Mortality Reporting 
 
Regardless of causality or which randomisation arm the participant is assigned to, all cases of 
mortality are reported to the Data Safety Management Board and regulatory authorities. 
 
Termination and Safety 
 
It is intended that the trial will run for the projected duration of 4 years from recruitment of 
the first patient. A DSMB has been established for this study and is independent of the 
Investigators. Investigators provide intermittent reports to the DSMB with any information 
relating to safety analyses, and monitor instances of adverse. The DSMB provides 
recommendations regarding the continuation of the study. 
 
Sample size determination 
 
Due to variations in definitions and cut-off criteria, measuring the effects of POCD, in the 
context of previous literature, is extremely difficult. Additionally, there is no literature 
available examining the use of the CBB for the detection of POCD, despite being 
theoretically suited to the task. However, literature that examines differences between healthy 
controls and mild cognitive impairment (MCI) provides a close approximation of the 
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quantifiable effects of cognitive change after surgery. An examination of the available 
research utilizing the CBB provides an estimated effect size of cognitive change in 
comparison to healthy controls, MCI, and Alzheimer’s disease participants. 
 
 
Literature suggests a strong correlation between the two tasks of the psychomotor-attention 
composite, detection and identification, for simplicity’s sake assumed to be in the region of r 
=0 .8 is expected (for example, see the similarities present on scores from the research of 
Hammers and colleagues, 2012; and Lim and colleagues, 2012). Further, the variances for 
pre- and post-surgery will be standardised to 1. The variance of the composite is calculated as 
the sum of pre- and post-surgical variances plus 2x the correlation of the composite tasks; 2 + 
2 (0.8) = 3.6. Therefore, to estimate the effect of MCI (and by extension, cognitive change 
after surgery), we divide the combined effect size for the psychomotor-attention composite 
by the standard deviation of the effect size, that is the square root of the variance of the 
composite. From Lim and colleagues, the effect of MCI size of the change in reaction speed 
for the detection and identification tasks were -0.33 and -0.63 respectively, giving a total 
reduction in reaction speed effect size of -0.96. Therefore, the total effect of MCI (and by 
extension, cognitive change after surgery) upon the psychomotor-attention composite is equal 
to: - 0.96/√3.6 = -0.51. Given that NAC is unlikely to improve cognition beyond baseline 
estimates, it is proposed that NAC may instead ameliorate the severity of cognitive 
dysfunction compared with placebo. Given limited available data, we have attempted to 
estimate an approximate protective effect based on the use of NAC in analogous conditions, 
such as traumatic brain injury (Hoffer et al. 2013). Additionally, it is unrealistic to assume 
complete prevention of cognitive dysfunction. Therefore, a relative reduction in severity of 
cognitive dysfunction of 50% represents an appropriate compromise to calculate the power. 
 
 
Given the likelihood of significant correlation in pre- and post-surgery cognition scores, 
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and in the absence of any identifiable correlation size, it is prudent to include an estimation 
of correlation patterns in the medium range (r = 0.50). A protective effect due of NAC of 
50% would then set the expected effect of post-operative cognitive change as modulated 
by NAC at =-.255. Assuming an alpha level =.05, power = 80%, and a pre- and post-
surgical score correlation =0.5, a sample size of 370 participants will have 80% power to 
detect a minimum absolute effect size of 0.255 using an Analysis of Covariance 
(ANCOVA) model. This sample size includes approximately equal representation across 
stratification by age and surgery type for intervention. 
 
Primary analysis 
 
The primary study hypothesis states that the perioperative administration of NAC is superior 
to placebo in reducing the severity of post-operative dysfunction, as measured by the CBB at 
post-operative day (POD) 7, and compared with baseline. Analysis of the primary outcome 
will be via ANCOVA, utilising the baseline psychomotor-attention composite score as a 
covariate. Assumptions of the ANCOVA will be examined through standard tests and 
residual plots, with transformation of variables being considered if normality of the residuals 
is not met. The psychomotor-attention composite is made up of the detection and 
identification tasks on the CBB and represents the reaction time of the participant, where 
higher scores indicate lower reaction speed and can be used to suggest the presence of 
impairment. The composite score is calculated by standardising each task score and adding 
them together. All analyses will be performed as intent-to-treat, in order to best emulate 
practice settings. 
 
Secondary Analyses 
 
Linear mixed model ANCOVA will be conducted to model the differences in cognitive 
changes between treatment groups by fitting a linear curve to represent the relationship 
between performance on tasks and time-point. The magnitude of the differences between 
142  
treatment groups will be expressed as Cohen’s d. Between groups differences on the 
individual tasks of the neuropsychological battery will be examined. Similar to the primary 
analysis, an ANCOVA will be used to examine the performance of participants on each of 
the neuropsychological battery tasks. Included in the analyses will be the individual CBB 
tasks, detection, identification, one-card back, and one- card learning; RBANS tasks, the 
COWAT, and Trail Making Tests A & B. Data will be represented as a linear mixed-effects 
model, comparing the performance of the NAC group compared to the control group over 
time. The magnitude of difference between treatment groups will be calculated as Cohen’s 
d. 
 
 
Between groups differences on measures of delirium and mood dysfunction will be analysed 
using a Chi-square test using the CAM and HADS measures. Participants will be classified 
dichotomously as displaying symptoms of delirium or mood dysfunction according to 
established cut-off points; 11 points on either anxiety or depression for the HADS, or 
fulfilment of delirium criteria according to the CAM. 
 
 
Between groups differences on measures of quality of life will be analysed using an 
ANCOVA to examine changes over the course of the trial, controlling for baseline values as 
a covariate. Between groups differences will be examined for change across time from 
baseline scores to 3 months and 12 months. A linear mixed-effects model will be used to 
represent the data comparing treatment groups, with the magnitude between treatment groups 
expressed as Cohen’s d. 
 
 
Between groups differences in serum levels of biological markers will be examined prior to 
surgery and at POD2 in order to capture the surgical stress response. An ANCOVA will be 
performed to examine the between groups differences over time, with baseline values acting 
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as a covariate. Data will be graphed using a linear mixed-effects model, with the magnitude 
of difference between treatments groups expressed as Cohen’s d. 
A bivariate correlation analysis exploring serum biological marker levels and cognitive 
function will be calculated for each of the battery tasks. 
 
Exploratory Analyses 
 
Subgroup analyses will be undertaken to examine the role of variables that may contribute to 
risk factors associated with POCD, such as demographic information, health and medical 
history, socio-economic status and other data collected during the study. These subgroup 
analyses can be examined using a multilevel modelling approach. For example, by treating 
the presence of POCD in a participant as an outcome level, it will be possible to examine the 
relative contributions of each independent variable to POCD (e.g. varying treatment effects 
for differing levels of demographics). This approach can also be expanded to further examine 
other participant outcomes, such as the presence of delirium, mood dysfunction, or a 
significant change in quality of life. For exploratory analyses focussed upon proportionate 
data, such as comparisons of dichotomous delirium or mood dysfunction outcomes, 
McNemars’ test can be used to examine within-groups differences across time points. The 
role of perioperative pain upon POCD may also be explored as a potential cognitive 
trajectory modulator. 
 
Missing or incomplete data 
 
All participants recruited into the study, regardless of treatment group, are to have as much 
data as possible recorded, as fully as possible in accordance with this protocol. Missing data 
is monitored so as to avoid bias by attrition or patterns of missing data. All cases of missing 
data, including instances of non-retention of participants or withdrawal of consent, are to be 
recorded by research staff. Where data is missing, the frequency and reasons for missing data 
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are to be recorded. Missing data is to be examined to see if there are patterns informative to 
the study; for example, if certain variables are missed in a systematic way by an identifiable 
pattern of participant. 
 
 
In situations where data is missing, for example with participants who are lost to the 12 
month follow up, the data collected up to that point should still be used provided the 
participant has not withdrawn their consent or requested that the information be removed. If 
missing data is considered Missing at Random (MAR, i.e. without a pattern), then multiple 
imputation methods should be used to estimate missing values. The accepted minimum 
number of imputations is five, to estimate the missing data from existing data. This can be 
achieved using statistical software. If data appears to be missing in a way that is not random 
(Missing Not At Random, MNAR), then this data can be examined for potential biases or 
patterns statistically, and missing values can then be estimated using monotonistic methods. 
Discussion 
Our study is the first randomised control clinical trial on the efficacy of perioperative NAC 
administration upon cognition. Because the trial will aim to recruit 370 participants and 
primarily examine the efficacy and safety of NAC, we consider this to be a phase 2 trial. 
Australia’s population is ageing, and will continue to require greater numbers of surgeries. 
The commonness of cognitive dysfunction after surgery ((Moller et al., 1998, Rasmussen, 
2006, Rundshagen, 2014, Zywiel et al., 2014) and the significantly increased risk of 
expedited morbidity and mortality (Krenk and Rasmussen, 2011, Nadelson et al., 2014, 
Steinmetz et al., 2009, Abildstrom et al., 2000) provide a strong community motivation to 
investigate potential interventions, and it is hoped that NAC may fulfil that need. 
The PANACEA trial is not without limitations, particularly the risk of attrition common in 
longitudinal studies. The potential for increased risks of nausea and vomiting may also result 
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in participant withdrawal. While all reasonable attempts to reduce the influence of attrition 
bias are employed, the possibility cannot be ruled out. 
 
Trial Status 
 
The PANACEA trial commenced recruitment in March 2015. The study has been registered 
with the Therapeutic Goods Administration, and the Australian New Zealand Clinical Trials 
Register (ANZCTR): ACTRN12614000411640. The study is performed in accordance with 
ethical and good clinical practice principles detailed by the Declaration of Helsinki and 
International Conference on Harmonisation (Mellin-Olsin et al. 2010). 
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Linking the PANACEA protocol to the 
preliminary analyses 
What questions needed to be answered? The early chapters of this thesis presented an 
argument for the neuroinflammatory hypothesis of cognitive dysfunction, and specified the 
potential of the antioxidant N-acetylcysteine to reduce the severity of this dysfunction across 
a range of populations. However, as mentioned in Chapter 2, little research has directly 
examined the efficacy of N-acetylcysteine for POCD, and thus chapter 4 laid out a research 
design examining the potential mitigating effect of perioperative N-acetylcysteine upon 
POCD. While the primary hypothesis of the PANACEA trial is not yet able to be tested due 
to the ongoing nature of the trial, the collection of data allowed the exploration of a multitude 
of contributing factors to cognitive change, including alternate interventions beyond the 
eponymous N-acetylcysteine for which the trial was named. The presented protocol therefore 
provides a useful context for investigating pre-, peri, and post-operative risk and protective 
factors for POCD, and further allows the proposal of predictive algorithms for cognitive 
change based upon these factors. 
 
 
What new questions arise? 
 
Numerous risk and protective factors for POCD have been proposed in the literature to 
varying degrees of substantiation, such as the role of advancing age, history of psychiatric 
disorders, substance use history, and the like. However, due to the relatively small amount of 
research available, few attempts at examining a comprehensive set of contributing factors 
exist and even fewer present statistical models. Chapter 5 therefore serves to provide a 
preliminary examination of these contributing factors in several ways – firstly, each potential 
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contributing factor to cognitive dysfunction is examined twice, once for univariate predictive 
utility, and secondly in concert with other significant predictors. Secondly, cognitive 
dysfunction is examined using two alternate models to reflect the differing interpretations in 
the literature and account for a spectrum of diagnostics. This is achieved using a conservative 
dichotomous model, and a more flexible and permissive linear model. 
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Abstract 
 
INTRODUCTION: Post-operative cognitive dysfunction (POCD) is a common condition 
associated with increased risk of long-term cognitive decline. Little is known about the 
mechanisms of the condition, though numerous contributing factors have been proposed. 
METHOD: 174 patients of major, non-cardiac surgery (Mean age = 70 years; 65% female) 
were assessed before and after surgery. Theoretical contributing factors were entered into 
two models adjusted for participant characteristics. 
RESULTS: Most participant characteristics did not differ significantly between those with 
POCD and those without. Pre-operative use of COX-II inhibitors was negatively associated 
with POCD, and POD2 pain, cardiovascular complications, and history of malignant tumours 
may all contribute to a predictive model of cognitive change. 
DISCUSSION: Pre-operative use of COX-II inhibitors is associated with reduced incidence 
of POCD, while other characteristics including pre-surgical cognition may be predictive. 
Further research into the use of anti-inflammatory strategies for the mitigation of post- 
operative decline is warranted. 
 
Keywords: 
 
Cognitive change, surgery, post-operative cognitive dysfunction, Alzheimer’s disease, 
dementia 
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Introduction 
Post-operative cognitive dysfunction (POCD) is a condition affecting an estimated 10% of 
non-cardiac surgical patients up to 3 months after surgery (Paredes et al., 2016).This may be 
much greater in cardiac patients, especially in the early post-operative period linked to 
inflammatory and oxidative events (Evered et al., 2011). POCD is typically characterised by 
deficits in cognitive function in the early post-operative period, with a small minority of 
patients experiencing persistent symptoms even years later (Steinmetz et al., 2013). Recently 
it has been suggested that the presence of POCD can agitate existing cognitive deterioration 
and exacerbate, in particular, cases of mild cognitive impairment, dementia, and Alzheimer’s 
disease (Inouye et al., 2016; Lingehall et al., 2017). In addition to cognitive deficits, POCD is 
longitudinally associated with a significantly higher risk of morbidity and mortality, and 
reduced quality of life (Nadelson et al., 2014; Steinmetz et al., 2009). Risk factors of POCD 
include advanced age, history of substance use or psychiatric disorders, and previous 
ischaemic events (Monk et al., 2008). Other proposed contributing factors such as the 
variance of surgery duration and type or anaesthesia modalities are currently the subject of 
much debate and ongoing research (Evered et al., 2011; Shoair et al., 2015). 
 
 
The mechanisms of POCD are similarly unknown though numerous theories have been 
proposed, the most promising of which is the neuroinflammatory/oxidative stress hypothesis 
(Kapila et al., 2014; Vacas et al., 2013). In conjunction with the lack of a mechanism 
consensus, there are currently no established interventions or preventative therapies for 
POCD, and the current research is relatively nascent. Most promising is the clinical data for 
dexmedetomidine (Liu, Ma, Gao, Guo, & Ma, 2016) and COX-II inhibitors (Zhu, Yao, 
Zhang, Xu, & Wang, 2016) both of which have shown some efficacy for the mitigation of 
POCD; further supporting the notion that POCD may be due in part to a neuroinflammatory 
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response. Further, while research has examined numerous other potential therapies, clinical 
trials are relatively rare. 
 
 
The Post-Anaesthesia N-Acetyl-Cysteine Cognitive Evaluation (PANACEA) trial is a large, 
randomised, double-blind, placebo controlled trial intended to examine the potential of the 
antioxidant N-acetylcysteine (NAC) for the mitigation of POCD. Details of the research 
design and methodology are provided in full elsewhere (Skvarc et al., 2016). In brief, the 
PANACEA trial seeks to recruit 370 participants over the age of 60 years and undergoing 
major non-cardiac surgery to receive either perioperative NAC (1200mg twice daily, 9600mg 
in total) or a matched placebo, according to random allocation stratified by age and surgical 
type. Full neurocognitive assessments are completed prior to surgery, 7 days, 3 months, and 
12 months after surgery, and post-operative performance is then compared to baseline scores. 
The PANACEA trial began recruitment in early 2015 at University Hospital, Geelong and as 
of early 2017, has recruited over 180 participants with 60 having completed all time points. 
 
 
The field of POCD research is relatively nascent and the comparative lack of large studies 
means that many of the proposed issues of identification, measurement, and mitigation for 
POCD remain controversial. As such, the continued development of the field of evidence for 
contributing factors and potential protective agents is necessary to properly inform clinical 
practice. Thus, is timely to examine the collected data of the PANACEA and compare with 
expected trends, broadly examine any cognitive changes across the cohort, and examine for 
contributing factors to any change. Firstly, it is hypothesized that the rates of POCD in the 
current study will approximate 10% as per the current literature for non-cardiac surgical 
patients in the post-operative period. Exploration of risk and protective factors will be made 
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for participants for whom cognitive declines were observed compared with those with no 
significant change, and also with those where a significant improvement has been observed. 
It is hypothesized that increasing age, increased duration of surgery, history of substance use, 
history of ischaemic events, and presence of medical or psychiatric diagnoses will be 
significantly associated with POCD in the early post-operative period. 
Method 
 
Participants 
 
174 participants (84 female) completed the full assessment prior to undergoing surgery. 151 
also completed the repeated assessment at POD7. The average age of participants was 70.19 
years (SD = 6.7). 130 participants underwent orthopaedic surgery, the remainder underwent 
non-orthopaedic surgery. Hip replacement surgery was the most common procedure with 67 
hip replacement surgeries, followed by knee replacement with 58. Non-orthopaedic surgeries 
were much less homogenous in comparison. Nephrectomies and thyroidectomies were the 
most common non-orthopaedic surgeries with five procedures each. 
 
 
Materials 
Demographics, medical history, and psychiatric history are all recorded through an interview 
with the participant and/or supplemented through consultation of the participant’s records. 
Chronic medical or psychiatric conditions are recorded as lifetime yes or no items; acute 
items are limited to events in the past 6 weeks. Pre-operative medication use is recorded as 
medications that the participant is taking at least daily up until the day of surgery. 
The CogState Brief Battery (CBB) is a computerised battery designed to measure attention, 
concentration, reaction speed, and visual memory. The CBB consists of four tasks: detection, 
identification, one-card learning, and one-card back. The detection and identification tasks 
can be standardised and combined to form the psychomotor composite and the one-card 
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learning and one-card back tasks can be combined in a similar fashion to form the learning- 
memory composite (Maruff et al. 2013). 
 
 
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) is an 
established pen-and-paper neuropsychological battery consisting of 12 subtests. The RBANS 
provides measures of short term and delayed visual memory, short term and delayed verbal 
memory, visual reasoning, executive function, processing speed, and recognition. The scores 
for each subtest can be combined and converted into indices according to age, or combined to 
provide an estimate of full-scale IQ. The scores for the individual tests themselves may also 
be interpreted (Duff et al. 2008). 
 
 
The Controlled Oral Word Association Test (COWAT) is a verbal test of executive function 
and verbal fluency. Participants are given a letter and are instructed to come up with as many 
words beginning with that letter as they can within 60 seconds (Malek-Ahmadi et al., 2011). 
The Trail Making Test (TMT) is a task of visuospatial reasoning, processing speed, and 
executive function consisting of two trials, A and B. Participants are timed until completion 
of each task, with faster completion purported to indicate better performance (Tombaugh, 
2004). 
 
 
Finally, participants were asked to give an estimate of their pain at three time points: prior to 
surgery, POD2, and POD7. This was estimated by asking participants to provide a numerical 
rating of their pain at its worst point over the past 24 hours, between 0 and 10. 
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Statistical analyses 
 
Cognitive change calculation 
The calculation of cognitive change ( Z) is as follows: 
 
 
Where = Z scores for each of the included tests, 
 
And = the standard deviation of the sum of Z scores in the control group. A 
decline in post-operative performance of Z > 2 compared with pre-surgical baseline is 
considered indicative of POCD (Lewis et al., 2004). This will allow the categorization of 
participants into those in whom a cognitive decline was observed at POD7, those who 
improved, and participants where no significant change was observed. The primary outcome 
of the PANACEA project, the psychomotor-attention composite of the CogState Brief 
Battery (CBB), will be used for this categorization. 
 
 
Bivariate and multivariate modelling 
 
Continuous change from baseline 
Cognitive change amongst the entire sample is to be examined using paired sample t-tests in 
SPSS (IBM, 2013) and Cohen’s d, and η2 effect sizes for change in performance from 
baseline to POD7 are calculated using the effect size calculation software by Lenhard and 
Lenhard (2014). Effect sizes can be interpreted as follows: 0.10, 0.30, and 0.50 respectively 
represent small, medium, and large effect sizes (Cohen, 1992). 
To examine for predictors of statistically significant cognitive change that did not meet the 
criteria for POCD, linear regression analysis for each predictor variable was also performed 
in the same way as the logistic model. 
 
 
Dichotomised change from baseline 
To explore potential predictors of cognitive decline, each participant was categorised as 
either declining or not declining in performance at POD7 using the criteria outlined earlier, 
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and this classification was used as the outcome. Predictor variables were entered individually 
into bivariate logistic regression models to check for predictive utility, and those with 
significance at 0.05 were then entered into multivariate binary logistic regression models. 
The multivariate logistic model's adjusted participant characteristic for each cognitive 
predictor one at a time to avoid collinearity. Model adjusted odds ratios (ORs) and 95% 
confidence intervals (CIs) of the predictive factors are reported. 
 
 
Given the exploratory nature of the analysis, a post-hoc power analysis was performed to 
determine if the present sample size was sufficient to detect the cognitive change observed. 
Using the psychomotor composite as the outcome measure and the observed change from 
baseline to POD7, the range of OR’s detectable for a minimum sample size of 151 was 
calculable with G*Power software (Faul et al., 2007). The effect size for change from 
baseline to POD7 was d = 0.052, R2 = .144, with 9% meeting criteria for POCD. Using these 
values, the power analysis revealed the current sample was sufficient to reliably detect ORs 
lower than 0.43 or greater than 2.35 inclusive, or Δη2 = 0.12 for each step of the continuous 
analysis (1- β = 80%, α 0.05). 
 
 
Each variable was entered and analysed individually and the results are presented here in full. 
Some variables were excluded from the analysis due to the insufficient presence in the data; 
these include the history of rheumatoid arthritis, peptic ulcer disease, schizophrenia, learning 
disorder, or previous dementia or cognitive impairment diagnosis. Similarly, there was 
insufficient variance to examine the influence of intraoperative clonidine administration or 
atrial fibrillation. Postoperative incidence of atrial fibrillation, acute kidney injury, hepatic 
failure, surgical site infection, anastomotic leak, or cardiovascular complication was 
insufficiently represented to be included. 
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Results 
 
174 participants were consented, randomised, and performed baseline pre-surgical cognitive 
assessments. 151 of these participants completed sufficient cognitive assessment at POD7 
for inclusion in the analysis. 
Through the use of the criteria established in Lewis, Maruff, and Silbert (2004), participants 
were categorized according to their performance upon the psychomotor-attention composite 
of the CBB. A significant decline was observed in 14 participants, significant improvement in 
17 participants, and no significant changes observed in 120. Significant improvement was not 
associated with any predictor variable. 
Table 1 – Descriptive statistics for decliners and participants with no decline 
 No decline (n=137) Declined (n=14) 
Gender (female) 90 (65.6%) 8 (64%) 
Age 69.96 (6.61) 70.01 (6.71) 
BMI 30.62 (6.77) 30.45(6.36) 
MMSE 28.77 (1.26) 28.78 (1.47) 
ASA Status 2.24 (0.56) 2.42 (0.51) 
Education (Did not complete  
High School) 
58.94% 71.42% 
Surgery duration in minutes  
Median (IQR) 
135 (60) 141 (85) 
Orthopaedic surgery 85.71% 73.75% 
Pain score Baseline 6.13 (3.02) 6.85 (3.18) 
Pain score POD2 5.67 (2.66) 7.62 (3.15)* 
Pain score POD7 5.03 (3.07) 5.58 (3.55) 
*Significantly different from non-declining participants at p<.05. 
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Cognitive changes from Baseline to POD7 (whole sample) 
 Table 2 - Cognitive change from T1 to T2, paired t-test 
 T1 Mean (SD) T2 Mean (SD) P-value Cohen’s d 
Detection 434.55 (151.46) 434.07 (148.03) .837 0.017 
Identification 667.41 (167.82) 659.5 (157.89) .643 -0.042 
One Card Learning  
(reaction) 
1321.763 (405.96) 1233.2 (339.59) .003 -0.227 
OCL (accuracy) 0.62 (0.09) 0.64 (0.9) .018 0.19 
One Card Back  
(reaction) 
1032.85 (281.25) 1005.2 (266.96) .185 -0.085 
OCB (accuracy) 0.86 (0.15) 0.88 (0.13) .016 0.189 
List Learning  
Immediate 
23.69 (5.49) 24.1 (5.52) .313 0.075 
Story Memory  
Immediate 
13.7(4.87) 15.07 (4.2) >.0001 0.3 
Figure Copy 14.34 (3.05) 13.28 (3.16) >.0001 -0.337 
Line Orientation 16.95 (3.05) 16.94 (3.22) .952 0.046 
Picture Naming 9.92 (0.29) 9.92 (0.31) .842 0.024 
Semantic Fluency 19.87 (4.68) 19.77 (4.7) .815 -0.02 
Digits Forward 10.25 (2.68) 10.59 (2.94) .131 0.121 
Coding 38.52 (9.91) 36.17 (11.34) >.0001 -0.169 
List Recall 4.09 (2.81) 3.93 (2.6) .444 -0.06 
List Recognition 18.71 (1.88) 18.02 (1.87) >.0001 -0.366 
Story Recall 6.87 (3.08) 7.65 (2.96) .001 0.263 
Figure Recall 9.6 (3.86) 9.81 (3.98) .489 0.056 
COWAT total 36.46 (12.71) 37.54 (13.6) .111 0.082 
COWAT Errors 0.6 (1.05) 0.79 (1.17) .121 0.166 
COWAT  
Perseverations 
13.35 (5.52) 11.72 (5.13) >.0001 -0.342 
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TMTA 39.67 (15.25) 38.21 (15.37) .125 -0.094 
TMTB 100.99 (44.93) 100.66 (53.19) .911 0.006   
The statistically significant decline in performance from baseline to POD7 was observed for 
the Figure Copy, Coding, and List Recognition tasks. Statistically significant improvement in 
performance was observed for One Card Learning speed and accuracy scores, Story Memory 
Immediate and Recall tasks, and COWAT Perseverative error score. Effect sizes were mostly 
small-to-moderate in size. 
Risk and predictive factors for cognitive dysfunction at POD7 
 
Analysis predictors of cognitive decline at POD7 
 
The logistic regression analysis revealed a number of participant characteristics that could be 
used to predict cognitive dysfunction at POD7. The results of the individual bivariate 
continuous regression analyses are presented on the left side of the table (Table 3), while the 
multivariate model adjusted values for each variable are presented on the right. The second 
set of analyses treating the outcome variable as dichotomous was performed in a similar 
fashion, and the results are reported in Table 4. Results of all analyses for all variables are 
reported in full in Appendices A and B. 
 
Baseline cognitive predictors for cognitive performance at POD7 
 
For the linear model, story memory, line orientation, picture naming, digit span, coding, 
COWAT Perseverations, TMTA and TMTB seconds each independently and significantly 
predicted cognitive performance at POD7. For the logistic model, line orientation, COWAT 
Perseverations, and the TMT tasks significantly predicted POCD at POD7. 
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With the exception of TMTB, all B coefficients were negative indicating that with the 
exception of COWAT perseverative errors, baseline cognition could be used to predict 
performance at POD7. Because TMTB is also a timed task, higher scores on the TMT 
indicate decreasing performance. Curiously, COWAT perseverative errors appeared to be 
inversely correlated with scores on the psychomotor composite, indicating that participants 
who made more errors of this kind also tended to perform better at POD7. 
 
Participant characteristics 
 
No demographic variables, including age, gender, education level, or BMI significantly 
predicted cognitive performance in either the logistic or linear models. In the linear 
regression model, pain at POD2, history of malignant or solid tumours, and presence of post- 
operative cardiovascular complications were significantly and positively associated with 
cognitive decline at POD7. For the logistic model, the pre-operative use of COX-II inhibitors 
was significantly and negatively associated with cognitive dysfunction. The Odds-ratio of 
0.23 for pre-operative COX-II inhibitor use for cognitive dysfunction at POD7 is indicative 
of a 77% protective effect. 
 
 
With the exception of TIVA use, no intraoperative factors were significantly associated with 
cognition at POD7. The use of TIVA was inversely associated with cognitive dysfunction. 
Post-operative benzodiazepine use, cardiovascular complication, and increased pain at POD2 
were all independently and significantly associated with decreased cognitive performance at 
POD7. 
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Table 3 - Regression analysis, predictors of cognitive dysfunction at POD7  
Bivariate analysis 
  Multivariate linear regression Power  
achieved? 
   
     Participant  
Characteristics 
 η2   
 
Variable 
 
Beta 
95%  
CI OR 
 P  
value 
 
Beta 
95%  
CI OR 
  P  
value 
 
  Lower Upper   Lower Upper    
POD2 Pain .214 .03 .19 .01 .20 1.01 1.21  .02  
Benzodiazepines Post  
Op 
 
.180 
 
-.19 
 
1.49 
 
.04 
 
.08  0.62  3.54   .36  
Cardiovascular 
Complications Post 
Op 
 
.199 
 
.34 
 
4.62 
 
.02 
  
.25 
  
2.93 
  
183.57 
   
>.01 
 
 
TIVA 
-  
.176 
 
-1.06 
 
-.02 
 
.04 
 
-.14  0.39  1.10   .11  
Malignant/Solid  
Tumour 
 
.225 
 
.25 
 
1.85 
 
.01 
 
.21 
 
1.23 
 
5.66 
  
.01 
 
 Model   .17 >.01 Yes 
     Cognitive predictors Δη2   
Story Memory  
Immediate 
-  
.213 
 
-.11 
 
-.02 
 
.01 
 
-.22  0.89  0.98  .05  .01  No 
 
Line Orientation 
-  
.208 
 
-.17 
 
-.02 
 
.01 
 
-.18  0.85  1.00  .03  .04  No 
 
Picture Naming 
-  
.187 
 
-1.75 
 
-.12 
 
.03 
 
-.16  0.20  1.02  .02  .1  No 
 
Digit Span 
-  
.210 
 
-.2 
 
-.03 
 
.01 
 
-.15  0.84  1.01  .02  .06  No 
 
Coding 
-  
.273 
 
-.06 
 
-.02 
 
>.01 
 
-.22  0.95  0.99  .04  .01  No 
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List Learning  
Recognition 
-  
.258 
 
-.32 
 
-.08 
 
>.01 
 
-.21  0.75  0.97  .04  .02  No 
 -  
.207 
        No 
Story Recall -.17 -.02 .01 -.19 0.85 0.98 .04 .02  
COWAT Total Per.  
Errors. 
-  
.183 
        No 
-.09 -.01 .03 -.09 0.93 1.02 .01 .28  
TMTB .260 .00 .01 >.01 .19 1.00 1.01 .03 .03 No    Table 4 - Logistic Regression, predictors of cognitive dysfunction 
Bivariate analyses     Multivariate logistic regression   
Variable 
 
OR 
95% CI  
OR 
 P  
value 
 
OR 
 95% CI  
OR 
P  
value 
Power  
achieved? 
  Lower Upper   Lower Upper   
POD2 Pain 1.28 1.05 1.63 .04 1.25 .99 1.58 .062 No 
COX-II Inhibitors  
Pre Op 
 
.24 
 
.07 
 
.88 
 
.03 
 
.230 
 
.06 
 
.87 
 
.03 
 
Yes 
Line Orientation 1.15 1.01 1.38 .04 1.20 1.02 1.41 .02 No 
COWAT  
Perseverations 
 
1.13 
 
1.02 
 
1.27 
 
.03 
 
1.18 
 
1.04 
 
1.34 
 
.01 
 
No 
TMTA .97 .94 .99 .03 .96 .92 .99 .01 No 
TMT B .99 .98 1 .05 .99 .98 .99 .04 No 
 χ2 df p     
Hosmer and Lemeshow Chi-square 
Goodness-of-fit test* 
6.74 8 .41     
R2-2ll .21  .004     
 
*A non-significant Hosmer and Lemeshow test indicates that the model is a good fit for the data.Missing 
Data Analysis 
 
The missing data analysis revealed that with the exception of surgery type, missing and 
present data did not significantly differ. 
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Table 5 - Comparison of missing and present data 
 Data present (n = 151) POD7 missing (n = 23) 
Gender 48% Female 47% Female 
Age 69.25 (5.4) 70.2 (6.89) 
MMSE 28.76 (1.28) 28.91 (1.12) 
BMI 30.34 (6.16) 33.04 (7.22) 
ASA Status 2.27 (0.63) 2.25 (0.55) 
Did not complete High School 54.96% 65.21% 
Surgery Duration in minutes 151.49 (79.28) 140.35 (42.76) 
Orthopaedic surgery 80.13%* 43.74% 
Pain score POD2 5.81 (2.73) 6.26 (2.97) 
*Missing data significantly different to present data, χ2 = 14.82, p < .05. 
 
 
 
Reasons for missing data were recorded for each instance. Five participants requested to skip 
POD7 assessments due to ongoing fatigue and soreness. Six participants were non- 
contactable by any means prior to POD7. Three participants had ongoing health or medical 
concerns that took priority over the assessment. Two participants missed their assessments 
due to a computer scheduling error. Two participants travelled outside the local region and 
were unavailable for assessments at POD7, and one participant refused any further computer 
use after the baseline assessment. Four participants withdrew prior to POD7 after providing 
baseline data. 
163  
Discussion 
 
Categorization of the sample using the psychomotor composite of the CBB revealed that 
approximately 9.1% of the sample displayed a significant cognitive decline in comparison to 
baseline performance. This is in accord with the estimates of POCD (Paredes et al., 2016), 
albeit at the lower end. 
 
Risk and protective factors for cognitive decline 
 
The hypothesis that there would be significant differences between participant 
categorizations across protective and risk factors was partially supported. The use of COX-II 
inhibitors was the only variable to remain significant once entered into the adjusted logistic 
regression model, and the use of COX-II inhibitor medications in the lead up to surgery was 
strongly associated with preserved cognitive function after surgery. This strong protective 
effect of COX-II inhibitors provides support for a neuroinflammatory model of POCD, 
though this requires additional scrutiny through the examination of inflammatory biomarkers 
in particular. Interestingly, a recent large-scale RCT found no protective effect of the COX-II 
inhibitor celecoxib for cognitive decline in participants with family history of Alzheimer’s 
disease despite daily treatment for over 12 months (ADAPT-FS research group, 2015). This 
may be indicative that COX-II inhibitors may be protective for cognitive change associated 
with acute inflammatory states, but less so in chronic conditions. While most risk and 
protective factors for POCD are subject to varying degrees of debate, increasing age is 
considered to be one of the more robust risk factors (Monk et al., 2008). However, the 
present analysis did not support this hypothesis as no difference in age was detected between 
declining and non-declining participants. Further, no individual demographic variable was 
significantly associated with cognitive decline at POD7. It is likely that pain played a 
significant role in modulating cognitive performance after surgery; the results indicated that 
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participants in whom no significant cognitive decline was detected reported significantly 
lower levels of pain at POD2 in comparison to declining participants. 
Interestingly, this was the only postoperative variable to significantly differ between the 
groups but this effect did not persevere at POD7 when the cognitive assessments were 
performed. Contrary to expectations, medical and psychiatric histories were similarly limited 
for differentiating between POD7 performances, with the exception of tumour history. It is 
not entirely clear why most expected contributing factors failed to significantly associate with 
cognitive dysfunction, though the relatively low levels of comorbidities present in the sample 
meant that the sample may be healthier entirely and not entirely representative. 
 
 
Limitations 
 
The results of this analysis are preliminary, and this is best reflected in the number of 
statistically significant results in the present analysis that were rejected due to lack of 
statistical power. Further, the participants of this study were taking part in the PANACEA 
drug trial but were not yet unblinded at the time of this analysis. While the allocation to 
treatment was randomised, it is unknown what effect, if any, the intervention drug may have 
produced in the sample. It is similarly impossible to determine how many of each 
categorization of participants (improvers versus decliners, for example) received an active 
intervention versus a placebo. 
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Further discussion of contributing factors 
to cognitive change 
Rationale for the inclusion of this section 
 
Chapter 5 was prepared in expectation of submission to the journal Journal of Experimental 
Psychology - Learning, Memory, Cognition and thus was required to be written more 
succinctly and targeted than would normally be expected. For example, the introduction text 
also places far more emphasis upon the potential association of POCD and dementia in 
comparison with other chapters in order to better suit the journal content, and the discussion 
section is truncated to focus on the findings most relevant to those outcomes. It is the purpose 
of this supplementary section to provide greater detail and discussion around some of the 
more interesting findings of the paper, as well as transparently analyze some of the 
limitations. In addition, plans for overcoming the shortcomings present in the analysis are 
suggested to serve as a guide for future investigation. 
 
Analysis of findings 
 
Significant findings – Cognitive performance 
 
The prevalence of POCD at post-operative day 7 (POD) amongst the present sample was just 
over 9%, which falls within the lower end of expected values. In accordance with this 
finding, any analyses that sought to dichotomize cognitive outcomes at POD7 would be much 
harder to generalize outside of the sample. The inclusion of continuous analyses, therefore, 
sought to serve as a hypothesis generation tool by examining for any changes from baseline 
to POD7 as long as they met statistical significance. This then allows the comparison 
between the findings of the conservative 2 Z score decline from pre-surgical performance 
required for POCD, and other cognitive change that did not meet this threshold. 
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Not all cognitive change after surgery was negative. When examining the entire sample, 
significant improvement was observed in a number of different tests. On the CogState Brief 
Battery, One Card Learning reaction speed and accuracy both significantly improved from 
baseline to POD7, as did One Card Back accuracy (d = -.22, p =.007; d = 0.19, p = .018; d = 
0.18, p = .016, respectively). Improvements of similar magnitude were observed using the 
Story Memory Immediate and Recall, and COWAT perseverative errors. This roughly 
corresponds to small-to-moderate improvements in performance upon measures of reaction 
speed, visual memory, and verbal memory. 
 
 
However, the delineation between improved cognitive domains and declining was not 
entirely distinct. Declining domains broadly corresponded to processing speed, visuospatial 
reasoning, and visual and verbal memory as measured by alternate assessments. In 
comparison to baseline performance, participants performed worse at the List Recognition 
task at POD7 when asked to recognise previously listed words from a larger list, but had no 
significant change in performance for immediate recall. It is interesting that although 
participants were not warned that they would be required to remember any information later 
during the assessment, participants may have known this from experience at POD7 and thus 
were given the opportunity to commit more of the detail to memory. Therefore, we would 
have expected either no change or a slight improvement in performance on this measure if 
there was no cognitive change attributable to the impact of surgery. Further, given the 
approximately equivalent improvements in performance upon the Story Memory Immediate 
and Story Memory Recall, we can perhaps see that semantic memory is not as susceptible to 
change as other forms of verbal memory. 
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Change in performance upon memory tasks at POD7 is also informed by the improvement 
observed upon COWAT Perseveration, which presents a further complication for interpreting 
the effect of surgery upon immediate memory. In the COWAT task, participants are asked to 
list as many non-proper noun words as they can within a time limit, and also instructed not to 
repeat any words with alternate suffixes. For example with try and trying, only the first use 
would be considered a correct response and included in the total score, with other iterations 
recorded as perseverative errors. Perseverative errors can, therefore, be interpreted to be at 
least partially predictive of short-term verbal memory deficits, as participants are either 
unable to remember words they have previously said or unable to recall the instructions. The 
effect size of the change from baseline to POD7 for perseverative errors was one of the 
largest and highly significant observed within the sample (d = -.34, p < .001), but is still 
roughly equivalent to the decline observed for List Recognition over the same period (d = - 
.36, p < .001). The change in memory performance may then be related to the subject being 
recalled – the list recognition tasks involves being read a list of 20 words, with ten being 
having been previously read to the participant earlier. By contrast, the COWAT task is 
guided entirely by the participant themselves and is not limited to semantically related words. 
 
 
The RBANS Coding task is roughly equivalent to a Digit Symbol Substitution Task, with the 
main difference that participants are provided with a cypher and legend, and asked to match 
numbers to symbols as quickly and as accurately as possible in 90 seconds. The task is 
purported to measure attention, but also captures processing speed, visual memory, and motor 
speed. These same domains are captured using the One Card Learning task, however, the One 
Card Learning task only requires participants to remember a maximum of six cards (though 
this is not revealed to the participant), and contains a large proportion of non-repeating cards. 
Participants are shown, one by one, a random card from a standard deck of playing cards and 
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must respond either “yes” or “no” to the prompt “Have you seen this card before?” Reaction 
speed is only recorded for correct responses to eliminate rushed guesses. In contrast with 
performance on the One Card Learning task, there was a significant decline in performance 
for Coding (d = -.17, p < .001). Participants also demonstrated an improvement in One Card 
Back accuracy at POD7 in comparison to baseline performance (d = .19, p = .016), where in 
participants are asked to respond “yes” or “no” to the prompt “is this card the same as the 
previous?”. The One Card Back task is purported to measure visual short term memory and 
attention, so it is interesting that inverted performance responses would be recorded for the 
Coding and One Card Back tasks. Given the differences in memory requirements for each 
task, it may be that the One Card Learning and One Card Back tasks measure a less complex 
form of visual memory in comparison to the Coding task. Thus, on the basis of the present 
results, it appears as though complex visual memory may be more susceptible to deficit after 
surgery, while less complex visual memory may even improve. 
 
 
Significant findings – Participant characteristics 
 
The majority of participant characteristics did not significantly predict the presence of POCD 
or cognitive decline at POD7, contrary to expectations. Further, those characteristics that 
were predictive tended to not persevere after other potential predictors were controlled for in 
a multivariate model. Pain at POD2 was reported as significantly higher in patients with 
POCD compared with those without. This is particularly interesting because the POD7 pain 
scores (taken at the same time as the POD7 cognitive evaluations) did not differ between the 
two groups. Further, there was no apparent relationship between POCD and post-operative 
analgesia, so it does not appear that the presence of POCD can be attributed to increased 
levels of painkilling medication in response to heightened pain at day 2. While POD2 pain 
remained a significant predictor of cognitive function when using the multivariate continuous 
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model, this was not observed upon entry into the multivariate logistic regression model once 
the other potential predictors were controlled for. Thus, POD2 pain can be considered a 
useful predictor of smaller, less severe cognitive decline, but not POCD. 
 
 
The health of participants both before and after surgery appeared to be predictive of POCD. 
Cardiovascular complications in the post-operative period were significantly associated with 
decreased cognitive performance at POD7, but not POCD. However, only two instances of 
cardiovascular complications were observed in the entire sample at POD7, so it is difficult to 
extrapolate much from this result alone. Similarly, history of malignant or solid tumours 
significantly predicted cognitive decline at POD7 but not POCD. Of 16 participants with a 
tumour history, three also experienced POCD at POD7 which did not reach statistical 
significance (χ2 = 2.898, p = .117.) These findings can at best be described as hypothesis 
generating but should be explored with larger samples. 
 
 
The only variable to significantly predict POCD at POD7 was the preoperative administration 
of COX-II inhibitors. 19 participants were taking daily administrations of COX-II inhibitors 
in the lead up to the surgical day, and four of these experienced POCD at POD7 (χ2 = 5.258, 
p < .05), and this association persisted even after controlling for other potential predictors. 
However, the specific protective effect of COX-II inhibitors is difficult to attribute. For 
example, COX-II inhibitors are usually taken to control pain in inflammatory conditions such 
as osteoarthritis, but the presence of osteoarthritis itself was not significantly associated with 
POCD (χ2 = 1.69, p = .194), nor the preoperative use of COX-II inhibitors (χ2 = .443, p = 
.39). Most interestingly only the pre-operative use of COX-II inhibitors was predictive of 
cognitive function at POD7, but not intra- or post-operative use. This may suggest the 
potential of pre-operative pain to act as a contributing factor to cognitive function at POD7 
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despite the lack of significant association in either of the present models. Given that the pre- 
operative pain scores were obtained at the same time as the pre-operative cognitive 
evaluation, any patients who were using COX-II inhibitors as regular pain control may have 
benefited both from the anti-inflammatory effects of the medication, and comparative lack of 
pain distraction during assessments. This does not explain why only pre-operative use 
appeared to protect cognition but may explain why the effect of pain, POD2 aside, appears to 
also be suppressed. 
 
 
Non-significant findings (of interest) 
 
Due to the exploratory nature of the analyses, numerous potential contributing factors were 
considered and ultimately discarded, and some were of greater interest than others. It was 
also clear that there were numerous issues related to the design and timing of the 
assessments. For example, increasing age was by far the most well established predictive 
factor for POCD and cognitive decline after surgery, and yet in the present analysis, no 
significant effect of age was detected. A likely explanation for this is that because the 
research design excluded those aged less than 60 years and eventually resulted in a sample 
with a mean age of approximately 70, the effect of advancing age may have already been 
accounted for, particular if the risk of cognitive change after surgery plateaus earlier in the 
lifespan. It may also be possible that long-term cognitive change may take longer than one 
week to materialize, and future investigation should examine the possibility that some risk 
factors may only apply to later emergences of cognitive change. 
 
 
Education status can be used as a proxy measure of cognitive reserve, but also likely has at 
least some overlap with broader socioeconomic factors. The majority of participants had 
completed less than 12 years of formal education, and progressively fewer had completed 
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additional levels of post-secondary education including associates, bachelors, or post- 
graduate degrees. However, individual variation of educational attainment is likely to have 
been underestimated due to the recording of the variable as ordinal rather than continuous, 
and this is particularly problematic for the category that was largest not only in final 
proportion but also in the magnitude of potential values. For example, participants who left 
formal education during primary school were given the same classification as those who had 
completed all but the final year of high school (a designation of “did not complete high 
school”). Thus, in future research designs, it may be prudent to record the number of years in 
education, as well as the highest level attained, in order to more clearly explore the role of 
educational attainment as a cognitive reserve proxy. Other measurements of cognitive reserve 
such as the pre-surgical Mini Mental State Exam were similarly unrelated to post-surgical 
cognitive performance but also revealed a highly cognitively intact sample– the average score 
on the assessment was just below 29/30 for the whole sample, and there was very little 
variability within-groups. Therefore, it is likely that the protective role of cognitive reserve 
was under-explored in the included analyses. 
 
 
There was no significant difference in the likelihood of POCD or cognitive decline when 
comparing orthopaedic surgical patients to non-orthopaedic surgical patients; however, it is 
likely that important relationships have been overlooked within the data due to the presence 
of heterogeneous subgroups within the sample. In similarity with the aforementioned 
difficulties examining educational attainment, the dichotomization of surgery type meant that 
potentially meaningful intra-surgical comparisons were likely obscured. For example, the 
majority of participants received orthopaedic surgery to repair or replace worn joints and 
while few restrictions were originally placed upon acceptable surgery types for inclusion into 
the study, practicality would later reduce the inclusion of certain surgery patients and 
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necessitate accommodations for some participants that likely influenced the results. For 
example, it became clear quite early in the project that participants having shoulder 
replacement surgery upon their dominant arm would be unfairly disadvantaged during 
psychomotor tasks, and so these assessments would have to be skipped or risk providing a 
biased estimate of performance. Because the primary outcome of POCD relies upon the use 
of the psychomotor composite of the CogState Brief Battery, non-completion of these tasks 
meant that this distinction was not possible. In a similar vein, thyroidectomy patients 
experienced speech difficulties that likely led to verbal fluency performance being 
underestimated. It is clear then that the presence of various subgroups within the sample 
could influence the results and would need to be accounted for in future analyses. 
 
 
The influence of heterogeneous subgroups within the data can also be seen when examining 
the role of pain. In the original analyses, pain at POD2 predicted cognitive decline but not 
POCD, and pain scores at pre-surgical baseline and POD7 were not associated with any 
outcome of interest. This finding is interesting given the generally non-significant findings 
for pre-operative analgesia and may provide further clues for investigation of the role of not 
only pain but also the interaction of surgical procedure and post-operative pain. For example, 
the original analysis did not account for the potential variability of pain scores prior to and 
post different surgical procedures, where some participants may experience greater levels 
after surgery compared to beforehand while others may experience the reverse. There 
originally appeared to be no significant difference between orthopaedic and non-orthopaedic 
participants for POCD, and likewise no association of pre-surgical pain and POCD, but 
subsequent analysis shows that orthopaedic participants experienced a significant decrease 
pain from baseline to POD2 while non-orthopaedic participants experienced a significant 
increase. At POD7, the pain reported by orthopaedic participants remained steady while that 
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of non-orthopaedic participants returned to pre-surgical levels. The interaction of pain and 
surgery type was observed to be significant, F (2, 298) = 14.975, p <.001, and satisfied the 
assumption of sphericity. Thus, it was likely that the inverted pain response of the two 
surgical types may have obscured the predictive power for POCD of reported pain when the 
whole sample was examined. This was confirmed in subsequent analysis that examined 
POD2 pain scores for each surgical type separately; increasing levels of pain at POD2 were 
significantly predictive of POCD at POD7 for orthopaedic participants (OR[CI95%] = 1.32 
[1.02, 1.72], p <.03), but not for non-orthopaedic participants (OR[CI95%] = 1.04 [0.59, 
1.84], p = .875). In a practical sense, it may be possible to use the success or failure of pain 
control in the early post-operative period to predict subsequent cognitive recovery. It is also 
possible that other potentially significant findings remain within the data, and future 
investigations should control for the presence of heterogeneous subgroups within the sample. 
 
Analysis of limitations 
 
The examination of significant and non-significant findings alike would be incomplete 
without an inclusion of the limitations of the current analyses, some of which have been 
discussed in the previous sections or mentioned in the preceding chapter. 
The foremost limitation of the analyses in the preceding chapter is that due to the PANACEA 
trial is still ongoing, it was not (and is not yet) possible to unblind the participants to reveal 
who received the active NAC intervention or matched placebo. The protective efficacy of 
NAC against POCD was theorized to be be a roughly 50% reduction in the severity of 
cognitive dysfunction (see Chapter 4 – The protocol), and if correct, this means that the 
observed POCD rate of 9% for the entire sample is unlikely to be reflective of the rated 
within the NAC and placebo arms of the study. It is difficult to quantify exactly much this 
may have influenced the results of the analyses, but it is likely that the results of the logistic 
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regression analyses (where participants were dichotomized as to whether they met the criteria 
for POCD or not) will change once the intervention is accounted for. The intervention 
assignment of participants is potentially one of the most significant divisions within the 
sample, and heterogeneous subgroups that were not fully controlled for in the primary 
analyses will typically only reduce the predictability of the data, but not improve it. As 
demonstrated in the example of the interaction of pain and surgical type, potentially 
meaningful associations can be hidden. While the use of subsequent analyses can mitigate 
this effect somewhat, the continual splitting of samples into smaller categorisations reduces 
statistical power and in the same fashion as the example from POD2 pain should be guided 
by the initial results. 
 
 
The inability to unblind the data in order to test the primary and secondary hypotheses 
necessitated the use of exploratory analyses, the statistical power of which could only be 
examined through post-hoc analyses. Although all the variables used in the study were 
included on the basis of theoretical relevance, a priori selection of individual variables for 
hypothesis testing was limited to the estimation of POCD prevalence. While it was possible 
to make some predictions regarding the role of the more established risk factors of POCD, 
because most potential contributing factors were relatively unexplored it was decided to treat 
all the variables equally within the analysis and to present all results transparently as post- 
hoc. While this approach arguably reduces the quality of the work from a purely scientific or 
philosophical perspective, the inclusion and examination of so many potential contributing 
factors serve to generate a large number of hypotheses for POCD research and provides a 
basis for future research in an emerging field. 
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A further limitation of the present analysis is the relatively high functioning nature of the 
sample, reflecting a high level of cognitive reserve and thus a protective factor against 
decline. Global cognitive performance at baseline was quite high, with no participants 
scoring below the cut-off for cognitive impairment of less than 24 out of 30 on the Mini 
Mental State Exam and a very low rate of pre-existing cognitive impairment within the data. 
For example, only two participants entered the study with a diagnosis of dementia, and both 
presented with POCD at POD7. While it is difficult to extrapolate much from such a small 
subsample, it serves to highlight that the present sample is generally functioning at a level 
that is protective from decline, and the findings may nto be entirely generalizable to other 
elderly populations. This is further demonstrated in the remarkably low incidence of post- 
operative delirum present in the sample with just one recorded occurrence at the time of this 
analysis, and the complete absence of any recorded learning disorder or other cognitive 
impairment diagnoses. 
 
Interpretation 
 
The findings both in the initial analysis and the subsequent discussion presented here 
represent a number of clear outcomes and provide important guidance for future 
investigation. First and foremost, it is clear that even in a sample largely comprised of both 
intact cognitive functioning and with at approximately 50% having a theoretically effective 
POCD mitigator, some degree of cognitive decline is observable in the early post-operative 
period. The present analyses provide some level of indication about the mechanisms of this 
change particularly for the role of inflammation but present additional questions in most other 
areas of inquiry. The protective effect of pre-operative COX-II inhibitors coupled with the 
lack of apparent protective effect of either intra- or post-operative COX-II inhibitors suggests 
that the timing of the interventions is crucial and that once periphery inflammation has begun 
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mitigation of cognitive decline resultant from surgery may no longer be possible, or at least 
less effective. This finding may also explain why other intra- and post-operative interventions 
with anti-inflammatory mechanisms, such as ketamine or propofol were similarly 
unassociated with cognitive decline at POD7 in the present analysis. As in most medical 
conditions, it is clear that prevention is better than a cure, and future investigations should 
consider the impact of pre-surgical management strategies for cognitive protection. 
 
Chapter 6: Conclusions 
The overarching theme of this thesis was the examination of an inflammatory model of 
cognitive change, in particular, the cognitive change secondary to surgery in the elderly. The 
sum of the knowledge gained over the course of producing this thesis can be simplified into 
three broad research questions, as follows: 
Research question 1 – What is driving cognitive change after surgery, and what can be done about 
it? 
 
The introduction of this thesis described the current population level trends for aging, 
dementia, and surgery in Australia, and proposed that the correlation of all three factors 
contributed to increased social and financial burden and reduced welfare among the elderly. 
Simplified, the model can broadly be expressed as increasing age is positively associated 
with increased likelihood of necessary major surgery, and that surgery is also associated with 
an increased risk of accelerated cognitive decline. Thus, it was proposed that the act of 
undergoing surgery must activate some sequence of physiological triggers that alter the 
cognitive trajectory. This purported mechanism was introduced in Chapter 1 and explained in 
detail in Chapter 2. It was proposed that in vulnerable populations the presence of increased 
peripheral inflammation, such as that secondary to tissue damage, could exacerbate a cascade 
of reactions that ultimately lead to neurotoxicity and subsequent decline of mental status or 
Post-Operative Cognitive Dysfunction (POCD). Importantly, the second half of the chapter 
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identified and critically examined a host of potential novel therapies for the mitigation of 
POCD. The antioxidant N-acetylcysteine, among others, was identified as a suitable 
candidate for more focused research, and the potential cognitive effect of the substance was 
evaluated and quantified in Chapter 3. Further, the role of aggravating comorbidities to the 
neuroinflammatory hypothesis was explored in a range of cognitively impacted samples, 
including Alzheimer’s disease, TBI, and psychiatric disorders. 
 
 
Research question 2 – Can N-acetylcysteine mitigate cognitive decline? 
 
The results of the systematic review (and subsequent meta-analyses) suggested that N- 
acetylcysteine represented a likely candidate to modulate POCD via the inflammatory 
pathways, and so the Post-Anaesthesia N-Acetylcysteine Cognitive Evaluation (PANACEA) 
trial was planned and designed according to the protocol in Chapter 4. Finally, the results of a 
pilot subsample of the PANACEA trial were then analysed in Chapter 5 in order to evaluate 
the cognitive impact of surgery and explore potential contributing factors to cognitive 
change. While the antioxidant N-acetylcysteine was not directly examined in this chapter, a 
large number of alternate contributor variables including some of similar mechanism were 
evaluated, and the results of this analysis were then examined in greater detail in the 
supplemental section. In particular, the significant association of anti-inflammatory 
medications prior to surgery with cognitive preservation bolsters the inflammatory hypothesis 
of POCD, as does the non-significance of most other expected contributing variables. 
However, these findings are preliminary and must be interpreted in accordance with the 
identified limitations, as well as the new avenues of investigation that present after the 
analysis. 
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Research question 3 – What can we learn about Post-Operative Cognitive Dysfunction, and what 
can the current and future research teach us? 
 
 
The results of the PANACEA trial to date have answered some questions about POCD, but 
have also raised a great deal more. For example, it is clear that POCD exists as a stable and 
detectable condition in the early post-operative period, and it is also clear that patient 
characteristics and differences in medical histories can be predictive of cognitive dysfunction. 
However, the relationship between these variables and cognitive outcome after surgery is 
quite complex with few variables remaining predictive once other significant variables are 
controlled for. For example, increasing levels of participant pain at POD2 was shown to be 
individually predictive of the risk of POCD at POD7, but this was reduced to non- 
significance once the analgesic presence of COX-II inhibitors was included in the model. 
However, pain at POD2 was significant when examining for sub-POCD cognitive 
dysfunction at POD7, and remained so when included in a larger model that controlled for 
tumour history and post-operative cardiovascular complications. As a further complication, 
COX-II inhibitors were non-predictive of sub-POCD cognitive dysfunction in any model. For 
that reason, we can tentatively conclude that while some cognitive change after surgery is 
explained best by the presence of various patient characteristics and medical conditions, 
severe change that meets the criteria for POCD is likely driven by an inflammatory response 
and can be addressed accordingly. It further seems likely that the presence of pain after 
surgery is intrinsically linked with that of cognitive change, and that the control of this pain 
by non anti-inflammatory agents can mitigate cognitive decline to some degree. 
 
 
Future Research directions 
 
The inclusion here of two reviews and an exploratory paper provides stimulus for future 
research. Only a small number of potential POCD intervention agents were examined in the 
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preceding chapters, and only N-acetylcysteine received an in depth examination for cognitive 
change, and even this was not entirely explored due to the blinded nature of the PANACEA 
trial. The full unblinding of the PANACEA sample will allow a much more accurate 
investigation of the true degree of change attributable to POCD, and also the influence of N- 
acetylcysteine to mitigate neuroinflammatory biomarkers. Participants in the PANACEA 
trial provide two sets of blood samples for biomarker analysis both before and after surgery, 
and it is intended that these samples will be subject to analysis once the sample has been 
unblinded. 
 
 
While some intervention agents such as dexmedetomidine have been fairly well established 
as effective intraoperative protection against cognitive change, most other promising agents 
require substantially more high quality research, preferably in the form of randomised, 
placebo-controlled studies. These include COX-II inhibitors, minocycline, ketamine, 
lidocaine, and even the exploration of pre-surgical cognitive stimulus to increase cognitive 
reserve. When examining these interventions, future research efforts should strive to address 
some of the limitations identified in the current model. 
 
 
One of the identified limitations of the current study model was the lack of additional pre- 
surgical assessments. By including more pre-surgical cognitive assessments to the research 
design, it becomes possible to develop a much more accurate cognitive trajectory. For 
example, participants who are already beginning to experience cognitive decline prior to 
surgery and subsequently continue to decline after surgery may erroneously be considered as 
having POCD. Alternatively, a matched cohort of non-surgical participants could be used to 
map a comparative cognitive trajectory. The purpose of including such a comparative cohort 
allows the estimation of cognitive change attributable to non-surgical triggers, such as the 
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course of natural ageing. The inclusion of age as a predictive variable should likewise be 
implemented with care. 
 
 
While most research has established advancing age as a risk factor for cognitive change in 
general and POCD in particular, limiting the sample to this high risk group of 60+ years 
diminishes the utility of age as a predictive factor. While this is logistically important and 
methodologically sound for intervention studies, for research that is more focussed upon the 
incidence of cognitive change or for other observational studies the inclusion of younger 
adults (potentially 50+ years) would allow a more comprehensive investigation and still 
include a large cohort of joint replacement surgeries. Importantly, when combined with the 
above point regarding non-surgical comparative cohorts, allowing the inclusion of a younger 
demographic allows a deeper investigation into the age when surgery becomes a significant 
risk factor for cognitive change if an interaction between age, surgery, and cognition truly 
exists. The investigation of increasingly complex analyses and interactions between variables 
requires larger samples to ensure sufficient power, and this includes ensuring a representative 
sample of the various subgroups present within surgical cohorts. 
 
 
The heterogeneity of the PANACEA sample presents a challenge for the present analysis but 
also an opportunity for future research direction. With recruitment ongoing and an increasing 
sample size, there is great potential for continued investigation of additional subgroups within 
the data. For example, the role of anaesthesia subtypes has frequently been investigated 
without much success. As pertains to the neuroinflammatory hypothesis of cognitive change, 
the use of total intravenous anaesthesia such as propofol has been proposed as a potentially 
safer alternative in comparison to gas anaesthesia, but research is relatively scant so far. 
Likewise, the framework for the investigation of the biological correlates of cognitive change 
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is present within the ongoing PANACEA trial and will benefit from having the full sample 
available for analysis at the conclusion of the trial. 
 
 
This thesis has explored the neuroinflammatory model of cognitive change and includes the 
predictive and summary variables of 174 elderly surgical patients. Throughout the thesis, the 
potential of novel anti-inflammatory interventions for the mitigation of cognitive change has 
been examined and tested, and the results of the analysis suggest that pre-operative 
intervention agents hold great promise. 
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Appendix C - Descriptive statistics for continuous measures 
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Demographics 
 Decline at POD7 
(N = 14) 
No decline at 
POD7 
(N = 137) 
Sig? 
Age in years 70.94 (7.76) 69.96 (6.61) NS 
BMI 30.01 (6.45) 30.62 (6.77) NS 
MMSE score 29 (1.41) 28.77 (1.26) NS 
Education level (1-5) 1.78(1.48) 1.98(1.3) NS 
 
Medical data 
Pain baseline 6.85 (3.18) 6.13 (3.02) NS 
Pain POD2 7.62 (3.15) 5.67 (2.66) <.05 
Pain POD7 5.58 (3.55) 5.03 (3.07) NS 
Surgery duration in minutes 162.07 (63.38) 159.44 (81.35) NS 
Highest level of postoperative 
creatinine (umol/L) 95.583 (32.2) 93.836 (29.77) 
NS 
 
Cognitive measures 
List Learning 23 (5.56) 23.35 (5.42) NS 
Story Memory 13.31 (4.69) 13.49 (4.79) NS 
Figure Copy 14.62 (2.81) 13.97 (3.19) NS 
Line Orientation 15.54 (4.48) 16.97 (2.99) <.05 
Picture Naming 9.77 (0.59) 9.94 (0.24) NS 
Semantic Fluency 19.38 (5.26) 19.79 (4.6) NS 
Digit Span 9.15 (2.41) 10.41 (2.68) NS 
Coding 34.54 (12.27) 38.7 (10.06) NS 
List Recall 4.46 (2.81) 3.95 (2.76) NS 
List Recognition 18.69 (0.85) 18.65 (1.93) NS 
Story Recall 7.31 (2.86) 6.78 (3.13) NS 
Figure Recall 9 (4.54) 9.39 (3.97) NS 
COWAT Total words 32.38 (12.84) 36.58 (12.77) NS 
COWAT Errors 0.77 (1.11) 0.62 (1.05) NS 
COWAT Perseverations 10.62 (4.61) 13.77 (5.496) <.05 
TMTA Seconds 50.75 (20.47) 38.75 (14.57) NS 
TMTB Seconds 124.66 (49.14) 98.13 (43.94) <.05 
Anxiety 6.07 (2.46) 5.26 (4.14) NS 
Depression 4 (2.16) 3.58 (3.44) NS 
WHOQOL Physical Domain 20.34 (7.63) 22.51 (5.73) NS 
WHOQOL Psychological 
Domain 23.84 (3.73) 23.183 (3.78) 
NS 
WHOQOL Social 
  Relationships Domain  12.31 (1.97) 11.71 (2.137) 
NS 
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Appendix D – Bivariate analyses 
 
Demographic and medical factors 
With the exception of previous diagnosis of a malignant or solid tumour, no demographic, medical, or psychiatric history was 
significantly associated with cognitive change at POD7. 
Variable B Std. Error Beta T P value 
Female .074 .241 .026 .308 .759 
Age (years) .005 .017 .023 .268 .789 
BMI -.002 .019 -.009 -.112 .911 
Gender .074 .241 .026 .308 .759 
Education .001 .091 .001 .014 .989 
ASA Classification .319 .203 .135 1.571 .119 
Pre-op pain .023 .040 .048 .578 .564 
Smoking status -.412 .386 -.095 -1.068 .288 
Rheumatoid Arthritis -.530 1.455 -.032 -.364 .716 
Inflammatory Bowel 
Disease 
.688 .561 .109 1.228 .222 
Hypertension .367 .267 .122 1.378 .171 
Coronary Artery Disease -.279 .398 -.062 -.702 .484 
Heart Failure -1.137 .730 -.137 -1.558 .122 
Previous Myocardial 
Infarction 
-.550 .499 -.098 -1.102 .273 
Peripheral Vascular 
Disease 
.407 .661 .055 .616 .539 
Stroke or TIA .564 .562 .089 1.004 .317 
Atrial Fibrillation .545 .663 .073 .822 .413 
COPD .179 .334 .048 .537 .592 
Dementia or Cognitive 
Impairment 
.504 1.456 .031 .346 .730 
Connective Tissue 
Disease 
-.884 1.031 -.076 -.857 .393 
Peptic Ulcer Disease .603 .846 .063 .713 .477 
Renal Disease -.594 .342 -.153 -1.737 .085 
Malignant/Solid Tumour .980 .378 .225 2.594 .011 
Liver Disease -.890 .844 -.094 -1.055 .294 
Diabetes -.005 .334 -.001 -.015 .988 
Depression -.155 .314 -.044 -.493 .623 
Anxiety -.325 .457 -.063 -.713 .477 
Bi polar disorder -1.780 1.022 -.153 -1.742 .084 
Pre Op Medications      
Beta blockers -.095 .302 -.026 -.313 .755 
Diuretics .316 .046 .555 .580 .175 
ACE Inhibitors -.040 .236 -.014 -.169 .866 
Insulin -.022 .841 -.002 -.026 .979 
Benzodiazepines .629 .415 .123 1.513 .132 
Statins -.032 .346 -.008 -.092 .927 
Oral Antidiabetics -.071 .381 -.015 -.187 .852 
COX-II Inhibitors .614 .377 .134 1.632 .105 
Steroids -.042 .240 -.014 -.175 .861 
Tramadol .924 .596 .126 1.550 .123 
Opioid Analgesia .392 .286 .112 1.371 .172 
Antiepileptics .070 .405 .014 .173 .863 
Antidepressants .243 .278 .072 .874 .384 
 
 
 
 
 
 
 
 
 
 
 
 
 
282  
Pre Op Cog Tests B Std. Error Beta T P value 
List Learning Immediate 
- Total 
-.034 .022 -.126 -1.520 .131 
Story Memory 
Immediate - Total 
-.063 .024 -.213 -2.612 .01 
Figure Copy Immediate - 
Total 
-.004 .040 -.009 -.105 .916 
Line Orientation - Total -.095 .037 -.208 -2.547 .012 
Picture Naming - Total -.889 .391 -.187 -2.271 .025 
Semantic Fluency - Total -.020 .025 -.067 -.808 .420 
Digit Span - Total -.111 .043 -.210 -2.568 .011 
Coding - Total -.038 .011 -.273 -3.388 .001 
List Learning Delayed -.045 .042 -.090 -1.082 .281 
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Recall - Total      
List Learning 
Recognition - Total 
-.190 .059 -.258 -3.199 .002 
Story Recall - Total -.094 .037 -.207 -2.532 .012 
Figure Recall - Total -.056 .029 -.159 -1.921 .057 
COWAT Total Words -.015 .009 -.141 -1.712 .089 
COWAT Total Errors .099 .108 .076 .916 .361 
COWAT Total Pers -.047 .021 -.183 -2.234 .027 
Trail Making Test A 
Completion time 
.014 .007 .152 1.864 .064 
Trail Making Test B 
Completion time 
.009 .003 .260 3.242 .001 
Anxiety - Total T1 .051 .030 .141 1.723 .087 
Depression - Total T1 .015 .036 .034 .414 .679 
WHOQOL Domain 1 - 
Total Physical health 
domain 
-.015 .020 -.063 -.765 .446 
WHOQOL Domain 2 - 
Total Psychological 
domain 
-.013 .032 -.033 -.401 .689 
WHOQOL Domain 3 - 
Total Social 
Relationships domain 
-.035 .056 -.052 -.621 .535 
WHOQOL Domain 4 - 
Total Environment 
domain 
-.047 .030 -.129 -1.570 .119 
Intraoperative factors 
With the exception of TIVA use, no intraoperative factors were significantly associated with cognition at POD7. The 
use of TIVA was inversely associated with cognitive dysfunction. 
Variable B Std. Error Beta T P value 
General Anaesthesia .242 .152 1.865 .064 .450 
Sedation -.492 .256 -.166 -1.927 .056 
Regional Anaesthesia .052 .260 .017 .199 .843 
Surgical duration 
(minutes) 
-.001 .002 -.038 -.433 .666 
TIVA -.568 .276 -.176 -2.055 .042 
Prophylactic Antibiotics -.314 1.491 -.018 -.211 .833 
Vasoactives used .285 -.035 -.407 .685 -.116 
Neuraxial Blockade with 
LA 
-.273 .259 -.092 -1.057 .293 
NSAIDS or COX-II 
Inhibitors 
-.161 .258 -.054 -.623 .534 
Nitrous Oxide .482 .366 .114 1.320 .189 
Tramadol .067 .300 .020 .224 .823 
Ketamine .633 .416 .131 1.523 .130 
Clonidine .084 .506 .014 .166 .869 
Benzodiazepine -.453 .338 -.130 -1.340 .183 
 
Post-operative factors 
Benzodiazepine use, Cardiovascular complication, and increased pain at POD2 were all independently and 
significantly associated with decreased cognitive performance at POD7. 
 
Post Op Medications B Std. Error Beta T P value 
COX-II Post op .059 .292 .019 .203 .839 
Opioids .115 .669 .015 .171 .864 
Antipsychotics 1.173 1.041 .099 1.128 .262 
Antiepileptics .252 .482 .046 .523 .602 
Benzodiazepines .725 .351 .180 2.067 .041 
Clonidine .856 .054 .612 .542 .524 
Ketamine .675 .667 .089 1.012 .313 
Tramadol .236 .260 .080 .909 .365 
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Variable B Std. Error Beta T P value 
Post Op Complications      
Respiratory 
Complications 
.109 .669 .014 .163 .870 
Cardiovascular 
complications 
3.310 1.444 .199 2.293 .023 
Sepsis -1.638 1.466 -.098 -1.118 .266 
Surgical site infection -.375 1.473 -.023 -.255 .799 
Atrial Fibrillation 1.287 1.043 .109 1.234 .219 
Creatinine levels -.007 .005 -.113 -1.258 .211 
POD2 Pain .114 .043 .214 2.653 .009 
 
Logistic Regression 
 
Variable 
 
B 
 
S.E. 
 
Wald 
 
df 
 
Sig. 
 
OR OR 
L 
OR 
U 
Gender 0.29 0.56 0.26 1.00 0.61 1.33 0.44 4.03 
 
Education 
 
0.13 
 
0.23 
 
0.30 
 
1.00 
 
0.58 
 
1.13 
 
0.72 
 
1.78 
 
ASA Classification 
 
-0.31 
 
0.54 
 
0.32 
 
1.00 
 
0.57 
 
0.74 
 
0.26 
 
2.12 
 
Smoking status 
 
-0.29 
 
0.81 
 
0.13 
 
1.00 
 
0.72 
 
0.75 
 
0.15 
 
3.67 
Rheumatoid 
Arthritis pre 
 
18.88 
 
40192.97 
 
0.00 
 
1.00 
 
1.00 
 
####### 
 
# 
 
0.00 
 
0.00 
Inflammatory 
Bowel Disease pre 
18.92 15191.51 0.00 1.00 1.00 ####### 
 
# 
0.00 0.00 
Hypertension pre -0.78 0.68 1.31 1.00 0.25 0.46 0.12 1.74 
Coronary Artery 
Disease pre 
 
0.62 
 
1.07 
 
0.34 
 
1.00 
 
0.56 
 
1.86 
 
0.23 
 
15.20 
Heart Failure pre 18.90 20096.48 0.00 1.00 1.00 ####### 
 
# 
0.00 0.00 
 
Previous 
Myocardial 
Infarction pre 
 
18.96 
 
11602.71 
 
0.00 
 
1.00 
 
1.00 
 
####### 
 
# 
 
0.00 
 
0.00 
Peripheral Vascular 
Disease pre 
 
-0.77 
 
1.14 
 
0.45 
 
1.00 
 
0.50 
 
0.47 
 
0.05 
 
4.31 
Stroke or TIA pre -1.36 0.87 2.40 1.00 0.12 0.26 0.05 1.43 
Atrial Fibrillation 
pre 
 
18.92 
 
16408.71 
 
0.00 
 
1.00 
 
1.00 
 
####### 
 
# 
 
0.00 
 
0.00 
COPD pre -0.54 0.70 0.58 1.00 0.44 0.58 0.15 2.31 
Malignant/Solid 
Tumour pre 
 
-1.03 
 
0.72 
 
2.03 
 
1.00 
 
0.15 
 
0.36 
 
0.09 
 
1.47 
Is patient sedated 
intraop 
0.35 0.60 0.35 1.00 0.55 1.42 0.44 4.57 
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Regional intraop 
 
-0.57 
 
0.62 
 
0.82 
 
1.00 
 
0.37 
 
0.57 
 
0.17 
 
1.93 
 
TIVA intraop 
 
0.50 
 
0.68 
 
0.54 
 
1.00 
 
0.46 
 
1.65 
 
0.43 
 
6.28 
Prophylactic 
Antibiotics intraop 
 
-18.84 
 
40192.99 
 
0.00 
 
1.00 
 
1.00 
 
0.00 
 
0.00 
 
0.00 
Vasoactives used 
intra op 
-0.23 0.69 0.11 1.00 0.74 0.80 0.21 3.05 
Neuraxial Blockade 
with LA intraop 
0.62 0.62 1.00 1.00 0.32 1.87 0.55 6.34 
NSAID or COX II 
 
Inhibitors intra op 
-0.28 0.60 0.23 1.00 0.64 0.75 0.23 2.42 
 
Nitrous Oxide for 
maintenance intra 
op 
 
-0.08 
 
0.81 
 
0.01 
 
1.00 
 
0.92 
 
0.92 
 
0.19 
 
4.48 
 
Tramadol intraop 
 
0.55 
 
0.79 
 
0.47 
 
1.00 
 
0.49 
 
1.73 
 
0.36 
 
8.20 
 
Ketamine intraop 
 
-0.41 
 
0.82 
 
0.25 
 
1.00 
 
0.62 
 
0.67 
 
0.13 
 
3.29 
 
Clonidine intraop 
 
18.92 
 
12118.64 
 
0.00 
 
1.00 
 
1.00 
 
####### 
 
# 
 
0.00 
 
0.00 
Benzodiazepine 
intraop 
 
0.22 
 
0.71 
 
0.09 
 
1.00 
 
0.76 
 
1.24 
 
0.31 
 
5.02 
Cox II Inhibitors 
 
postop 
-1.73 1.06 2.65 1.00 0.10 0.18 0.02 1.42 
 
Opiods postop 
 
-18.81 
 
15191.52 
 
0.00 
 
1.00 
 
1.00 
 
0.00 
 
0.00 
 
0.00 
Antipsychotics 
postop 
 
18.78 
 
23205.42 
 
0.00 
 
1.00 
 
1.00 
 
####### 
 
# 
 
0.00 
 
0.00 
Antiepileptic 
medication postop 
-1.05 0.85 1.54 1.00 0.21 0.35 0.07 1.84 
Benzodiazepines 
postop 
-0.74 0.71 1.07 1.00 0.30 0.48 0.12 1.93 
Clonidine postop -1.82 1.26 2.08 1.00 0.15 0.16 0.01 1.93 
 
Ketamine postop 
 
-1.11 
 
1.16 
 
0.92 
 
1.00 
 
0.34 
 
0.33 
 
0.03 
 
3.20 
 
Tramadol postop 
 
-0.80 
 
0.61 
 
1.70 
 
1.00 
 
0.19 
 
0.45 
 
0.14 
 
1.49 
 
Respiratory 
complications 
postop 
 
18.80 
 
16408.71 
 
0.00 
 
1.00 
 
1.00 
 
####### 
 
# 
 
0.00 
 
0.00 
Cardiovascular 
complications 
 
-2.52 
 
1.45 
 
3.03 
 
1.00 
 
0.08 
 
0.08 
 
0.00 
 
1.37 
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postop 
        
 
Sepsis postop 
 
18.78 
 
28420.72 
 
0.00 
 
1.00 
 
1.00 
 
####### 
 
# 
 
0.00 
 
0.00 
Surgical site 
infection postop 
 
18.77 
 
40192.97 
 
0.00 
 
1.00 
 
1.00 
 
####### 
 
# 
 
0.00 
 
0.00 
Atrial Fibrillation 
present postop 
18.79 23205.42 0.00 1.00 1.00 ####### 
 
# 
0.00 0.00 
Highest level of 
post operative 
creatinine umolL 
postop 
0.00 0.01 0.08 1.00 0.77 1.00 0.97 1.02 
 
NRS1 
 
0.06 
 
0.10 
 
0.41 
 
1.00 
 
0.52 
 
0.94 
 
0.87 
 
1.28 
 
NRS2 
 
0.25 
 
0.12 
 
4.42 
 
1.00 
 
0.04 
 
1.28 
 
1.05 
 
1.63 
 
NRS3 
 
0.03 
 
0.09 
 
0.11 
 
1.00 
 
0.74 
 
1.03 
 
0.85 
 
1.21 
 
Beta Blockers preop 
 
0.14 
 
0.79 
 
0.03 
 
1.00 
 
0.86 
 
1.15 
 
0.24 
 
5.47 
 
Diuretics preop 
 
0.14 
 
0.79 
 
0.03 
 
1.00 
 
0.86 
 
1.15 
 
0.24 
 
5.43 
ACE Inhibitors 
preop 
 
0.83 
 
0.58 
 
2.06 
 
1.00 
 
0.15 
 
2.30 
 
0.74 
 
7.19 
Insulin preop 18.82 20096.48 0.00 1.00 1.00 ####### 
 
# 
0.00 0.00 
Benzodiazepines 
preop 
 
-1.28 
 
0.72 
 
3.14 
 
1.00 
 
0.08 
 
0.28 
 
0.07 
 
1.15 
NSAIDS preop(1) -0.56 0.69 0.66 1.00 0.42 0.57 0.15 2.22 
Oral Antidiabetics 
preop 
 
-0.18 
 
0.80 
 
0.05 
 
1.00 
 
0.82 
 
0.83 
 
0.17 
 
4.01 
COXII inhibitors 
preop 
-1.42 0.66 4.61 1.00 0.03 0.24 0.07 0.88 
Steroids preop -0.34 0.56 0.36 1.00 0.55 0.71 0.24 2.13 
 
Tramadol preop 
 
-1.62 
 
0.89 
 
3.31 
 
1.00 
 
0.07 
 
0.20 
 
0.03 
 
1.13 
Opioid Analgesics 
preop(1) 
 
-1.11 
 
0.58 
 
3.69 
 
1.00 
 
0.05 
 
0.33 
 
0.11 
 
1.02 
Antiepileptics preop -0.87 0.70 1.53 1.00 0.22 0.42 0.11 1.66 
Antidepressants 
preop 
 
-0.15 
 
0.62 
 
0.06 
 
1.00 
 
0.81 
 
0.86 
 
0.26 
 
2.90 
General -0.86 0.67 1.63 1.00 0.20 0.42 0.11 1.58 
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Name and affiliation of contributor Contribution Signature* and date 
   
   
 
* If an author or contributor is unavailable or otherwise unable to sign the statement of authorship, the Head of 
Academic Unit may sign on their behalf, noting the reason for their unavailability, provided there is no evidence to 
suggest that the person would object to being named as author 
 
7. Data storage 
 
The original data for this project are stored in the following locations. (The locations must be within an appropriate 
institutional setting. If the executive author is a Deakin staff member and data are stored outside Deakin University, 
permission for this must be given by the Head of Academic Unit within which the executive author is based.) 
 
Data format Storage Location Date lodged Name of custodian if other 
than the executive author 
Manuscript data is stored on a secure 
closed network. 
Barwon Health. - - 
  - - 
This form must be retained by the executive author, within the school or institute in which they are based. 
If the publication is to be included as part of an HDR thesis, a copy of this form must be included in the thesis with 
the publication. 
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  - - 
This form must be retained by the executive author, within the school or institute in which they are based. 
If the publication is to be included as part of an HDR thesis, a copy of this form must be included in the thesis with 
the publication. 
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Appendix F – Participant Information and Consent Form 
 
Anaesthesia, Perioperative & Pain Management 
Telephone: 03 42151901 
Facsimile:   03 42151949 
 
 
 
Title 
The Post Anaesthesia N-Acetyl-Cysteine 
Evaluation trial 
Short Title The PANACEA Trial 
HREC Ref No. 13/111 
Protocol Number 3 
Project Sponsor Barwon Health – University Hospital 
Principal Investigator Dr Andrew Marriott 
Associate Investigator(s) 
 
 
 
Research Assistants 
Prof Michael Berk, Dr Olivia Dean, Dr Linda Byrne, Dr 
Laura Gray, Dr Matthew Lewis, Dr Cameron Osborne, Mr 
Douglas Stupart, Dr Eileen Moore 
 
Ms Nicole Duggan, Ms Melissa Formica, Mr David Skvarc 
 
Location 
 
Barwon Health -University Hospital 
 
1 Introduction 
 
You have been invited to take part in this research project because you will be having non- 
cardiac surgery at the University Hospital and are over the age of 60 years. The research 
project is testing a medication that may be able to prevent a condition known as Post-Operative 
Cognitive Dysfunction, or POCD. POCD is a condition where a person who has undergone 
surgery can sometimes experiences changes to their memory, mood, and other cognitive areas. 
While often short in duration, POCD can sometimes remain for years. At present, there are no 
medicines available to prevent or treat POCD. The medicine we are investigating is called N- 
Acetyl-Cysteine, or NAC for short. 
 
This Participant Information Sheet/Consent Form tells you about the research project. It 
explains the tests and treatments involved. Knowing what is involved will help you decide if you 
want to take part in the research. Please read this information carefully. Ask questions about 
anything that you don’t understand or want to know more about. Before deciding whether or 
not to take part, you might want to talk about it with a relative, friend or your local doctor. 
 
Participation in this research is voluntary. If you don’t wish to take part, you don’t have to. You 
will receive the best possible care whether or not you take part. 
If you decide you want to take part in the research project, you will be asked to sign the consent 
section. By signing it you are telling us that you: 
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• Understand what you have read 
• Consent to take part in the research project 
• Consent to have the tests and treatments that are described 
• Consent to the use of your personal and health information as described. Research staff 
may also contact you in future to see how you are going. 
 
You will be given a copy of this Participant Information and Consent Form to keep. 
 
You should not participate in this study if: 
If you have or suspect you might have an allergy to NAC, if you are already taking NAC 
If you are taking nitrates 
If you will not be able to perform the tests required as part of the project 
Please speak to the research assistant if you are not sure about any of the above 
 
 
2 What is the purpose of this research? 
 
NAC is approved in Australia by the Therapeutic Goods Administration to treat overdoses of 
paracetamol, or Panadol. NAC is also be used to treat bronchitis. However it has not been used 
to prevent POCD. Therefore, its use for POCD is experimental. This means that it must be 
tested to see if it is effective. While NAC has been widely studied for many different conditions, 
this is the first major study of the effects of NAC on POCD in humans. 
 
At present, the exact causes of POCD, how POCD works, and the long term consequences of 
POCD are not entirely understood. This project will help us understand the causes of POCD, 
any details about a person that makes them more likely to experience POCD, and provide 
important information about how we can treat POCD. 
 
Although POCD is not entirely understood, there are theories about how it happens. One of the 
theories is that POCD can be caused by the physical stress the body experiences when having 
surgery. NAC is a type of medicine known as an antioxidant, and can help reduce the type of 
stress the body experiences when having surgery. 
 
This research has been initiated by the study doctor, Dr Andrew Marriott. 
This research has been funded by the Barwon Health Department of Anaesthesia, Perioperative 
Medicine, and Pain Management [and Barwon Health Clinical Research grant]. 
This research is being conducted by a collaborative research group from Barwon Health and 
Deakin University, called the PANACEA group. 
This research is being conducted by and is sponsored in Australia by Barwon Health. 
The results of this research will be used by the research assistant, David Skvarc, to obtain a 
PhD in Psychology. 
 
3 What does participation in this research involve? 
 
Participation in this project will not require any alterations to your surgery or care after your 
surgery. You will receive a routine anaesthetic, with all care and monitoring according to the 
highest international standards. 
 
You will be randomly allocated (a process like tossing a coin) to either receive NAC or placebo. 
A placebo is a medication with no active ingredients; it looks like the real thing but is not. Neither 
you nor the researcher will know if you’re receiving the NAC or Placebo. We have designed the 
study to make sure the researchers interpret the results in a fair and appropriate way. Both 
groups (NAC and placebo) will take two tablets twice a day, for four days, starting on the day of 
surgery. 
 
Four interviews testing cognition will take place during your participation. These interviews will 
take place prior to your surgery, 7 days, 3 months, and 1 year after your surgery. Each interview 
is approximately 60 minutes long, where you will be given tests of cognition, attention and 
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memory. If you are unable to come to the hospital for any of these interviews, a researcher may 
be able to come to your residence. 
You will be required to give two blood samples during your hospital stay. This is so we can 
monitor markers of stress in your body. The first sample will be taken on the day of surgery and 
the second sample will be taken two days after your surgery. 
 
There are no additional costs associated with participating in this research project, nor will you 
be paid. All medication, tests and medical care required as part of the research project will be 
provided to you free of charge. If you have a local doctor, we strongly recommend that you 
inform them of your participation in this research project. 
4 What do I have to do? 
 
The majority of this study will take place during your stay in hospital, and as such your lifestyle 
will only be restricted as is normal during your recovery from surgery. You can continue to take 
your regular medication. During your participation, the trial medication or placebo will be 
provided by the hospital pharmacy. The research staff will contact you by phone to arrange a 
convenient time for the 3 month and 1 year interviews following your surgery. We will review 
your medical record to see if you have had any complications. If we are unable to contact you 
about complications, we will check with your other doctors for this information. 
 
5 Other relevant information about the research project 
 
We aim to recruit 370 participants in this study, all of whom will be recruited from amongst 
patients at Barwon Health. Half of the participants in our study will be receiving NAC, and the 
other half will receive a placebo. 
This study is a collaborative effort between Barwon Health and Deakin University 
 
6 Do I have to take part in this research project? 
 
Participation in any research project is voluntary. If you do not wish to take part, you do not have 
to. If you decide to take part and later change your mind, you are free to withdraw from the project 
at any stage. 
Your decision whether to take part or not to take part, or to take part and then withdraw, will not 
affect your routine treatment, your relationship with those treating you or your relationship with 
Barwon Health or Deakin University. 
 
7 What are the alternatives to participation? 
 
You do not have to take part in this research project to receive treatment at this hospital. While 
there are currently no treatments for POCD, you may not experience POCD at all as a result 
from your surgery, and as such may not benefit directly from participation. 
 
8 What are the possible benefits of taking part? 
 
You will receive additional visits after your surgery, which may allow us to detect any problems 
at an earlier stage. We cannot guarantee or promise that you will receive any benefits from this 
research; however, possible benefits may include a reduction in POCD or similar symptoms 
after your surgery. Knowledge gained may be able to help prevent POCD in future surgical 
patients, and there may be a possibility of NAC playing a role in dementia prevention. 
 
9 What are the possible risks and disadvantages of taking part? 
 
Medical treatments often cause side effects. You may have none, some or all of the effects 
l i s t e d below, and they may be mild, moderate or severe. If you have any of these side effects, 
or are worried about them, talk with your study doctor. Your study doctor will also be looking out 
for side effects. 
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There may be side effects that the researchers do not expect or do not know about and that 
may be serious. Tell your study doctor immediately about any new or unusual symptoms that 
you get. Many side effects go away shortly after treatment ends. However, sometimes side 
effects can be serious, long lasting or permanent. If a severe side effect or reaction occurs, your 
study doctor may need to stop your treatment. Your study doctor will discuss the best way of 
managing any side effects with you. 
 
Side Effects of NAC: Vomiting, nausea, and flushing are the most common side effects of 
taking NAC. These side effects are unlikely to be serious or long lasting. Side effects will be 
treated by hospital staff where necessary and the details recorded. 
 
Risks of participation: As part of your participation in this study, we will require 2 blood 
samples from you on different days. One sample is taken as part of your routine care during 
your surgery, the other will be taken by research staff. Some people can experience nausea, 
light-headedness, and some soreness or bruising due to injections or giving blood. These side 
effects are easily treated. There is a very small risk of infection at the site of the blood test. 
Disadvantages: You may find that the assessments conducted by the research team may be 
time-consuming. We anticipate that each meeting will last approximately 60 minutes, and you 
may find some of the tasks repetitive. 
Possible detection of previously unknown conditions: As part of our tests, we may 
discover previously unknown conditions such as mood disorders or cognitive impairment. You 
may find this information distressing, and there is a chance that a previously unknown condition 
may affect your health insurance or participation in the project. Discussion of these results will 
include your general practitioner in order to ensure you receive the best care possible. 
If you become upset or distressed as a result of your participation in the research, the study 
doctor will be able to arrange for counselling or other appropriate support. Any counselling or 
support will be provided by qualified staff who are not members of the research project team. 
This counselling will be provided free of charge. Further, if you are an Australian citizen and 
covered by Medicare, you can receive free treatment at any Australian public hospital. 
 
10 What will happen to my test samples? 
 
You will be asked to provide additional consent for the collection of your blood during the 
research project. Your samples will be re-identifiable, this means that they will be treated 
anonymously unless there is some circumstance that requires us to identify your sample. We 
w i l l keep your samples in secure storage at Barwon Health in case future research examining 
POCD is necessary. Please inform a member of the research team if you do not want us to 
keep your blood samples. Only approved Barwon Health research staff will have access to your 
samples, and only after approval from the Barwon Health Human Research Ethics Council. 
Samples will be used by the investigators or collaborators for analyses and will not be 
commercially available to other research groups. Your samples will be stored at Barwon Health 
for up to 15 years, after which they will be destroyed. This is in accordance with Barwon Health 
privacy policies. 
 
11 What if new information arises during this research project? 
 
Sometimes during the course of a research project, new information becomes available about 
the treatment that is being studied. If this happens, your study doctor will tell you about it and 
discuss with you whether you want to continue in the research project. If you decide to 
withdraw, your study doctor will make arrangements for your regular health care to continue. If 
you decide to continue in the research project you will be asked to sign an updated consent 
form. 
 
Also, on receiving new information, your study doctor might consider it to be in your best 
interests to withdraw you from the research project. If this happens, he/ she will explain the 
reasons and arrange for your regular health care to continue. 
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12 Can I have other treatments during this research project? 
 
You should continue to take all of the medications and treatments you are currently taking, and 
take all of the medications you are prescribed whilst in hospital by your regular doctors. The 
study researchers will review the medications you are prescribed to ensure there are no 
potential interactions between the trial medications and medications you are prescribed. 
It may also be necessary for you to take medication during or after the research project to 
address side effects or symptoms that you may have. Any medication prescribed for this 
purpose will be provided free of charge. 
 
13 What if I withdraw from this research project? 
 
If you decide to withdraw from the project, please notify a member of the research team before 
you withdraw. This notice will allow that person or the research supervisor to discuss any health 
risks or special requirements linked to withdrawing. 
 
If you do withdraw your consent during the research project, the study doctor and relevant study 
staff will not collect additional personal information from you, although personal information 
already collected will be retained to ensure that the results of the research project can be 
measured properly and to comply with law. You should be aware that data collected by the 
sponsor up to the time you withdraw will form part of the research project results. If you do not 
want them to do this, you must tell them before you join the research project. 
 
14 Could this research project be stopped unexpectedly? 
 
This research project may be stopped unexpectedly for a variety of reasons. These may include 
reasons such as: 
• Unacceptable side effects 
An alternative treatment being discovered for POCD 
Decisions made by the investigators or local regulatory/health authorities 
 
 
15 What happens when the research project ends? 
 
At the end of the research project, the results of all the participants will be examined to see if 
there has been any effect of taking NAC. The results of the study will then be published in a 
journal for other researchers to examine. The information contained in the publication will be 
anonymous. If you would like to be kept informed about the results of this study, please tell a 
member of the research team and they will ensure that you will receive a summary of the 
results. 
 
16 What will happen to information about me? 
 
Any information obtained in connection with this research project that can identify you will 
remain confidential and will only be used for the purpose of this research project. It will only be 
disclosed with your permission, except as required by law. 
 
By signing the attached Consent Form, you authorise release of, or access to, this confidential 
information to the relevant study personnel and regulatory authorities as noted above. 
 
Your health records and any information obtained during the research project are subject to 
inspection for the purpose of verifying the procedures and the data. Your health records and 
any information obtained during the research project are subject to inspection (for the purpose 
of verifying the procedures and the data) by the relevant authorities and authorised 
representatives of the Sponsor, Barwon Health, the institution relevant to this Participant 
Information Sheet, The PANACEA group, or as required by law. 
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It is anticipated that the results of this research project will be published and/or presented in a 
variety of forums. In any publication and/or presentation, information will be provided in such a 
way that you cannot be identified, except with your permission. 
 
Information about your participation in this research project may be recorded in your health 
records. 
 
In accordance with relevant Australian and/or Victorian privacy and other relevant laws, you 
have the right to request access to the information collected and stored by the research team 
about you. You also have the right to request that any information with which you disagree be 
corrected. Please contact the research team member named at the end of this document if you 
would like to access your information. 
 
At the end of the study all study information will be stored securely for at least 15 years after 
completion of the trial, as is required. 
 
17 Complaints and compensation 
If you suffer any injuries or complications as a result of this research project, you should contact 
the study team as soon as possible and you will be assisted with arranging appropriate medical 
treatment. If you are eligible for Medicare, you can receive any medical treatment required to 
treat the injury or complication, free of charge, as a public patient in any Australian public 
hospital. 
If you have a complaint about how you have been treated by any member of the research team, 
you are able to take this complaint to the principal investigator, Dr Andrew Marriott, or to the 
Manager of the Office for Research on (03) 4215 3372. 
 
18 Who is organising and funding the research? 
 
This research project is being conducted by the PANACEA group; a collaboration between 
Barwon Health and Deakin University. 
This research project is being conducted by and sponsored in Australia by Barwon Health and is 
being funded by Barwon Health Department of Anaesthesia, Perioperative Medicine & Pain 
Management and the Barwon Health Clinical Research Grant. 
By taking part in this research project you agree that samples of your blood or tissue (or data 
generated from analysis of these materials) may be provided to Barwon Health. 
Barwon Health may directly or indirectly benefit financially from your samples or from knowledge 
acquired through analysis of your samples. 
You will not benefit financially from your involvement in this research project even if, for 
example, your samples (or knowledge acquired from analysis of your samples) prove to be of 
commercial value to Barwon Health or Deakin University. 
In addition, if knowledge acquired through this research leads to discoveries that are of 
commercial value to Barwon Health or Deakin University, the study doctors or their institutions, 
there will be no financial benefit to you or your family from these discoveries. 
No member of the research team will receive a personal financial benefit from your involvement 
in this research project (other than their ordinary wages). 
 
19 Who has reviewed the research project? 
 
All research in Australia involving humans is reviewed by an independent group of people called a 
Human Research Ethics Committee (HREC). The ethical aspects of this research project have 
been approved by the HREC of Barwon Health and Deakin University 
 
This project will be carried out according to the National Statement on Ethical Conduct in 
Human Research (2007). This statement has been developed to protect the interests of people 
who agree to participate in human research studies. 
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20 Further information and who to contact 
 
The person you may need to contact will depend on the nature of your query. 
If you want any further information concerning this project or if you have any medical problems 
which may be related to your involvement in the project (for example, any side effects), you can 
contact the research assistant on 0411 399 025 or any of the following people: 
 
 
Clinical contact person 
Name Dr Andrew Marriott 
Position Principal Investigator and Specialist Anaesthetist 
Telephone 03 4215 1916 
Email amarri@barwonhealth.org.au 
 
For matters relating to research at the site at which you are participating, the details of the local 
site complaints person are: 
 
Complaints contact person 
Name Dr Giuliana Fuscaldo 
Position Manager of the Office for Research 
Telephone 03 4215 2030 
 
If you have any complaints about any aspect of the project, the way it is being conducted or any 
questions about being a research participant in general, then you may contact: 
 
Reviewing HREC approving this research and HREC Executive Officer details 
 
Reviewing HREC name Barwon Health 
HREC Executive Officer Dr Giuliana Fuscaldo 
Telephone 03 4215 2030 
Email gfusca@barwonhealth.org.au 
 
Local HREC Office contact (Single Site - Research Governance Officer) 
Name Dr Giuliana Fuscaldo 
Position Manager of the Office for Research 
Telephone 03 4215 2030 
Email gfusca@barwonhealth.org.au 
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Consent Form 
 
Title The Post-Anaesthesia N-Acetyl-Cysteine Evaluation Trial 
Short Title The PANACEA trial 
Protocol Number 3 
HREC Ref No. 13/111 
Project Sponsor Barwon Health – University Hospital 
Principal Investigator Dr Andrew Marriott 
 
Associate Investigator(s) Prof Michael Berk, Dr Olivia Dean, Dr Linda Byrne, Dr Laura Gray, Dr Matthew Lewis, Dr Cameron Osborne, 
Mr Douglas Stupart, Dr Eileen Moore 
Research Assistants 
 
Ms Nicole Duggan, Ms Melissa Formica, Mr 
David Skvarc 
Location Barwon Health - University Hospital 
Declaration by Participant 
I have read the Participant Information Sheet or someone has read it to me in a language that I 
understand. 
I understand the purposes, procedures and risks of the research described in the project. 
I give permission for my doctors, other health professionals, hospitals or laboratories outside this 
hospital to release information to Barwon Health concerning my treatment for the purposes of this 
project. I understand that such information will remain confidential. 
I have had an opportunity to ask questions and I am satisfied with the answers I have received. 
I freely agree to participate in this research project as described and understand that I am free to 
withdraw at any time during the study without affecting my future health care. I understand that, if I 
decide to discontinue the study treatment, I may be asked to attend follow-up visits to allow 
collection of information regarding my health status. Alternatively, a member of the research team 
may request my permission to obtain access to my medical records for collection of follow-up 
information for the purposes of research and analysis. 
I understand that I will be given a signed copy of this document to keep. 
 
 
Declaration by Study Doctor/Senior Researcher† 
 
I have given a verbal explanation of the research project, its procedures and risks and I believe that 
the participant has understood that explanation. 
 
† A senior member of the research team must provide the explanation of, and information concerning, the research 
project. 
Note: All parties signing the consent section must date their own signature. 
Name of Participant (please print)     
 
Signature  Date   
Name of Study Doctor/ 
Senior Researcher† (please print)      
 
Signature  Date   
Master Participant Information Sheet/Consent Form (5) 16/06/2017 Page 2 of 2  
I consent to the storage and use of blood samples taken from me for use, as described in the 
relevant section of the Participant Information Sheet, for: 
• This specific research project 
• Other research that is closely related to this research project 
• Any future research under taken by the research team 
 
 
 
† A senior member of the research team must provide the explanation of and information concerning the research 
project. 
 
Note: All parties signing the consent section must date their own signature. 
Name of Participant (please print)     
 
Signature  Date   
Name of Study Doctor/ 
Senior Researcher† (please print)      
 
Signature  Date   
Master Participant Information Sheet/Consent Form (5) 16/06/2017 Page 2 of 2  
Form for Withdrawal of Participation 
 
 
Title The Post-Anaesthesia N-Acetyl-Cysteine Evaluation Trial 
Short Title The PANACEA Trial 
Protocol Number 3 
HREC Ref No. 13/111 
Project Sponsor Barwon Health – University Hospital 
Principal Investigator Dr Andrew Marriott 
 
Associate Investigator(s) 
Prof Michael Berk, Dr Olivia Dean, Dr Linda Byrne, Dr 
Laura Gray, Dr Matthew Lewis, Dr Cameron Osborne, 
Mr Douglas Stupart, Dr Eileen Moore 
 
Research Assistants 
 
Ms Nicole Duggan, Ms Melissa Formica,Mr David 
Skvarc 
Location Barwon Health - University Hospital 
 
Declaration by Participant 
 
I wish to withdraw from participation in the above research project and understand that 
such withdrawal will not affect my routine treatment, my relationship with those treating 
me or my relationship with Barwon Health or Deakin University. 
 
 
If verbal withdrawal, Study Doctor/Senior Researcher to provide description below: 
 
 
   Declaration by Study Doctor/Senior Researcher† 
I have given a verbal explanation of the implications of withdrawal from the research project 
and I believe that the participant has understood that explanation. 
 
† A senior member of the research team must provide the explanation of and information concerning withdrawal 
from the research project. 
Name of Participant (please print)     
 
Signature  Date   
Name of Study Doctor/ 
Senior Researcher† (please print)      
 
Signature  Date   
